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ABSTRACT
The prevalence and characteristics of cytomegalovirus
(CMV) infection in homosexual men was investigated. CMV
infection may affect various immune functions under different
circumstances. The acquired immune deficiency syndrome (AIDS)
has been reported with increased frequency in male
homosexuals and the possibility that CMV infection may
contribute to the observed immune impairment was considered.
It is necessary to study CMV infection in the absence of AIDS
in order to assess its individual contribution to immune
deficiency. To this end a population of male homosexuals and
heterosexual controls where no cases of AIDS had been reported
was selected for study.
Virological, immunological and serological parameters of
CMV infection were assessed. Virus isolation in cell culture
was used to detect oral and urinary excretion of virus.
Virus-specific and general cell-mediated immunity was
investigated using lymphocyte proliferation assays and a
range of serological assays were used. IgG antibodies to CMV
were detected by indirect ELISA to determine the prevalence
of past infection in the two study populations. Antibodies to
CMV immediate early and early antigens were detected by
indirect immunofluorescence, as an indication of the extent to
which humoral immunity is stimulated during CMV infection. An
IgM capture ELISA was developed to detect IgM antibodies to
CMV. Together with data obtained from virus isolation studies,
this provided an indication of the prevalence of current or
i
recent active CMV infection.
CMV infection was found to be highly prevalent in male
homosexuals. This did not appear to be due to increased
frequency of sexual contact within this group. Rather
homosexual contact in itself would seem to result in
efficient transmission of infection as evidence of past
infection was highly prevalent among young, sexually
inexperienced homosexuals. Active CMV infection was largely
confined to this group.
There was little evidence of deficient cell-mediated
immune function in the homosexuals studied as a whole or in
those with active CMV infection. However CMV-specific humoral
immune parameters indicated that CMV infection frequently
resulted in a greater stimulation of immunity in homosexuals.
This may reflect a reduced capacity to contain active viral
replication in this group. Some defect in immune function
which is not detected in lymphocyte proliferation assays may
be responsible. Alternatively, the extent of viral
replication may be determined to some extent by the route of
infection.
The high level of pre-existing CMV infection in
homosexuals, and its active state in many support the
hypothesis that CMV infection may influence the development
of immune deficiency both during and subsequent to infection
with the causative agent of AIDS.
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GENERAL INTRODUCTION
A number of viral infections of man and animals cause a
suppression of immune functions. Included in this group are
Epstein-Barr virus (EBV) infection (Mangi et al.. 1974), the
cytomegalovirus (CMV) infections of man (Ten Napel et al.,
1980a; b) and of mice (Howard et al.. 1974). acute and
chronic hepatitis B virus (HBV) infections (Barnaba et al.,
1983; Thomas. 1981), measles virus infection (Whittle et al..
1978), feline leukaemia virus (FeLV) infection (Essex et al„
1975; 1976), and in mice, lymphocytic choriomeningitis virus
(LCMV) infection (Mims & Wainwright, 1968) and lactic
dehydrogenase virus (LDV) infection (Howard et al.. 1969).
The range of immune functions impaired and the extent of
their suppression differ in each case and the underlying
mechanisms which may be responsible are diverse.
The acquired immune deficiency syndrome (AIDS) caused by
the human T-lymphotropic retrovirus type III (HTLV III) is
perhaps the supreme example of a viral-induced immunodeficiency
in man. The cause of immune suppression in this case appears to
be the elimination of a subgroup of T lymphocytes, however
other factors may contribute prior to this late-stage event as
only a proportion of infected individuals proceed to this phase
of disease. AIDS often occurs in association with other viral
infections including some of those mentioned above, in
particular CMV and EBV infection. Of particular interest
therefore is the possibility that such viral infections may
predispose to greater pathogenic expression of HTLV III
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infection, which may subsequently proceed to AIDS and related
conditions with greater frequency.
This thesis examines the possibility that CMV infection
may play such an accessory role by investigating the extent
of CMV infection in a population which may be at increased
risk for AIDS, namely male homosexuals. The group studied
were free of AIDS and its related complex. This avoids the
difficulty of determining whether CMV infection in
symptomatic individuals contributes to immune deficiency, or is
merely arising in an opportunistic fashion in the presence of
immune deficiency due to other causes.
The following chapters lay the basis for understandimg
the pathogenesis of CMV infection, of HTLV III infection, and
their possible interactions in AIDS. Chapter 1 reviews
aspects of the biology of CMV important in comprehending the
nature of the virus-host interaction at the cellular level.
This material also forms the basis on which much experimental
work with CMV is designed. Chapter 2 considers
epidemiological aspects of CMV infection, upon which much of
our understanding of the pathogenesis of CMV infection lies.
Chapter 3 extends the consideration of CMV pathogenesis in
various clinical situations and provides a grounding for
investigating its possible role in AIDS. Chapter k reviews
microbiological, immunological and other pathological aspects
of AIDS and discusses the small but rapidly growing




THE BIOLOGY OF HUMAN CYTOMEGALOVIRUS
History and classification
In 1956 Smith reported the isolation and in vitro
propagation of a virus from autopsy specimens of salivary
gland and kidney tissue (Smith, 1956)- These specimens were
derived from two infants found to have salivary gland inclusion
disease (cytomegalic inclusion disease) - a diagnosis made on
the basis of the large intranuclear inclusions seen in
histological sections (Pinkerton, 1950). The virus was
implicated as a cause of the disease, as nuclear inclusions
were seen in cells infected in culture wh-ich bore resemblance
to the In vivo inclusions and were identical to those
produced in mouse cell cultures infected with mouse salivary
gland virus (Smith, 195^). Like the mouse virus, the human
virus was species-specific and the latter could not be
transmitted to suckling mice. This observation distinguished
the human virus from that of the mouse, and also from herpes
simplex virus (HSV) which may have been responsible for the
inclusions in histological section (Pinkerton, 1950). The
virus was also distinguishable from varicella-zoster virus
(VZV) which induces similar inclusions in cell culture
(Weller, 1953) by the presence of infectious virus in the
culture medium.
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Subsequent isolates were made from cultured adenoid
tissue (the Ad 169 strain), liver biopsy tissue (Davis
strain), and from urine (Kerr and Esp strains) and these
viruses were shown to be related to the original isolates by
their serological cross-reactivities and cell cultural
similarities (Rowe et al„ 1956; Weller et al„ 1957). All,
apart from the Ad 169 strain were isolated from infants with
cytomegalic inclusion disease. Weller et al. (i960) coined
the name "cytomegaloviruses" (CMV) for these viruses and
those of other species previously known as salivary gland
viruses or cytomegalic inclusion disease viruses. This change
of nomenclature was in recognition of the fact that virus
isolation could be made from numerous sites other than the
salivary glands, and could not always be associated with any
disease syndrome. Indeed, a large proportion of the
population had serological evidence of past, undetected
infection with human CMV.
Electron microscopy of infected cells suggested that CMV
was enveloped, the internal capsid being 80-100 nm in
diameter (Luse & Smith, 1958; 1959) however detailed
characterisation was hampered initially by the low in vitro
infectivity of CMV and its strong cell association (Benyesh-
Melnick et al., 1966). This made the preparation of
concentrated virus impractical. Improved preparation
techniques which increased the sensitivity of electron
microscopy (Smith & Melnick, 1962) allowed Smith & Rasmussen
(1963) to determine that CMV was probably a DNA virus and was
very similar to HSV in its size and capsid architecture.
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These observations made a strong case for including CMV in
the group known as the herpes type viruses. This
classification was borne out in due course as the
ultrastructure and biology of the virus was further
elucidated.
CMV is one of four herpesviruses that regularly infects
man (Timbury & Edmond, 1979). The others are HSV (the
prototype of the group), VZV and Epstein-Barr virus (EBV).
Herpesviruses have also been found in many other eukaryotic
species (Plummer, 1967). This has undoubtedly been a major
factor in stimulating research on CMV; much of the extensive
literature that now exists was initially prompted by
observations made in other herpesvirus systems, several of
which lend themselves more readily to laboratory
investigation.
The herpesviruses are structurally similar, but
biologically diverse and exist in a wide variety of host-
parasite relationships with perhaps an even greater variety
of disease manifestations, ranging from the inapparent to the
rapidly fatal. In common with at least some animal
herpesviruses and the other three viruses of humans, CMV may
exist in a carrier state following primary infection and this
may give rise to a re-emergence of active infection at a
later date (Jack, 1974-5 Plummer, 1973; Weller, 1971).
Strucutre and replication of CMV
The molecular biology of CMV has stimulated interest
both as a model for investigating the control of eukaryotic
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cell function and as a means of understanding the
pathogenesis of CMV infection. In this context, an account of
the structure, composition and replication of CMV serves also
as an introduction to the antigenic complexity of the virus
and as a rationale for certain aspects of experimental
design. The molecular events have been studied at various
levels; initially most investigation was of necessity
indirect in approach, using light and electron microscopy,
and immunofluorescent and immunoperoxidase staining
techniques most commonly. These methods are now supplemented
by sophisticated physical, biochemical and immunological
techniques.
In an account of this nature certain points should be
borne in mind:
a) Much of current knowledge in this area is derived from
studies in in vitro experimental systems. Because of the
species specificity of human CMV (as with most CMV's of other
species) there is no animal model available. CMV infection in
these systems differs fundamentally from that in an in vivo
situation in a number of respects:
i) There are fewer physiological constraints on viral
replication operative in an in vitro system.
ii) The cell types which permit productive infection in
vitro (fibroblasts) are probably not the major cell types
infected in vivo.
iii) The virus strains most commonly employed are those
which have become adapted by serial passage to these culture
conditions.
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b) It is not uncommon for different investigators to obtain
different results for similar experiments. Factors which may
account for these discrepancies include the type of
fibroblasts used (Wroblewska et al„ 1981) and their
physiological state (De Marchi & Kaplan,1977a), the strain of
virus, multiplicity of infection (moi), the relative numbers
of defective and non-defective particles in the viral
inoculum, and the incubation conditions employed (Albrecht et
al.. 1980a; b; Stinski et al., 1979a). These variables will
be referred to in greater depth in subsequent sections.
c) Our understanding of many of the molecular processes is
based on evidence which is lacking in conclusive proof. It
should therefore be remembered that some conclusions drawn
from experimental data are probabilities rather than
statements of fact.
Structure and composition
The herpesviruses are defined by their virion structure:
the capsid has icosahedral symmetry and is constructed of 162
capsomeres. The genome is a single, linear, double stranded
DNA molecule and the nucleocapsid is surrounded by a lipid
envelope (Lwoff et al., 1962). The herpesviruses are large in
comparison to most animal viruses; at 100-150 nm in diameter,
only the poxviruses are larger (Fenner, 1968).
The genome of CMV is larger than that of most other
herpesviruses, being approximately 150 x 10" daltons in
molecular weight as determined by sedimentation rates in
sucrose density gradients and contour length measurements by
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electron microscopy (De Marchi et al.. 1978; Geelen et al.,
1978; Kilpatrick & Huang, 1977; Stinski et al., 1979a). The
DNA of other herpesviruses is typically 90-100 x 106 daltons
(Becker et al., 1968; Soehner et al., 1965). Smaller DNA
molecules of about 100 x 106 daltons predominate in many CMV
preparations but these are genetically incomplete and
probably non-infectious (Kilpatrick & Huang, 1977; Stinski et
al., 1979a). Restriction endonuclease (RE) analysis of the
genome indicates the presence of four isomeric forms as some
fragments are present in quarter-molar amounts (Kilpatrick &
Huang, 1977). This is best explained by considering the
genome as consisting of two unique sequences, one longer than
the other, each of which is bounded by inverted repeat
sequences. These repeats permit each segment to lie in either
orientation relative to the other segment, RE fragments
generated from the joint region being those found in submolar
amounts. The isomeric variants probably arise during the
replication process. A similar genome organisation is
observed with HSV (Hayward et al., 1975b). With some other
herpesviruses only one or two isomers exist (Honess & Watson,
1977).
The CMV genome consists of approximately 2U0 kilobase
pairs and has considerable coding potential. It is known to
specify at least 23 non-structural polypeptides involved in
modulating host cell metabolism and viral replication (to be
discussed subsequently) and at least 33 virus-specified
structural polypeptides (i.e. associated with the free
virion) have been identified to date (Kim et al., 1976). The
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same number of structural proteins has been reported for HSV
(Heine et al., 1974) and EBV (Dolyniuk et al., 1976).
Although these proteins are predominantly structural in
function, some enzymatic functions are associated with free
virions (Mar et al., 1981) which may conceivably play some
role in viral entry and initiation of replication. At least
eight of the structural proteins are glycosylated and these
are associated with the viral envelope (Stinski, 1976).
Given that the lipid component of the viral envelope is
derived from cellular membranes (Kanich & Craighead, 1972b;
Smith & De Harven, 1973) it is perhaps surprising that
cytomegalovirions appear to contain no host cell
polypeptides; antisera raised against purified virions do not
react with uninfected cells (Oefinger & Arenius, 1983;
Stinski, 1976). It is suggested that the presence of viral
proteins in the membrane or on the surface of the capsid as
it associates with the membrane sterically precludes the
presence of other proteins in the membrane in the vicinity
where envelopment occurs.
Variation in composition
The functional integrity of proteins are dependent on
their amino acid sequence and conformation. Nevertheless,
some degree of variation is frequently possible without
substantial loss of function. Variation in CMV proteins can
be demonstrated at two levels: the base composition of the
DNA that encodes the proteins, and in the proteins themselves.
Variation in base composition of CMV DNA has been
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demonstrated in two ways. The extent of DNA-DNA reassociation
between heterologous strains of virus is usually less than
that of the homologous strain and the percentage
reassociation (relative to the homologous DNA) is an
expression of the similarity of the two DNA types. Huang et
al. (1976) demonstrated more than 80% reassociation between
Ad 169 strain and all other human CMV's tested except strain
Colburn, which, although a human isolate (Charamella et al.,
1973). bears more resemblance to simian CMV strains (Huang et
al., 1978; Kilpatrick et al., 1976). The technique is useful
for distinguishing human CMV from non-human strains and other
herpesviruses which show no significant DNA-DNA reassociation
(Huang & Pagano, 1974).
Differences in DNA base composition are also reflected
in the number and size of fragments generated by RE digestion
of DNA, which is visualised by polyacrylamide gel
electrophoretic separation (PAGE) of the restricted DNA.
Unrelated human CMV isolates have similar but non-identical
cleavage patterns (Kilpatrick et al ., 1976) which are again
useful for distinguishing CMV from other herpesviruses and
have also been used epidemiologically to determine paths of
transmission of infection (Huang et al., 1980; Spector et
al., 1983).
Inter-strain variation in the composition of viral
proteins can be detected as slight differences in the PAGE
profiles of the proteins (Gupta et al.. 1977) or, more
commonly as differences in antigenicity. Antigenic variation
is apparent as differences in neutralisation of infectivity
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kinetics between homologous and heterologous strains
(Andersen, 1970; Waner & Weller, 1978; Weller et al., i960),
in complement fixation (CF) testing using different strains
as antigens (Huang et al., 1976; Medearis, 1964) and as
differences in the lymphocyte proliferative response of
immune individuals to different strains (Beutner et al.,
1978; Gartner et al., 1982b). No strain differences have been
detected by indirect immunofluorescene (IIF) with IgM
antibody (Gartner et al., 1982a).
Several investigators have attempted to exploit the
above differences in virus composition as a means of
classifying or subgrouping human CMV isolates. Waner & Weller
(1978) and Weller et al. (i960) have suggested that
reciprocal cross-neutralization kinetics may provide a basis
for such a grouping. Differences in RE cleavage patterns are
probably too small and too continuous to be useful in this
respect. Certainly, no subgrouping comparable with that of
HSV is possible, where HSV type 1 (HSV 1) and HSV 2 show only
40% DNA homology by reassociation kinetics (Kieff et al.,
1972), are readily distinguishable on the basis of PAGE
profiles of RE digested DNA (Hayward et al., 1975a) and form
two distinct serotypes (Pauls & Dowdle, 1967). In contrast,
EBV isolates show little variation in their DNA composition
(Kawai et al. (1973) or antigenic properties (Gerber et al.,
1976). The significance of variability in CMV proteins will
be discussed in later sections.
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The CMV replication cycle
The CMV in vitro replication cycle proceeds efficiently
to completion only in human fibroblasts (Rowe et al.. 1956).
Human epithelial cells (Figueroa et al.. 1978; Knowles, 1976;
Vonka et al„ 1976), peripheral blood leukocytes and
lymphoblastoid lines (Furukawa et al., 1979; St. Jeor &
Weisser, 1977) yield only very low titres of infectious
virus. A variety of other human and non-human cell types
permit limited expression of the viral genome, but no
detectable viral DNA (vDNA) replication or progeny virus
release occurs (De March!, 1983b; Einhorn et al., 1982;
Einhorn & Ost, 1984; La Femina & Hayward, 1983).
CMV replicates slowly in fibroblast culture in
comparison with many other herpesviruses (Rapp & Benyesh-
Melnick, 1963). At high moi the growth cycle of a typical
laboratory strain lasts 7-8 days from initiation of infection
to destruction of the cell monolayer, whereas that of HSV
lasts 1-2 days (Smith & De Harven, 1973). Following entry of
virus into a permissive cell type (i.e. one which allows the
complete viral replication cycle to take place, giving rise
to infectious progeny virus) the events can be grouped into
three distinct, chronological phases; immediate early (IE),
early and late phases (De Marchi et al., 1980) which are
broadly analogous to the three phases of HSV replication
(Honess & Roizman, 1974). Proteins synthesised in the IE
phase regulate the synthesis of early proteins (Wathen et
al., 1981; Stinski et al., 1982). Both these classes of
proteins are synthesised before vDNA replication takes
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place and In the presence of Inhibitors of DNA synthesis.
Late protein synthesis only occurs after vDNA replication is
initiated (Stinski, 1978). Towards the end of the growth
cycle virus particles at various stages of maturation are
present in infected cells and infectious virus can be
detected in the culture medium (Kan i ch & Craighead, 1972b).
Entry of virus into cells
The adsorption of CMV to cell membranes and its
subsequent penetration has been studied electron
microscopically by Smith & De Harven (197^). Adsorption of
both enveloped and naked particles occurs, and a variety of
human and non-human cell types are capable of adsorbing
virions (Einhorn et al„ 1982). This is similar to the
adsorption of HSV, which has been likened to the uptake of
inert particles (Epstein et al., 1964-) but is in sharp
contrast to the adsorption.of EBV which is mediated by a
receptor possibly unique to B lymphocytes (Jondal & Klein,
1973). There may however be adsorption mechanisms in addition
to non-specific interactions as enveloped CMV particles are
adsorbed preferentially over naked particles, and enveloped
particles adsorb far more efficiently to some cell types than
to others.
Adsorption of virus is rapidly followed by entry of
virus into the cytoplasm. This may be direct, by fusion of
the viral envelope with the plasma membrane, or indirect, by
phagocytosis of the virions, singly or in groups, followed by
fusion of the viral envelope with the membrane of the
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phagosome (Smith & De Harven, 1974). Thus although non-
enveloped particles can adsorb to the cell membrane and be
phagocytosed they cannot enter the cytoplasm and are degraded
on phagolysosome formation.
Within minutes of entering the cytoplasm viral particles
are transported towards the nucleus and accumulate in the
Golgi region and around nuclear pores. Up to this point, CMV
and HSV particles behave similarly. However following entry,
HSV nucleocapsids are rapidly disassembled and few can be
seen two hours after penetration whereas CMV nucleocapsids
appear to become coated following entry and retain their
characteristic morphology for up to 36 hours (Cavallo et al„
1981; Smith & De Harven, 1974). This may play a part in
extending the time scale of the CMV growth cycle over that of
HSV.
Immediate early events
Within the first hour of infection a group of infected
cell-specific polypeptides (IC-SP) can be detected by indirect
immunofluorescence in the nuclei of infected cells
(Michelson-Fiske et al., 1977). These immediate early
antigens (IEA) are defined as those ICSP's whose mRNA's are
transcribed in the absence of de novo protein synthesis and
are translated immediately on the removal of a cycloheximide
protein synthesis block. They are encoded by the viral genome
(De Marchi, 198I; Wathen et al., 1981). The presence of these
proteins so shortly after the initiation of infection must be
reconciled with the fact that CMV nucleocapsids remain intact
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within the cytoplasm for much longer periods. It is possible
that only a few nucleocapsids undergo disassembly, making the
vDNA available as a transcriptional template and that those
particles present at later times do not contribute to the
replicative cycle, at least in the earlier stages.
Nine predominant IE proteins have been identified by
PAGE to date (Wathen et al., 1981); the genes for these
proteins have been mapped by hybridisation with labelled IE
mRNA to Southern blots of restricted vDNA and are located
primarily within restricted regions of the genome.
Transcription of the remainder of the genome would appear to
be blocked at this stage (Wathen et al.. 1981; Wathen &
Stinski, 1982).
The function of the IE proteins is only partially
understood; none are incorporated into progeny virions
(Stinski, 1978). Since proteins synthesised in the first two
hours of infection control the transcription of early mRNA
(De Marchi, 1981; Wathen et al., 1981) it is likely that IE
proteins with or without additional host cell functions
effect this regulation. The finding that interferon (IFN)
pretreatment of infected cells, which selectively inhibits
vmRNA translation also results in reduced early mRNA
transcription (Stinski et al., 1982) enforces this view. The
function of the corresponding proteins of HSV (the cx proteins)




Approximately six hours after infection the synthesis o
most IE proteins terminates although some are expressed
constitutively (Jahn et al., 1984). A second group of non¬
structural proteins, the early proteins appear in infected
cells at this time (Wathen et al., 1981). In common with the
IE proteins, they are synthesised in the absence of vDNA
replication (Stinski, 1978). At least 16 early proteins have
been detected by radioimmunoprecipitation (Blanton &
Tevethia, 1981). IE mRNA continues to be synthesised at early
times but early mRNA is preferentially translated, possibly
due to retention of IE mRNA in the nucleus (Wathen & Stinski,
1982). Transcription of early mRNA occurs from most regions
of the genome, the block operative at IE times having been
reversed, probably by an IE function (De Marchi, 198I; Wathen
et al., 1981; Wathen & Stinski, 1982). Together with the IE
transcripts, the early mRNA's account for about 12% of the
coding capacity of the genome (Stinski, 1978). In contrast to
most IE mRNA's transcription and translation of early mRNA if
sustained and continues into the late phase (Wathen &
Stinski, 1982). In common with most IE proteins, most early
proteins accumulate in the nucleus (Reynolds, 1978). However
at least one early protein associates with the plasma
membrane (Tanaka et al., 1981).
During the early phase a number of changes take place
infected cells which are attributed to the activity of IE or
early proteins. Around the onset of the early phase the
fibroblastic morphology is lost and infected cells assume a
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rounded shape (Cavallo et al., 1981; Furukawa et al., 1973;
Smith & De Harven, 1973) possibly due to the inhibition of
fibronectin synthesis (Ihara et al., 1982). This process is
dependent on de novo protein synthesis but independent of
vDNA synthesis and host cell viability, and only occurs at
high moi. This early cytopathic effect (CPE) often appears as
focal lesions in the cell sheet but can be more generalised
at higher moi (Kanich & Craighead, 1972a), Where the virus is
poorly adapted to growth in cell culture and the inoculum is
small, as is usually the case with clinical sources of virus,
development of this CPE is delayed for several days or weeks
(Weller et al., 1957), It is probable that several rounds of
replication are required to generate a sufficient titre.
At the same time as the appearance of early CPE, early
nuclear inclusions are visible by electron microscopy as
electron-dense spherical bodies with electron-lucent cores.
These subsequently mature, the central areas becoming
compartmentalised by the electron-dense material, and
probably form centres of vDNA replication and, later on,
nucleocapsid assembly (Cavallo et al„ 1981).
Clumping and margination of host cell chromatin takes
place, but is transient (Cavallo et al., 198I; Ruebner et
al., 1965) unlike HSV-infected cells which show chromatin
reorganisation throughout the replication cycle (Smith & De
Harven, 1973). This organisation of chromatin may be similar
to the genetically inactive heterochromatin of highly
differentiated cells (Berlowitz, 1965; Frenster et al.,
1963); certainly HSV infection is associated with decreased
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cellular macromolecular synthesis (Roizman et al., 1965). In
contrast CMV infection results in a general stimulation of
cellular metabolism, with induction of cellular DNA
polymerase (Hirai & Watanabe, 1976) and thymidine kinase
(Estes & Huang, 1977). increased cellular DNA synthesis (St.
Jeor et al., 197^-) and chromatin template activity (Kamata et
al.. 1978) and increased synthesis of cellular RNA (Tanaka et
al., 1975) and protein (Stinski, 1977). Although these
increases are not always detectable early in infection they
are dependent on virus-coded early functions. In productively
infected cells stimulation of host DNA synthesis is shut down
before it reaches detectable levels (De March! & Kaplan,
1977a). This shutdown is accomplished by early gene
function(s) (De Marchi, 1983a) but frequently does not occur
in cells in the Go or Gi phase of the cell cycle as a result
of contact inhibition or serum starvation. Such cells
synthesise cellular DNA at an increased rate but do not
express detectable amounts of viral antigen, or release
progeny virus (De Marchi & Kaplan, 1977a).
In one non-permissive cell type in contrast, host DNA
synthesis is stimulated and most but not all early antigens
are expressed (De Marchi, 1983b). Those not expressed
presumably include those responsible for shutdown of cellular
DNA synthesis. Another early gene function expressed in
productively infected cells is a viral DNA polymerase (Huang,
1975a). Unlike HSV and VZV, CMV does not encode a viral
thymidine kinase (Miller et al., 1977) and vDNA synthesis is
probably dependent on increased expression of the cellular
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thymidine kinase. Thus the way in which IE and early gene
functions are expressed plays a major part in determining the
outcome of infection. The incomplete viral replication cycle
that takes place in non-permissive cells and non-productively
infected permissive cells may be achieved by modulating the
expression of one or more of these genes. This may result in
cell death from subversion or inhibition of cellular
biosynthetic apparatus by viral macromolecules (Riepenhoff-
Talty & Flanagan, 1982), or in the elimination of virus.
Human CMV infection of mouse (La Femina & Haywood, 1983) or
guinea pig cells (Fioretti et al., 1973) usually results in
limited IE and early protein synthesis but no vDNA
replication, and vDNA and antigens are undetectable 24-4Sh
after infection.
Late events
The late phase of the CMV replication cycle begins with
the onset of vDNA synthesis. This is detectable 15-24h post
infection depending largely on the sensitivity of the
detection method (Goodheart et al., 1964; Stinski, 1978; St.
Jeor & Hutt, 1977). In HSV-infected cells vDNA synthesis
begins around 6h post infection (Levitt & Becker, 1967), the
period when (2> proteins are synthesised most abundantly
(Honess & Roizman, 1974). The extended early phase and delay
in vDNA replication in CMV-infected cells accounts in part
for the longer growth cycle. This may be because one or more
events in the early phase proceeds slowly or inefficiently.
Alternatively, there may be little vDNA present in the
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nucleus to act as a template for vDNA synthesis due to the
inefficiency of disassembly of input virus.
Prior to, or during vDNA replication some of the genomes
lose their linear form and become "endless", either by
circularisation, concatemerisation or, less likely, by random
integration into cellular DNA (La Femina & Haywood, 1983). It
is not known if only one or both genomic forms contribute to
the replicative pool, however endless forms are not
detectable in at least one non-permissive cell type,
suggesting that their presence is associated with a complete
replication cycle. Circular and concatameric genomes are a
feature of the rolling circle DNA replication mechanism
(Gilbert & Dressier, 1968) which could allow isomeric
variants of the genome to be generated during cleavage of the
concatamer, as has been demonstrated in HSV DNA replication
(Jacob et al., 1979). vDNA synthesis continues throughout the
late period, peaking at 24-36h post infection then increasing
again from ii8-72h post infection (Stinski, 1978; St. Jeor &
Hutt, 1977). This biphasic pattern of DNA synthesis is
consistently observed. The first peak may serve to increase
the pool of template molecules for subsequent rounds of
replication after a period of late gene transcription
(Cavallo et al., 1981).
Early genes are still expressed during the late period
and may be responsible for the continuous replication of vDNA
as proposed by Wathen & Stinski (1982). The presence of these
proteins is however increasingly overshadowed by that of the
late proteins, which are synthesised sequentially and in
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proportion to the extent of vDNA synthesis (Stinski, 1978).
While vDNA synthesis proceeds and late proteins, which
include the structural proteins, accumulate in the nucleus,
the CPE develops further. Infected cells assume a
fibroblastic or epithelial morphology but are still
considerably larger than uninfected cells, and
polykaryocytosis is occasionally observed (Albrecht et al.,
1980a; Cavallo et al., 1981; Smith & De Harven, 1973). Early
in the late phase (2ih post infection) a large cytoplasmic
inclusion visible by light and electron microscopy is
sometimes observed which displaces the nucleus, causing it
to take on an elliptical or reniform shape (Albrecht et al.,
1980a; Kanich & Craighead, 1972a; Smith & De Harven, 1973).
This inclusion appears to consist of accumulated Golgi and
other organelles possibly involved in viral protein
synthesis, but is clearly not essential for virus production
which can proceed in its absence (Kanich & Craighead, 1972a).
The nuclear inclusion, which was present during the
early phase becomes larger and better defined in the late
phase (Cavallo et al., 1981) and is visible by light
microscopy in fixed, stained cells (Albrecht et al., 1980a).
It continues to develop and by i8h post infection is
compartmentalised into a number of electron-lucent areas
separated by a meshwork of electron-dense fibrillar material
(Cavallo et al., 1981). These may be areas of vDNA synthesis
surrounded by accumulated viral structural proteins.
Capsids and nucleocapsids first appear in the nucleus
around this time and are found particularly around and within
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the nuclear inclusion (Cavallo et al., 19Sl; Smith & De
Harven, 1973). These particles increase in number over the
next 2Lh and also begin to appear in the cytoplasm (Kanich &
Craighead, 1972b). Particles enter the cytoplasm by budding
into the perinuclear cisterna and from there into vacuoles
formed by evagination of the outer lamina, or into the
cytoplasm via the rough endoplasmic reticulum. Naked
nucleocapsids are also present in the cytoplasm, possibly
arising from fusion of the membrane acquired at the inner
lamina of the nuclear membrane with the outer lamina.
Particles which do not retain the membrane acquired at the
inner nuclear lamina become enveloped by budding into
cytoplasmic tubules and vesicles.
Later on in the late phase electron-dense bodies of
variable size arise in the nucleus and bud into the cytoplasm
in the same way as viral particles (Kanich & Craighead,
1972b; Sarov & Abady, 1975). These dense bodies probably
consist of excess, abberantly assembled structural proteins
without a DNA core.
Late cytoplasmic inclusions arise late in infection
(Kanich & Craighead, 1972a), some comprised of naked
nucleocapsids and dense bodies, others of enveloped viral
particles associated with cytoplasmic membranes and
organelles.
Free virus appears in the extracellular environment from
120h onwards (Kanich & Craighead, 1972a; Smith & De Harven,
1973). Virus probably leaves the cytoplasm via vacuoles
formed from cytoplasmic tubules and vesicles, which then fuse
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with the plasmalemma, releasing virus into the exterior. Cell
lysis does not appear to play an important part in release of
infectious virus, except perhaps at very late times (7-8
days; Smith & De Harven, 1973). Cell lysis at earlier times
frequently occurs with low passage, wild virus isolates but
little infectious virus is released during this process
(Kanich & Craighead, 1972a).
Persistent CMV infections
The ability of herpesviruses to persist in the host
without any overt virus replication for long periods of time
has led numerous investigators to study persistent infection
in culture in an effort to explain this phenomenon in
biochemical terms. In vitro persistent infections have been
established, although mainly in cells of a different type or
species from those infected in nature. The relevance of these
laboratory phenomena to persistent infection in the natural
host is debatable but what has become apparent is that the
replication cycle of herpesviruses can be blocked at a number
of stages, the result of which may be a persistent infection.
For the viral genome to persist it must replicate at
least as often as cellular DNA. This may be accomplished by
autonomous replication or by integration into a cellular
chromosome. Expression of late antigens and virus production
need not be an essential feature of persistence and once the
DNA synthesis necessary to establish the persistent state has
occurred, expression of IE and early genes may also cease.
EBV is well known for its ability to persist in vitro
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(Zur Hausen et al., 1972). Persistently infected cells are of
an immortalised phenotype. The viral genome persists in an
episomal form, as it does in lymphoblastoid lines established
from Burkitt's lymphoma tissue (Lindahl et al., 1976) and
also occasionally in an integrated form (Anderson-Anvret &
Lindahl, 1978). Expression of the genome in these cell lines
is variable; some, termed producer lines express viral
structural antigens and release varying amounts of infectious
virus. Other non-producer lines exhibit a more restricted
expression of the viral genome (Epstein & Achong, 1977).
The first persistent CMV infection to be established in
vitro was in hamster fibroblasts which had been exposed to
ultraviolet inactivated virus (Albrecht & Rapp, 1973). Cells
thus infected were of a transformed phenotype and induced
tumours in hamsters. Only a proportion of the transformants
expressed late antigens and infectious virus could not be
rescued. This suggests that an incomplete viral genome
persisted in these cells. Around the same time, similar
experiments were performed with HSV 1 and HSV 2 (Duff & Rapp,
1971; 1973).
More recently transformation of human fibroblasts has
been achieved using an unusually slowly replicating CMV
isolate (Geder et al., 1976). Inactivation of virus was not
necessary in this case, however infectious virus could not be
rescued. This too is suggestive of persistence of a defective
viral genome.
Boldogh et al. (1977) have described a persisent human
CMV infection of mouse cells in which no early antigens were
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detectable, suggesting that the genome was replicated,
possibly in an integrated form by host cell enzymes. As such
this may represent a truly latent infection. The complete
genome persisted; antigen expression could be regained by
fusion of the infected cells with permissive human cells and
virus production was observed on treatment of the
heterokaryons with the base analogue 5-iodo-2' deoxyuridine.
Gadler & Wahren (1983) established a persistent
infection in fibroblasts in the presence of phosphoformic
acid, which selectively inhibits vDNA polymerase. Viral
sequences were associated with high molecular weight species
of DNA which had a density close to that of cellular DNA. The
complete genome may have become integrated into cellular DNA.
The resumption of virus production on removal of the
inhibitor, even after long periods of culture indicates that
it persisted by some means.
Of these persistent infections, those from which
infectious virus can be recovered are potentially useful as
models of in vivo persistence. Others may be relevant in
considering the possible oncogenic role of CMV. It is evident
that the viral replication cycle may be aborted at various
stages. Factors which bear upon this are the nature of the
infecting virus, the cell type and the metabolic state of the
cells. Other factors which may exert additional influences in
the host are the presence of immune functions, of hormones




EPIDEMIOLOGY OF CMV INFECTION
The epidemiology of CMV infection can be studied by
monitoring either the prevalence of current virus excretion or
of CMV-specific antibody. Current infection in the individual,
which may or may not be primary, is frequently demonstrable by
detecting virus in body tissues, fluids and excretions, and by
measuring the developing immune response to the virus.
Most individuals who have experienced infection in the
past are readily recognised by virtue of the long term
persistence of specific immune functions, most obviously the
presence of serum IgG antibody. Such seropositive individuals
comprise what is often referred to as the immune population.
The term "immune" should not be taken to mean insusceptible to
further active CMV infection; it merely indicates that
virus-specific immune functions are demonstrable. Individuals
with long-standing immunity to CMV can occasionally be shown to
be excreting virus. This infection may be local, where virus is
shed from one anatomical site only or may be generalised,
usually in patients who are immunodeficient or
immunosuppressed. It is frequently impossible to determine
whether this virus excretion is due to persistence of active
viral replication for months or years following primary
infection, reactivation of endogenous latent infection, or
reinfection from an exogenous source. Huang et al. (1980)
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compared serial isolates from women and from their congenitally
infected infants by restriction endonuclease analysis and found
that isolates from the same woman or from mother-infant pairs
were nearly always genetically related, even when isolations
were up to seven years apart. Thus reinfection could be
excluded as a cause of viral excretion and subsequent
intrauterine transmission in seroimmune women in most cases.
In addition, there is evidence that reactivated infection,
that is viral replication following an apparently
non-productive phase of infection, can also occur. In pregnant
women the frequency of isolation of virus increases with
increasing gestational age (Montgomery et al., 1972; Reynolds
et al.. 1973) although this may actually be dueto a reduced rate
of excretion early in gestation compared with nonpregnant women
(Stagno et al., 1973a)- This pattern of excretion, together
with the predominance of shedding from the cervix alone and the
stability of antibody titres suggests that this type of
infection is the result of localised, reactivated virus
replication which is in some way influenced by maternal
physiological factors. Knowles et al. (1982) in studying
cervical excretion in non-pregnant women found that the
majority of women who shed virus did so during the first half
of the menstrual cycle. Excretion for such a brief period which
again appears to be influenced by physiological factors will be
further evidence that reactivation of infection can occur, if
this limited survey is confirmed on studying larger numbers.
Further evidence for reactivation of infection comes from
studies of infection in allograft recipients and is discussed
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below. The actual frequency with which reactivation occurs in
healthy adults is unknown as the infection is asymptomatic.
Figures of U-lk% for pregnant and post partum women (Knowles et
al., 1982; Montgomery et al., 1972; Reynolds et al., 1973;
Stagno et al.. 1975a) must be regarded as minimums as isolation
can only be attempted on a limited number of occasions and
excretion resulting from reactivated infection may be transient
or Intermittent. In the above studies there was noted a general
trend towards a lower frequency of excretion in older and more
multiparous women. Although clinically inapparent, reactivated
infection is of epidemiological significance in congenital and
perinatal transmission of infection and probably in other
transmission routes also.
Human CMV infection is ubiquitous in all populations
(Krech, 1973) and can occur at any age. Infection can be
transmitted by various routes, some of which are important in
particular groups of individuals where infection may be
associated with pathological syndromes. These infection routes
and the clinical features sometimes associated with them are
described below. A discussion of the pathogenesis of infection
in different clinical settings is reserved for the following
chapter.
CMV infection in infancy
Exposure to CMV in infants who have not been infected in
utero may begin during delivery if virus is present in the
birth canal. Infants infected from this source usually begin to
excrete virus three to twelve weeks after birth (Reynolds et
al.. 1973). Excretion of virus occurs in about 10% of women at
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some time during pregnancy and usually begins late in
gestation, continuing into the post-partum period (Stagno et
al., 1975a)- The frequency of infection in the newborn
developing during the post-natal period is higher when maternal
cervical excretion occurs close to term; when excretion occurs
in the third trimester and in the post partum 57% of infants
become infected postnatally, compared to 12.5% when maternal
excretion occurs in the first or second trimester, and less
than 1% when mothers do not excrete or shed virus only in urine
or saliva (Reynolds et al.. 1973; Stagno et al.. 1980).
The other main mode of transmission of infection to the
neonate is breast feeding. Excretion of virus in colostrum and
milk is more common than excretion from any other maternal
site. Stagno et al. (1980) found a minimal excretion rate of
13% in one population and 30% of seropositive mothers may
excrete from this site during the nursing period (Dworsky et
al., 1982). The incidence of neonatal infection among infants
fed infective breast milk is high: 58% and 82% respectively in
the cohorts studied by Stagno et al. (1980) and Dworsky et al.
(1982). In a community where most mothers were seropositive
(98%) and most breast fed their offspring (88%) Stagno et al.
(1982a) found that *10% of infants became infected during the
first year of life. This population is typical of many in
developing nations. The high prevalence of past infection in
the adult population and of breast feeding among mothers
undoubtedly accounts to a large extent for the relatively high
infection rate within the first year of life in these
communities; figures as high as 92% have been observed in other
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underdeveloped countries compared wth 3~5% in communities with
a high standard of living (Krech & Tobin, 1981).
The effect of CMV infection during the first year of life
may be minimal, except in those born prematurely or with some
other condition where the outcome may be fatal (Gurevich et
al., 1981). Viral excretion continues for at least three years
(Stagno et__al.,1975b) but many infants remain asymptomatic
throughout (Reynolds et al., 1973). Mild symptoms consisting
mainly of respiratory infection or hepatosplenomegaly have been
associated with the onset of infection in about a third of
cases however (Kumar et al., 1975).
The prevalence of antibody to CMV in the population
continues to increase with age beyond the neonatal period
(Carlstrom, 1965; Krech & Tobin, 1981; Rowe et al., 1956; Stern
& Elek, 1965; Weller et al., 1957). The rate at which this
age-related increase proceeds varies considerably between
countries and between communities within countries: in most
third world countries the rate of exposure approaches 100% by
the fourth year of life, whereas in many developed nations the
prevalence in this age group is k%.
The high frequency of exposure during infancy in
underdeveloped nations is usually attributed to the
socioeconomic factor; most of the population lives under
crowded conditions and poor hygienic standards. Evidence from
at least two sources suggests that the former of these is the
more important determinant. Sarov et al. (1982) working in
southern Israel found a higher than expected number of
seroimmune children in kibbutz communities where hygienic
standards are relatively high but contact between children is
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constant. 76% of these children between one and two years of
age were seropositive whereas only 5&% of this age group had
antibody in urban communities. A significant difference in
antibody prevalence was observed among children from urban
communities when grouped according to the extent of crowding in
living quarters. In addition, the same investigators studied
exposure to CMV among children in a nomadic community living
under poor hygienic conditions and found that the major
age-related increase in exposure coincided with the start of
schooling, when the frequency of contact with other children
increased.
The other evidence linking close contact to CMV infection
rates in infants comes from the observations of Pass et al.
(1982a) who found an extraordinarily high incidence of viral
shedding (59%) in children attending day care centres, most of
whom came from a high socioeconomic background. Saliva was
frequently infective and this was deemed the most important
vehicle of transmission, either directly between infants or via
contaminated inanimate fomites. A relatively high prevalence of
past infection is observed in infants in Sweden (Carlstrom,
1965; Carlstrom & Jailing, 1970) despite its reputation as
having the highest living standard in the world. Weller (1971)
has suggested that this may be due to the widespread use of
nurseries in that country.
Community-acquired CMV infection in young children is
similar to maternally acquired neonatal infection in some
respects. Viral excretion is prolonged - for up to two years
following infection. The long term effects appear to be
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negligible but respiratory illness may be associated with viral
excretion (Stern, 1968).
Community-acquired CMV infection after infancy
In developed nations where a high percentage of the
population escape infection in early life, a significant
increase in the infection rate often begins in the adolescent
years and continues into adulthood (Collaborative study, 1970;
Krech & Tobin, 1981). The prevalence of antibody in the
population is 20-25% at the onset of puberty, rising to 50-60%
in the fifth and sixth decades of life (Carlstrom, 1965; Stern
& Elek, 1965). Considerable circumstantial evidence links this
to the onset of intimate salivary and sexual contact in this
age group. Virus can be found in saliva (Falx et al., 1893a;
Weller, 1971), semen (Biggar et al., 1983: Lang & Rummer, 1972;
1975; Lang et al., 1974), and cervical secretions (Faix et al.,
1983a; Knowles et al., 1982; Stagno et al., 1975a). CMV
infection occurs more frequently in women undergoing
examination for suspected sexually transmitted disease (STD)
compared to women examined for other reasons, both in terms of
cervical excretion frequencies (13% versus 0% respectively) and
antibody prevalence (83% versus 50% respectively; Jordan et
al., 1973). Infection is also more common in those, both male
and female, with a past history of gonorrhoea. 90% of these
patients are seropositive compared to about 60% of other STD
clinic patients (Jordan et al., 1973; Mindel & Sutherland,
1984). In addition, CMV infection is highly prevalent in
homosexual men, who are frequently more promiscuous than
heterosexuals. 76-94% of homosexuals have antibody, compared to
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around 50% of heterosexuals, and up to 8% of the former may be
viruric at any one time; viruria is rarely detectable in
heterosexuals (Drew et al., 1981; Goldmeier et al.t 1983;
Mindel & Sutherland, 1984; Mintz et al., 1983).
Primary CMV infection during adolescence and adulthood is
probably most frequently asymptomatic, but may on occasion
present as a mononucleosis-like syndrome clinically similar or
indistinguishable from that caused by primary EBV infection
(Klemola & Kaarianen, 1965). CMV is responsible for about half
of heterophile-negative cases of mononucleosis in over 15 year
olds (Klemola et al., 1969).
The prevalence of past infection continues to increase
with age at an estimated mean rate of 2% per annum until the
age of 50 (Kane et al., 1975). After this age there is a
reduced chance of acquiring CMV infection and in developed
nations 20-40% of the population may escape infection
altogether (Carlstrom, 1965; Stern & Elek, 1965).
Individuals who have immunity from past CMV infection may
be reinfected upon subsequent re-exposure. This may be more
likely when antigenic differences between the reinfecting
strain and the original strain to which immunity is directed
are significant. The in vitro immune response of seropositive
individuals is quantitatively and qualitatively different when
measured against different strains of virus as discussed in
Chapter I. This may be reflected in vivo by reduced
susceptibility to infection with a heterologous strain as
compared to the homologous strain. Huang et al. (1980)
identified two women in whom CMV isolates were genetically
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distinct from previous isolates from the same woman in one case
and from the congenitally infected infant of the other woman -
strong evidence of reinfection with different strains of virus.
Viral excretion in sexually active adolescents and young adults
may be due in part to reinfection resulting from frequent
exposure, although persistence or reactivation of the primary
infection may also be responsible.
Age, socioeconomic status, particularly with respect to
the extent of crowding in living quarters, and degree of sexual
activity then emerge as major factors that influence the
probability of CMV infection occurring or having occurred in
the past. There is no evidence that climate influences the
transmission rate of CMV (Krech, 1973). The possibility that
genetic factors may be of significance in this respect is
largely unexplored. Differences of this nature between racial
or ethnic groups may influence susceptibility to infection or
the extent and duration of viral shedding which would in turn
affect the size of the reservoir of infection. Luby & Shasby
(1972) reported a highly significant sex difference in the rate
of seropositivity; only 33% of males had antibody compared to
55% of females. As others have found no such association (Stern
& Elek, 1965), this may be due to social factors peculiar to
the population studied, for example, greater contact between
women and infants who may be excreting virus. Infected infants
are thought to be an important source of infection for
seronegative parents, particularly mothers, in other
communities (Stagno et al„ 1984; Yeager et al., 1982).
The epidemiological behaviour of community-acquired CMV
infection is similar to some extent to that of EBV and HSV 1
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infection. The prevalence of both these herpesvirus infections
increases with age and is influenced by socioeconomic factors.
The influence of sexual activity is less prominent than with
CMV infection however. Where the standard of living is high the
proportion with antibody to HSV-1 increases from 20% in early
infancy to 97% in those over 60 years old (Smith et al„ 1967).
Among poorer communities as many as 71% are seropositive by the
second year of life and 90% of over 15 year olds have
experienced infection in the past (Buddingh et al., 1953). The
EBV infection rate is 20% by the second year of life in most
western nations, and reaches 70-90% in the adult population
(Henle & Henle, 1979). In many third world countries by
contrast, over 80% of the population are seropositive by the
age of two years, and by the sixth year the figure approaches
100% (Henle et al„ 1969). The reason for the greater frequency
of Infection with HSV-1 and EBV compared to CMV infection is
not known but may be due to differences in infectivity and a
greater dependence on close person to person contact for
transmission of CMV infection to occur. This may account for
the closer relationship between CMV infection and sexual
contact than is observed with other herpesvirus infections.
Congenital CMV infection
A prorportion of infants are found to have CMV infection
at birth. Such congenital infection is acquired from the mother
and can be diagnosed by isolating virus from the infant within
one week of birth, or detecting specific IgM antibody in the
cord serum.
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The clinical spectrum observed in congenitally infected
infants is broad. Many are apparently healthy and infection
would be unrecognised in the absence of laboratory evidence,
however a proportion of these infants show signs of some degree
of central nervous system (CNS) damage during follow up
(Peckham et al„ 1983; Reynolds et al., 1974; Starr et al„
1970). Others have mild symptoms which usually include
hepatosplenomegaly and slight disturbance of liver function
during the neonatal period (MacDonald & Tobin, 1978; Montgomery
et al., 1980). Cytomegalic inclusion disease at its most severe
is manifest by a range of symptoms and abnormal laboratory
tests including hepatosplenomegaly, liver dysfunction,
Jaundice, petechial haemorrhages, thrombocytopenia, leukopenia,
pneumonitis, microcephaly, cerebral calcification, motor and
sensorineural dysfunction and mental retardation. Those who
survive this rare syndrome usually suffer severe and permanent
CNS damage (McCracken et al.. 1969; Medearis, 1964; Weller &
Hanshaw, 1962). In all however, 7-10% of congenitally infected
infants may be left with serious brain damage (Hanshaw, 1971;
Peckham et al., 1983) and many more may be left with subtle
mental deficiencies resulting in poor educational progress or
behavioural problems (Williamson et al., 1982). Those with
symptoms attributable to congenital CMV infection at or shortly
after birth generally have a poorer long term prognosis in this
respect. Virus is commonly excreted in the urine of
congenitally infected infants for up to four years and
occasionally for even longer (Stagno et al., 1975).
Infection of the foetus may be more likely to occur when
maternal infection occurs late in pregnancy (Griffiths &
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Baboonian, 1984b; Nankervis et al., 1984) and may also be more
severe at this stage of gestation (Monif et al.. 1972) but
further investigation is required in this area as other groups
have failed to demonstrate such an association (Griffiths et
al., 1980; Stagno et al., 1982b). One problem is that very
large numbers of pregnant women must be closely monitored in
order to demonstrate a statistically significant relationship
between gestational age at the onset of infection and
Involvement of the foetus. Long-term collaborative work will
probably be necessary to this end.
By contrast, there is considerable evidence to support the
hypothesis that congenital infection is more likely and is
associated with greater morbidity and mortality when acquired
as a result of primary maternal infection. Congenital CMV
infection follows primary maternal Infection in about 50% of
cases (Stagno et al.. 1982b; Stern & Tucker, 1973). The
frequency with which congenital infection follows secondary or
reactivated maternal infection is unknown as diagnosis of this
type of infection is far less straightforward. Stern & Tucker
(1973) documented non-primary infection in eight pregnant
women, none of whom gave birth to infected infants. This may
have been due to the small numbers involved as others have
shown that transplacental transmission of infection can occur
frequently in this situation (Stagno et al., 1973; 1977;
Schopfer et al.. 1978). Medearis (1982) has estimated a
frequency of 6% for such an occurrence.
With respect to the relative effects of congenital
infections resulting from primary and non-primary maternal
37
infection, Stagno et al. (1982b) found that of 33 infants
infected following primary maternal infection five had
associated symptoms at birth. In contrast none of 27 infants
infected as a result of non-primary maternal infection had any
symptomatology, although such an event is not unknown (Ahlfors
et al., 1981; Embil et al., 1970). In addition, Stagno et al.
(1982a) found that CMV infection which was probably congenital
in origin was associated with 1% of neonatal deaths in a
relatively serosusceptible population. No such link was evident
in a highly immune population where the rate of congenital
infection was high but was largely due to secondary or
recurrent maternal Infections.
The reported incidence of congenital CMV infection around
the world varies from 0.6% to 2.5% of live births (Levinsohn et
al., 1969; Montgomery et al„ 1980; Peckham et al., 1983; Starr
et al., 1970; Stern, 1968; Stern & Tucker, 1973). On further
analysis it is apparent that congenital infection occurs more
commonly in highly immune populations than in less immune
populations (1.6% and 2.4% respectively; Stagno et al., 1977;
1982a; 1982b).
Thus CMV causes more congenital infections than rubella
virus (Griffiths et al., 1980; Griffiths & Baboonian, 1984b).
Transplacental transmission of maternal infection with the
latter occurs with a higher frequency - in as many as 90% of
serologically confirmed maternal infections in the first
trimester (Rawls et al.,1968; Thompson & Tobin, 1970), falling
to between 30% and 50% of cases thereafter (Cradock-Watson et
al., 1980). However the actual incidence of rubella infection
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during pregnancy is much lower than that of CMV infection;
White et al. (1969) identified clinical rubella in 0.04-0.08%
of pregnant women during a non-epidemic period and estimated an
overall incidence of 0.12-0.14% to account for subclinical
cases. (The frequency rises during rubella epidemics and Sever
et al. (1969) reported clinically apparent infection in 2% of
pregnant women in one such epidemic.)
Transfusion-associated CMV infection
Recipients of blood from seropositive donors are at risk
of acquiring CMV infection. In premature infants born to
seronegative women this infection occurs in 13-5% of those
receiving blood from immune donors but does not occur in those
transfused with blood from seronegative donors (Yeager et al,
1981). Half of these infections are complicated by serious or
fatal pneumonia or hepatitis. In infants born to seropositive
women transfusions do not appear to be an imporant source of
infection.
In adults who recefve blood transfusions CMV infection
occurs in 7~9% (Kane et al., 1975; Prince et al., 1971). This
infection is commonly asymptomatic but may be accompanied by a
"postperfusion syndrome" which is usually similar to CMV
mononucleosis in adults (Kaariainen et al., 1966; Lang et al.t
1968) although fatal complications have been encountered (Lang
& Hanshaw, 1969). Transmission of infection is particularly
associated with fresh blood (Lang et al„ 1968; Lang & Hanshaw,
1969). with leukocyte-rich fractions (Winston et al., 1980),
with multiple transfusions, when infection occurs in up to 20%
39
of recipients (Prince et al.. 1971; Stevens et al.. 1970), with
blood that has IgM antibody to CMV (Beneke et al., 1984), and
possibly with blood from cytomegalovirurlc donors (Kane et al„
1975).
Some investigators have found that pre-existing immunity
appears to protect against transfusion-acquired infection
(Henle et al.. 1970; Paloheimo et al.. 1968) while others have
found no difference in infection rates among immune and
non-immune recipients (Prince et al., 1971; Stevens et al.,
1970). The fact that the infection rate is not greater in
seropositive transfusion recipients suggests that reactivation
of infection in response to transfusion does not occur often
and that most infections are acquired from virus present in
blood products.
CMV infection in the immunocompromised host
a) Renal and cardiac allograft recipients
CMV infection is more common in renal transplant
recipients than in transfusion recipients, occurring in over
70% of patients who survive for at least one month after
transplantation (Craighead et al., 1967). There are a number of
possible sources of this infection. These patients are
immunosuppressed in order to suppress allograft rejection and
may therefore be more susceptible to reactivation of
endogenous, latent infection, reactivation of latent virus in
donor organ tissue or transfusion-acquired infection. Further
analysis of the statistics of renal transplant associated CMV
infections permits certain comments to be made regarding these
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possibilities. Patients who have serological evidence of past
Infection excrete virus more commonly than other patients
following transplantation; 80-90% of the former group become
infected compared to 50-60% of the latter group (Betts et al.,
1975; Craighead et al., 1967; Ho et al.. 1975)- Thus latent CMV
infection appears to be a significant source of infection in
seropositive individuals. This is in contrast to the situation
in blood transfusion and may be related to immunosuppressive
therapy or to complex immunological reactions in transplant
patients.
Over 80% of seronegative transplant candidates who receive
an allograft from a seropositive donor become infected compared
to 30% of cases where both recipient and donor are seronegative
(Ho et al.. 1975). The transplanted organ therefore appears to
be a major source of infection, at least in those without prior
latent infection. Infection in those cases where both donor and
recipient are serongative is probably acquired in most
instances from transfused blood and blood products.
A similar picture of CMV infection emerges among cardiac
transplant recipients. The actual figures are even higher,
infection being almost universal in seropositive recipients and
occurring in half of seronegative recipients who receive organs
from seropositive donors (Preiksaitis et al.. 1983). In this
study infection in seronegative recipients could be reduced by
using only serologically screened blood products for
transfusion. Again, at least three possible sources of
Infection can be identified; endogenous latent infection, the
donor organ and blood transfusions.
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CMV infection in renal and cardiac transplant recipients
is frequently more severe than in the general population,
presumably due to their reduced immunocompetence. In renal
transplant recipients symptoms arise predominantly but not
exclusively in those with primary infection (Betts et al..
1975; Ho et al., 1975). the most common symptoms being
hepatitis and pneumonia.
b) Bone marrow allograft recipients
CMV infection occurs in up to 60% of bone marrow
transplant recipients (Meyers et al., 1975; 1980c; Neiman et
al., 1973; 1977). Serological diagnosis of infection in these
patients is often unsatisfactory due to their profound
immunosuppressed state and viral excretion is frequently not
detectable even in the presence of disseminated infection
(Neiman et al.. 1973). The source of this infection is not
known with certainty. Neiman et al. (1977) found that patients
with antibody prior to transplantation were three times more
likely to shed virus post transplant. Meyers et al. (1975)
demonstrated an association between the incidence of
interstitial pneumonia, which is frequently associated with CMV
infection, and a positive donor serology. However a subsequent
survey by this latter group (Meyers et al., 1980c) suggested
that most infections were not attributable to the recipient or
the donor but were acquired from other exogenous sources such
as transfused blood products.
In these patients all infections are primary-like (Meyers
et al.. 1980) due to the ablation of immunological memory
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resulting from total body irradiation. Infection is often
associated with interstitial pneumonia, which is commonly
fatal.
c) Patients with acquired Immune deficiency syndrome (AIDS)
Homosexuals with AIDS frequently have elevated XgG and IgM
antibody titres to CMV, however the significance of serological
data in this situation is doubtful as B cell function is
profoundly abnormal (Lane et al.. 1983). CMV is nevertheless
excreted in a high proportion of cases; 30% of those with
Kaposi's sarcoma are viruric (Friedman-Kien et al., 1982) and
in those with severe opportunistic Infection virus shedding is
almost universal (Gottlieb et al., 1981). Reinfection resulting
from multiple exposure occurs and may be superimposed upon an
ongoing infection. This has been shown by the isolation of
genetically distinct strains of virus from different anatomical
sites in the same patient (Drew et al., 198/1; Spector et al.,
198/1). Reactivation of infection is also likely. Dissemination
of infection occurs in the absence of Immune restraint and
pulmonary involvement contributes to the high mortality rate
(Follansbee et al., 1982; Mildvan et al.. 1982).
Healthy homosexuals do not usually excrete virus after the
age of 30 (Drew et al., 1981), however older men who have
haematologic findings consistent with immune dysfunction which
may be a prodromal stage of AIDS, are occasionally virusemenic
(Biggar et al., 1983). Thus the emergence of active CMV
infection may take place early in the evolution of the syndrome
and may therefore be pathogenetically involved in some cases.
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d) Other Immunosuppressed patients
Patients who are immunosuppressed but are not
significantly exposed to exogenous infection (those not
receiving transfusions or organ allografts) often have active
CMV infection. Cytomegalic inclusions have been found at
autopsy, most frequently in the lungs, of adults with
malignancy (Rosen & Hajdu, 1971) and in those receiving
corticosteroid therapy (Evans & Williams, 1968). Cytomegalic
inclusions are rarely found in adults. This infection, which
probably represents persistence or reactivation of endogenous
viral replication, was asymptomatic and was not implicated as a
cause of death.
Conclusion
The epidemiological pattern of CMV infection that emerges
is similar to that of several other herpesviruses. Transmission
facilitated by contact with infective tissues and secretions is
a feature of HSV and EBV infection. Congenital transmission is
more unusual but is also known to occur in CMV infection of the
guinea pig (Choi & Hsiung, 1978; Kumar & Nankervis., 1978) and
the mouse (Johnson, 1969) and in alcelaphine herpes virus type
1 infection of the wildebeest (Plowright et al., i960).
Latency is a feature of herpesvirus infections and in the
immune population reactivation is an important source of
recurrent infection with HSV (Nahmias & Roizman, 1973) and VZV
(Hope-Simpson, 1965). In immunosuppressed patients these
reactivations become more frequent and severe (Gallagher &
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Merigan, 1979; Montgomerie et al., 1969; Sokal & Firat, 1965)
and reactivation of EBV infection also occurs (Cheeseman et
al., 1980; Spencer & Andersen, 1972). Reinfection with HSV has
been confirmed by RE analysis and it is likely that reinfection
with VZV is possible, at least in immunosuppressed patients
(Sokal & Firat, 1965).
Data from epidemiological studies in different patient
groups gives information regarding the site(s) and mechanism(s)
of viral latency and the pathogenesis of infection, and will be




THE PATHOGENESIS OF CMV INFECTION
The relationship between CMV and the host is essentially a
dynamic one. The ability to contain infection is dependent on
the capacity to develop and maintain effective antiviral
mechanisms, and while CMV infection may be quiescent and
apparently inconsequential for lone periods, physiological
changes in the host are liable to disturb this balance. Our
understanding of the factors which determine the expression of
this host/virus relationship is limited by certain aspects of
the virus and its host interaction. Firstly, because of its
species specificity no animal model is available for studying
infection with human CMV. Although similar herpesviruses have
been found in many other species, their classification as CMV's
is often based on their cytopathic effects and species
specificity; no other similarity to the human virus is
necessarily implied. Nevertheless some animal CMV infections
serve as useful models provided that their dissimilarities with
human CMV infection are borne in mind. Most extensively studied
are the CMV infections of the mouse and guinea pig.
A second limitation arises from the fact that active CMV
infection in most humans is unrecognised. As most
investigations are limited to individuals with clinically
apparent infection, or to those at increased risk of active
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infection, much current knowledge in this area pertains to
unusual manifestations of CMV infection. Active infection has
been studied mainly in those with a mononucleosis or
postperfusion syndrome, in congenitally and neonatally infected
infants, in pregnant women and in immunocompromised patients.
It is not known how this information relates to infection in
other milieux. The presence of clinical signs and symptoms in
association with infection may result from a host response
which is distinctly different from that in those who remain
asymptomatic. Alternatively the differences in response may be
quantitative rather than qualitative.
In this chapter current concepts regarding the host/virus
relationship are discussed. Particular emphasis is given to the
interaction of CMV with the immune system - the effect of CMV
infection on immune function, the immune response mounted in
the face of viral challenge, and the influence of this response
on the virological and clinical expression of CMV infection. As
the nature of this interaction and its outcome is dependent to
some extent upon the setting in which it occurs, the
pathogenesis of infection is discussed in the contexts of those
settings which are widely recognised and well studied. In order
to understand the interaction between CMV and the immune
system, it is necessary first of all to consider certain
aspects of immunological function of importance in controlling
viral infections. This discussion of CMV infection in various
settings will provide a basis for subsequent discussion on CMV
infection in homosexual men and its relationship with and
contribution to immune impairment.
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The Immune response In viral Infections
Viral replication results in the synthesis of proteins and
other macromolecules which are foreign to the host and many of
these molecular species will elicit a specific immune response.
The generation of immune responses has been studied extensively
in the mouse using in vitro but also in vivo experimental
systems. Characterisation of the human immune response has to a
large extent followed in the wake of the murine studies. The
main features are comparable in both species.
The induction of an immune response requires that antigen
be presented to the immune system in an appropriate form.
Antigen must be presented in association with major
histocompatibility complex (MHC) antigens. In the human and in
the mouse, these antigens are of two main classes: Class I
antigens (HLA-A, -B and -C in the human, H2-K and -D in the
mouse) and Class II antigens (HLA-DR in the human, la in the
mouse). Antigen present on the surface of infected cells is
usually associated with Class I MHC antigens as, with the
exception of B cells, activated T cells, specialised antigen
presenting cells, bone marrow precursor cells and spermatozoa,
most cell types do not normally express Class II antigens (Ko
et al„ 1979; Wernet, 1976; Winchester et al„ 1977), Antigen
presentation in association with Class II antigens is
accomplished by specialised cells expressing Class II antigens.
Traditionally regarded as the most important antigen presenting
cells are the mononuclear phagocytes (Bergholtz & Thorsby,
1977). These are present in peripheral blood as monocytes which
subsequently localise in various tissues where they undergo
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morphological changes and become fixed macrophages comprising
the reticuloendothelial system. Some other cells are also
capable of antigen presentation, including endothelial cells
(Hirschberg et al„ 1980), Langerhans cells (Braathen &
Thorsby, 198O) and dendritic cells (Crow & Kunkel, 1982). There
is evidence that these cells are actually more effective than
monocyte-macrophages at antigen presentation (Braathen &
Thorsby, 1983; Van Voorhis et al., 1983) but as most studies
have concentrated on antigen presentation by adherent
mononuclear leukocytes, these cells will be referred to in this
account.
Different T lymphocyte subpopulations recognise and
respond to antigen in association with different MHC class
products. Antigen in association with Class I antigens is
recognised by T lymphocytes which perform suppressor and
cytotoxic functions mainly (Engleman et al., 1981; McMichael et
al., 1977). In the human these T cells can be identified by
reaction with the monoclonal antibody OKT8 (Reinherz et al.,
1979b) and will be referred to as T8+ lymphocytes. T cells with
helper and inducer functions recognise antigen in association
with Class II MHC products (Engleman et al., 1981) and are
identifiable by reaction with the monoclonal antibody OKT4 (T4+
lymphocytes; Reinherz et al., 1979a). The correlation between
surface marker expression and effector function is not absolute
as both T4+ suppressor cells (Thomas et al., 1981) and T8+
helper cells (Friedman et al., 1981) have been described.
Interaction of antigen on the surface of a presenting cell
with memory T4+ cells specific for the presented antigen
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results in stimulation of the presenting cell to produce
interleukin 1 (IL 1) and in sensitisation of the TL+ cell
resulting in a shift from the resting (GO) phase to the G1
phase of the cell cycle (Stadler et al., 1981) and the onset of
synthesis of type II (immune or gamma) IFN and other
lymphokines (Hecht et al., 1983). At the same time, some of
these lymphocytes become responsive to IL 1, and others to IL 2
(Palacios, 1981). In the presence of IL 1, IL 1-responsive
lymphocytes produce IL 2 (Mizel & Ben Zvi, 1980) which acts as
a second signal for antigen-primed T8+ as well as TU+ cells,
driving them into the S phase of the cell cycle (Stadler et
al., 1981), leading to clonal expansion of antigen-specific
lymphocytes. This results in greatly increased release of
lymphokines necessary for the maturation or enhancement of a
variety of immune functions as described below.
The interaction of MHC antigens with T cell membranes is
also the initial activation signal in the mixed lymphocyte
reaction (MLR). In the autologous MLR T4+ lymphocytes
proliferate in response to HLA-DR antigens on non-T cells
(Engleman et al., 1980). In the allogeneic MLR TU+ lymphocytes
proliferate in response to allogeneic HLA-DR antigens and T8+
lymphocytes respond to allogeneic non-DR antigens, probably to
MHC Class I antigens, although this latter response is
dependent to a large extent on TL+ lymphocyte responses
(Engleman et al., 1981), possibly for IL 2 and other helper
factor production (Mannel et al., 1983; see below). In the MLR
monocytes are not required for antigen production, only for IL
1 production (Berlinger et al., 1976).
50
These MHC antigen-T cell membrane interactions which lead
to T cell activation and induction of responsiveness to IL 1 or
IL 2 can be mimicked in vitro by T cell mitogens such as
phytohaemagglutinin (PHA), concanavalin A (Con A) and the pan T
cell-reactive monoclonal antibody OKT3 (Palacios, 1982). PHA
stimulates TU+ cells preferentially while Con A induces a
comparable response in both subsets (Reinherz et al., 1979a).
In mitogen stimulated cultures lymphocytes of both subsets may
release IL 2 (Fishbein et al., 1983; Luger et al., 1982)
although TU+ cells are probably the main IL 2 producers under
most antigenic stimuli (Palacios, 1982).
Antigen- or mitogen-primed T8+ lymphocytes, as well as
releasing lymphokines involved in immune regulation (Haynes &
Fauci, 1977; Krammer et al„ 1982), are capable of maturing
into cytotoxic lymphocytes (CTL's). This is dependent on the
presence of IL 2 and two other lymphokines produced by
activated T4-+ cells (Biddison et al., 1981; Larsson, 198I;
Mannel et al., 1983). Mature CTL's recognise and kill cells
expressing the appropriate antigen in expression with Class I
MHC antigens (McMichael et al., 1977) or cells expressing
foreign Class I antigens. CTL's arising during viral infections
in the mouse have been shown to be extremely sensitive and may
be directed against antigens which are not usually considered
to be expressed in appreciable amounts on the cell surface,
such as influenza virus nucleoprotein (Townsend & Skehel, 198/1)
and viral polymerase (Bennink et al., 1982), ectromelia virus
early proteins (Ada et al., 1976) and the immediate early
proteins of HSV (Pfizenmaier et al., 1977) and murine CMV
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(Reddehase & Koszinowski, 1984; Reddehase et al., 1984b). The
action of these effectors may therefore be important in
eliminating infected cells prior to the assembly and release of
progeny virus.
The recognition of antigen by B cells is fundamentally
different from T cell recognition and is not MHC-restricted.
The initial event in B cell activation is the interaction of
the relevant antigen with specific immunoglobulin present on
the B cell membrane. Activated B cells are rendered responsive
to IL 1 (Howard et al.. 1983) and the T lymphokine B cell
growth factor (BCGF) which induces B cell proliferation
(Muraguchi & Fauci, 1982). The capacity of these cycling B
cells to secrete antibody is dependent on the activity of a
further two T lymphokines (Nakanishi et al., 1983). This
accounts for the requirement of T cell helper functions in the
development of humoral immune responses.
In addition to these acquired, specific immune responses,
several innate immune functions may be of importance during
viral infections. Natural killer (NK) cells are medium sized
non-T lymphocytes and may provide important cytotoxic functions
against virus-infected cells. Their function is not genetically
restricted or antigen-specific. The way in which NK cells
recognise infected cells is not understood, but may be mediated
by foreign viral antigens (Bishop et al., 1983) or by cellular
targets such as the transferrin receptor (Vodinelich et al.,
1983), the expression of which may be increased in
virus-infected cells (Borisiewicz et al., 1985)- This would
also explain the potent anti-tumour cell activity of NK cells
52
(Herberman et al., 1975) and provides a basis for understanding
their proposed role in regulating cell proliferation and
differentiation. Although active NK cells are present in
peripheral blood in the absence of infection or immune
stimulation, their function is greatly enhanced by immune IFN
(Weigent et al., 1983b). NK-like functions are also mediated by
mononuclear phagocytes.
Killer (K) cells are similar to NK cells but employ a
different recognition mechanism. Antibody-coated target cells
are susceptible to K cell lysis and interaction of the Fc
component of the coating antibody with the K cell Fc receptor
is necessary for this to occur (Melewicz et al., 1977). While
IgM cannot participate in this antibody-dependent cellular
cytotoxicity (ADCC) in itself, it can greatly enhance IgG-
mediated ADCC, probably by promoting effector-target contact
(Perlmann et al.. 1981). This may be important in the early
stages of an immune response when little IgG antibody is
present. ADCC may also be mediated by monocyte-macrophages and
polymorphonuclear leukocytes (PMNL's; Kohl et al., 1977;
MacDonald et al., 1975),
Type I IFN may be produced in varying amounts depending on
the infecting virus. Unlike type II IFN, type I IFN is not a
product of the specific immune response but is produced mainly
by leukocytes (alpha IFN) and fibroblasts (beta IFN) in direct
response to virus. Both types of IFN may inhibit viral
replication by direct effects on infected cells, although the
two types vary in relative activity against different viruses
(Rubin & Gupta, 1980). Both IFN types potentiate NK cell
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activity (Herberman et al., 1979), although type I IFN alone
gives only a weak enhancement (Weigent et al., 1983a). Type I
IFN may also enhance CTL function (Zarling et al., 1978), ADCC
mediated by K cells (Warren et al., 1980) and PMNL's (Hokland &
Berg, 1981), and the phagocytic and natural killing activities
of monocyte-macrophages (Huang, 1977; Schultz et al., 1977;
Stanwick et al., 1980). The effect of type II IFN on these
functions is not known, with the exception of monocyte-
macrophage mediated tumour cell killing which is enhanced
(Schultz & Kleinschmidt, 1983). Type II IFN also induces
increased Class II MHC antigen expression in macrophages (Steeg
et al., 1982) which may enhance antigen-presenting function.
Immune responses are controlled by a number of negative
feedback mechanisms. This is necessary to control the
inflammatory response and limit tissue damage. Some feedback
mechanisms act by recruiting or activating suppressor T cells.
Suppressor cells may be antigen-specific (Uytdehaag et al.,
1979) or non-specific (Kasakura et al., 1983b; Haynes & Fauci,
1977) in their effects and may act on other T cells, B cells or
antigen-presenting cells (Kasakura et al., 1983b; Warrington et
al.. 1983). The way in which suppression is mediated is not
fully understood; one mechanism is the inhibition of IL 2
production (Chouaib & Fradelizi, 1982). There is evidence that
both direct cell to cell contact (Kasakura et al., 1983a) and
release of soluble mediators (Uytdehaag et al., 1979;
Warrington et al., 1983) can result in suppression in different
circumstances. The induction of suppressor cells may be
mediated by the T lymphokine(s) suppressor cell induction
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factor (Eardley et al., 1978; Kasakura et al., 1983a) or by
prostaglandins produced by monocytes when present in high
numbers (Chouaib & Fradelizi, 1982). Prostaglandins also
inhibit NK and K cell activity (Droller et al., 1978).
Macrophages can suppress in vitro immune responses in much
lower numbers than monocytes (Rinehart et al., 1979) and may
have an important in vivo regulatory effect later in the
inflammatory response following localisation and maturation of
monocytes at the site of infection. This suppression is
mediated by soluble mediators which act directly on effector
cells or by inducing suppressor cells which probably act by
direct cell contact.
NK cells can suppress helper T cell function in an
analogous way to suppressor T cells (Arai et al., 1983).
IFN's, as well as potentiating immune functions, can suppress B
cell function (Brodeur & Merigan, 1975; Sonnenfeld et al.,
1978) and moncxyte to macrophage maturation (Lee & Epstein,
1980), and can activate T cells to release soluble mediators of
immune suppression (Aune & Pierce, 1982).
An appreciation of these events has led to a clearer
understanding of immune dysfunction in various pathological
situations and is important in understanding immunological
events in both CMV infection and in AIDS and related
conditions.
CMV-mononucleosis
The mononucleosis syndrome is diverse in its clinical
manifestations but has been defined as "an acute infectious
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disease characterised by fever, enlargement of the lymphatic
glands and changes in the blood, especially lymphocytosis."
(Tidy, 193^). Most cases are caused by EBV (infectious
mononucleosis [IM]; Niederman et al„ 1968) and can usually be
diagnosed in the laboratory by the presence of heterophile
antibody. Heterophile-negative cases of mononucleosis are
nevertheless common and diagnosis is justified in the absence
of heterophile antibody provided other features are consistent,
namely the persistence for at least ten days of a blood
condition where at least 50% of leukocytes are mononuclear
cells and where at least 10% of these are atypical (Klemola et
al„ 1970). One half to two thirds of such cases are caused by
CMV; the remainder are due mainly to EBV but occasionally to
other viruses or Toxoplasma gondii (Horwitz et al„ 1977;
Klemola et al., 1970).
Primary infection may present as a mononucleosis syndrome
usually only in individuals after the onset of puberty and in
adults (Klemola et al., 1970). The interval between infection
and onset of symptoms is impossible to ascertain in
community-acquired infections but is on average 3-tl weeks in
transfusion-associated infections, assuming that infection
occurs at the time of transfusion (Ten Napel & The 1980a). The
major clinical features are fever of 2-5 weeks duration,
lymphocytosis and abnormal liver function tests, often
accompanied with hepatosplenomegaly, and occasionally with
rash, haemolysis and jaundice. Unlike mononucleosis caused by
EBV or other agents pharyngitis or significant lymph node
enlargement are not present (Horwitz et al., 1980; Kaariainen
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et al., 1966; Klemola & Kaariainen, 1965; Klemola et al., 1969;
1970; Lang & Hanshaw, 1969; Lang et al., 1968).
During the acute phase of CMV-mononucleosis, virus is
readily isolated from buffy coat cultures (Lang et al.. 1968).
This virus is associated predominantly with adherent cells from
the PMNL-rich and mononuclear leukocyte-rich fractions. Virus
cannot be isolated from red blood cells, plasma or leukocyte
lysates (Carney & Hirsch, 198I; Rinaldo & DeBiaso, 1983;
Rinaldo et al., 1977). This evidence points to the PMNL and/or
the monocyte-macrophage cell type as the main reservoir of
virus in the blood during viraemia. In vitro attempts to infect
blood cells have found the monocyte to be the most permissive
host cell (Einhorn & Ost, 198/).). The association of virus with
these cells may be due to phagocytosis of virus released at the
site(s) of viral replication. That this association is not
merely passive however is suggested by the fact that virus
cannot be recovered from leukocyte lysates. In addition,
monocytes from viraemic patients have suppressor cell
properties similar or identical to those of monocytes actively
infected with CMV in vitro, but distinct from those of
monocytes passively exposed to virus (Carney & Hirsch, 1981;
see below). PMNL function is not altered during mononucleosis
(Rinaldo et al., 1979).
Virus is often, although not always detectable in saliva
and urine during the acute phase (Rinaldo & DeBiaso, 1983;
Rinaldo et al., 1977). Leukocyte-associated viraemia may be
responsible for dissemination of virus to anatomical sites
distant from the site of initial infection. Viral antigens have
57
been demonstrated in liver tissue during CMV-mononucleosis
(Sacks & Freeman, 1984) and involvement of the liver, kidneys
and salivary glands is well recognised in other CMV — related
syndromes to be described subsequently.
During convalescence virus can be isolated rarely from
leukocytes, occasionally from saliva and frequently from urine
(Rinaldo & DeBiaso, 1983). Viruria can persist for long
periods; frequently for two years, and longer on occasion
(Klemola et al., 1969). Virusemenia likewise has been shown to
persist for more than a year following primary infection (Lang
et al., 1974).
The acute phase of infection is characterised by an array
of haematologic and immunological peculiarities. A range of
unusual antibody reactivities are present, including
erythrocyte autoantibodies, rheumatoid and antinuclear factors,
cold agglutinins and cryoglobulins (Kantor et al., 1970). This
resembles the polyclonal stimulation of IgG and IgM synthesis
that occurs in IM (Wollheim & Williams, 1966). In both cases
this may result from the direct activation of immunoglobulin
secretion by B cells following exposure to EBV or CMV. This has
been clearly demonstrated in vitro (Hutt-Fletcher et al., 1983;
Rosen et al., 1977), although there is no evidence that CMV
infects B cells in vivo or in vitro.
The cause of lymphocytosis in CMV-mononucleosis may also
be similar to that in IM. In the acute phase of IM
lymphocytosis is evident both in the increased numbers of
circulating lymphocytes and in the lymphocytic infiltration of
lymphoid and many other organs and tissues (Carter 1972),
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accounting for the enlargement of lymph nodes, liver and
spleen. Lymphocytosis appears to be due to an initial
proliferation of B cells resulting from infection with and
activation by EBV, which is subsequently overshadowed by a
massive proliferation of T cells in response to infection
(Mangi et al„ 1974-). In addition to eliminating cells actively
infected with virus this response may be important in
curtailing B cell proliferation and hyperactivity (Carter,
1975). Of relevance in this respect is the observation that
increased numbers of circulating lymphocytes in IM is at least
partly due to elevated numbers of T8+ lymphocytes (De Waele et
al., 1981; Reinherz et al., 1980).
Although CMV does not infect lymphocytes, at least during
acute mononucleosis, it may stimulate their proliferation as
suggested by the in vitro experiments cited above, and the
proliferation of regulatory T cells may also be in response to
B cell hyperactivity in this instance. Indeed increased numbers
of T8+ lymphocytes are also observed in CMV-mononucleosis
(Carney et al., 1981; Rubin et al.. 1981). A vigourous T cell
response to viral antigens in other cells (e.g. PMNL's or
monocytes) may also contribute to lymphocytosis.
The presence of numerous "atypical" lymphocytes is also
reminiscent of IM. In the latter these have been shown to be
mainly T cells (Sheldon et al., 1973). The appearance of these
cells is due to their activated state. During acute IM high
numbers of virus-specific cytotoxic T cells circulate
(Rickinson et al., 1977a; Svedmyr & Jondal, 1975), and these
account for at least some of the atypical lymphocytes (Crawford
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et al„ 1981).
Accompanying these abnormalities in lymphoid cell
populations in both IM and CMV-mononucleosis is a generalised
state of reduced immuno-competence. This hyporesponsive state
is demonstrable in vitro as a reduced ability of peripheral
blood lymphocytes to proliferate and produce lymphokines in
response to certain mitogens and recall antigens (Carney et
al., 1983; Levin et al., 1979; Mangi et al., 197^; Rinaldo et
al., 1980; Ten Napel & The, 1980b; Wainwright et al., 1979) and
as an inability to develop cytotoxic effector lymphocytes
following in vitro sensitisation (Carney et al., 1983). This
defect may result in part from the imbalance of T cell subsets
caused by increased and decreased numbers of T8+ lymphocytes
and T4+ lymphocytes respectively (Carney et al., 1981).
Homeostatic regulation of immune responses is dependent on the
balance between these subpopulations (Reinherz & Schlossman,
1980) and a preponderance of T8+ cells resulting from a
vig o rous immune response may be accompanied by a large release
of soluble mediators of DTH suppression ("antigenic competion";
Mangi et al., 197^). Wainwright et al. (1979) have partially
characterised a serum factor present during acute IM which
inhibits DTH responses in vitro and may mediate this effect in
vivo.
Such a factor has not been demonstrated in
CMV-mononucleosis (Rinaldo et al., 1980) and in this case there
is evidence that alternative or additional immunosuppressive
mechanisms may operate, arising from the interaction of CMV
with monocytes. Monocytes play a role as helper cells for
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lymphocyte proliferation responses to concanavalin A (Con A)
and recall antigens in CMV-mononucleosis as shown by the
further reduction in proliferation that occurs following their
depletion (Rinaldo & DeBiaso, 1983). These monocytes, or a
subgroup of them, however may also have a suppressive effect
during acute infection. Preculturing lymphocytes from acutely
infected patients prior to stimulation leads to a partial
recovery of the Con A response which can be abrogated by the
addition of fresh autologous adherent mononuclear cells
(Rinaldo & DeBiaso, 1983; Rinaldo et al., 1979). Preculture has
been shown to selectively eliminate the preponderant con A-
hyporesponsive suppressor T cells, thus enriching for Ti+
lymphocytes which proliferate normally in response to Con A
(Carney et al.. 1983). It therefore appears that monocytes can
facilitate the proliferative response of T8+ cells while
inhibiting the response of T4+ cells. This inhibition is
associated with monocytes infected with CMV in vivo and a
similar effect on the Con A response of precultured lymphocytes
from healthy donors can be achieved with autologous monocytes
infected in vitro (Carney & Hirsch, 1981). This may be due to
interference with the antigen-presenting capacity of monocytes
to Tk+ lymphocytes, stimulation of the release of
prostaglandins or other substances resulting in the recruitment
of suppressor cells, or to other effects of CMV infection on
monocytes. Non-productive infection of monocytes, without
expression of late viral antigens also results in a similar
alteration of monocyte function (Rice et al., 198^).
The hyporesponsive state of T8+ lymphocytes and their
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inability to give rise to cytotoxic effector cells may be due
to prior immunological commitment resulting from their
activated state; mononuclear cells, particularly T8+ cells have
elevated spontaneous proliferation rates (Carney et al., 1983;
Rinaldo & DeBiaso, 1983; Rinaldo et al., 1980). In addition, a
high proportion of lymphocytes express HLA DR antigens,
characteristic of immunologically activated cells during the
acute phase (Carney et al., 1983).
The differential activity of infected monocytes on T cell
subpopulations may be responsible in vivo for both the
activation of and proliferation of suppressor T cells and the
suppression of immune responses to recall antigens which are
dependent on helper T cell function. Monocytes with enhanced
suppressor function have been observed in some other infectious
diseases of man (Ellner et al., 1978; Katz et al., 1979;
Piessens et al., 1980).
These immunological abnormalities are maximal during the
acute phase. Lymphocytosis and hypergammaglobulinaemia
disappear early in convalescence (Kantor et al., 1970). Other
features normalise much more slowly; although T8+ lymphocytes
are no longer activated, their numbers are still elevated
(Carney et al., 1981) and lymphocyte responses remain below
average for over two years in some cases (Ten Napel & The,
1980b).
During the second week following the onset of symptoms a
CMV-specific humoral immune response becomes detectable.
Specific IgM is always produced in previously immunocompetent
individuals with the mononucleosis syndrome and can be detected
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in serum around this time (Kangro et al„ 1982; Rasmussen et
al., 1982). Viral glycoproteins are major targets of this
response (Pereira et al., 1982b) and IgM is the major class of
antibody that reacts with early and late membrane antigens by
immunofluorescence (Landini et al.. 1984). This IgM frequently
has complement fixing (CF) activity (Booth et al., 198O; Cremer
et al., 1975) and a complement-dependent cytolytic activity in
vitro (Betts & Schmidt, 1981). IgM antibodies to late, and to a
lesser extent early intracellular antigens are also
demonstrable (Pereira et al., 1982b; Riggs & Cremer, 1980).
The IgG response becomes apparent at the same time as or
slightly delayed with respect to the IgM response (Kangro et
al., 1982). This response consists mainly of the IgGl and IgG3
subclasses, with the latter usually appearing first (Linde et
al., 1983), and is directed against various structural and
non-structural antigens including membrane glycoproteins
(Pereira et al., 1982b), nucleocapsid antigens (Cremer et al..
1975; Schmitz et al., 1980a), intracellular late antigens (The
et al., 197^) early antigens (Landini et al„ 19840 and
pre-early nuclear antigens (Gartner & Orstavik, 1984).
Neutralising antibody titres are often delayed with respect to
other measurements of antibody (Andersen, 1970; Carlstrom et
al., 1968). This is not simply due to the relative
insensitivity of this test as neutralising titres rise as CF
titres fall. Neutralising antibodies may be reactive with
different antigens, or alternatively may be of a different IgG
subclass from CF antibody.
Specific serum IgA titres usually rise concomitantly with
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IgM and IgG tires, although they are generally lower in
magnitude (Levy & Sarov, 1980). Both IgA subclasses are
produced (Linde et al., 1983) and this response has also been
shown to be directed against early and late antigens (Riggs &
Cremer, 1980).
This humoral response reaches its maximum during the acute
phase of infection. Maximum IgM titres are present 3-6 weeks
after onset of symptoms (Kangro et al., 1982) and coincide with
the viraemic phase (Rasmussen et al., 19S2). Titres decline
during convalescence and are usually undetectable after three
or four months (Kangro et al., 1982), although low titres may
persist for longer (Lang et al.. 1974; Rasmussen et al.. 1982).
Other antibody responses often remain elevated throughout
convalescence; IgA may decline in parallel with IgM but can
also persist for much longer on occasion (Levy & Sarov, 1980).
IgG titres persist indefinitely, although not at the elevated
titres observed during acute infection (Andersen, 1970; Klemola
et al., 1969) and IgG antibodies directed against some antigens
may decline more rapidly than others; antibody to early
antigens declines during the convalescent phase in some cases
(The et al., 1974).
In contrast, the development of the specific DTH response
is markedly delayed relative to the humoral response (Ten Napel
& The, 1980a); its appearance coincides with the start of the
recovery of other proliferative responses to mitogens and
recall antigens (Levin et al., 1979). Suppression of the
virus-specific DTH response during the acute phase may then be
mediated by the same factors that cause general
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immunosuppression. The specific proliferative response is
usually negative during the first month after onset and does
not reach levels comparable to those of healthy, immune persons
until after the third month (Carney et al., 1983; Levin et al.,
1979), when the response may actually be higher than average
for a time (Pollard et al., 1978). Other proliferative
responses begin to recover during this period also but as
already discussed, often do not attain levels comparable to
controls for many months. The developing immune response to CMV
during convalescence may thus prevent the complete restoration
of other responses by a mechanism analagous to antigenic
competition as proposed to take place in IM by Mangi et al.
(1974).
MHC-restricted and nonrestricted cytotoxic responses in
CMV-mononucleosis have not been studied in depth to date. In
IM cytotoxic effector cells are present during the acute phase;
there is a rapid proliferation of NK cells (Lipinski et al.,
1979) and K cells (Jondal, 1976). EBV-specific cytotoxic T
cells are also present early in infection - this response is
thought to contribute to the suppression of other T cell
functions, as specific DTH responses are absent during acute IM
also. These CTL's are unusual however as they are not
HLA-restricted, being able to kill all EBV genome-containing
lymphoid lines (Lipinski et al., 1979; Rickinson et al., 1977;
Svedmyr & Jondal, 1975) and many appear to lose characteristic
T cell markers following in vitro activation (Svedmyr et al.,
1974-). Typical HLA-restricted CTL's only appear during
convalescence (Misko et al., 1980; Moss et al., 1978; Rickinson
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et al., 1979; 1980). Comparison of CMV-mononucleosis with IM
may be misleading in this instance.
Cytotoxic responses in murine CMV infection have been
studied and may be comparable to the situation in primary
infection in the human. Primary CMV infection in the mouse also
results in a general suppression of DTH responses (Howard et
al., 197^; Osborn et al., 1968). Cytotoxic responses, in
contrast, are elicited rapidly. On the third day after
infection numbers of splenic NK and K cells increase rapidly
(Quinnan & Manischewitz, 1979). The rapid nature of this
response may be facilitated by the IFN response which is
present on the second day (Grundy et al.. 1982; Quinnan &
Manischewitz, 1979). These responses are transient, being
undetectable after six days, and are replaced by an H-2
restricted CTL response demonstrable in splenic and peripheral
blood lymphocytes on the fourth or fifth day and in lymph node
cells on the sixth day (Ho, 1980; Quinnan et al., 1978; 1980).
This response is maximal 7-10 days after infection, correlating
with the fall of infectious virus titres in the spleen, and
declines to undetectable levels 2-3 weeks after infection. It
is noteworthy that these responses precede the formation of
specific antibody, which becomes detectable 8-10 days after
infection (Manischewitz & Quinnan, 1980).
Cellular cytotoxic responses to CMV infection in humans
who have received bone marrow allografts have been studied and
will be discussed subsequently, however it is worth stating at
this point that specific cytotoxic responses develop relatively
quickly in those with non-fatal CMV infection despite their
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general immunosuppressed state and often precede the rise in
antibody titres (Quinnan et al., 1981; Rook et al., 19&U).
In view of these examples then, it is not unlikely that
thymic and non-thymic cytotoxic responses develop rapidly
during the course of CMV-mononucleosis. As already stated, the
generation of cytotoxic effector T cells following in vitro
sensitisation with allogeneic cells is suppressed in acute
mononucleosis (Carney et al.. 1983). It is of interest however
that murine CMV infection also inhibits primary and secondary
cytotoxic responses early in infection when the CMV-specific
CTL response is present (Ho, 1980). Again an antigenic
competition effect where the CTL response results in excessive
negative feedback inhibition which suppresses cytotoxic as well
as proliferative responses may be operative in both the murine
infection and in CMV-mononucleosis.
Mononucleosis is an unusual clinical response to primary
CMV infection. Whether or not the virological and immunological
features are also unusual, qualitatively or quantitavely, is
not known and any attempt to construct a comparable picture of
events in healthy adults who have asymptomatic primary
infection remains largely speculative at present as such cases
are rarely identified and followed prospectively. Whether
infection is asymptomatic or not may be determined by a variety
of factors such as the size of the infecting dose, the route of




Transmission of infection to the foetus occurs in a
proportion of women who experience CMV infection during
pregnancy. This has been associated with foetal loss in 15% of
primary maternal infections during early gestation (Griffiths &
Baboonian, 1984b) although it could not be ascertained if this
was actually due to intrauterine infection. Liveborn
eongenitally infected infants may manifest signs and symptoms
of cytomegalic inclusion disease or may be asymptomatic
initially, developing late onset disease during the neonatal
period. Most infections however remain subclinical throughout
(Chapter 2). Aspects of maternal infection which may influence
the risk of transmission to the foetus and its outcome are
discussed subsequently.
Whether symptomatic or not, congenitally infected infants
excrete virus in high titre in urine, although the former shed
significantly higher titres during the first months of life
(Griffiths et al., 1982a; Pass et al., 1983c; Stagno et al„
1975b). The amount of virus excreted falls with increasing age,
but most are still viruric at five years of age. Salivary viral
excretion is also prominent but is less chronic and generally
ceases by two years of age (Pass et al., 1983c). Little
information on the occurrence of viraemia is available however
Lang & Noren (1968) reported that three symptomatic cases
studied were all viraemic, in one case for at least five
months. Virus can readily be recovered at autopsy from numerous
organs, in particular the kidneys, liver, lungs, pancreas,
thymus and thyroid, but also from brain and skin (Benyesh-
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Melnick et al., 1961; Medearis, 1961). These infants therefore
carry an extremely large viral load and, at least in the most
severely affected, disseminated infection occurs. Extensive
lytic viral replication may by itself account for much of the
teratogenic potential of CMV.
It is not known what factors influence the extent of viral
replication in the foetus. Insofar as the extent of excretion
is reflected in pathological consequence, it would seem that
gestational age at the time of infection is important. Later
gestational ages are characterised by the developing foetal
immune system and lower cell division rates, both of which may
limit viral replication. The extent of placental infection may
also determine the size of the initial infecting dose of virus
and consequently the extent of foetal viraemia.
Most congenitally infected infants (89%) have detectable
levels of CMV-specific IgM in cord blood, provided the
detection system is sufficiently sensitive (Griffiths et al..
1982a) and most of those with symptoms either at birth or later
in infancy have significantly elevated titres. Specific IgM
titres may then reflect antigenic load, however it was noted by
this group that IgM titres did not always correlate with
urinary virus titres, suggesting that a vigourous immune
response might also contribute to symptomatology and sequelae.
Additional evidence implicating the antiviral immune response
in the pathology of congenital infection comes from studies of
immune complexes in infected infants (Stagno et al., 1977b).
Circulating complexes are frequently found in infected infants
but only occasionally in others, and these complexes are
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generally larger in those with symptomatic infection. Larger-
complexes, the formation of which may be favoured by conditions
of antigen excess, again may simply reflect a greater viral
load, nevertheless such complexes may also accumulate more
readily in body tissues. In a limited number of fatal cases
studied IgG and CMV antigen deposits were demonstrated by
immunofluorescent staining of sections of renal glomeruli and
tubules. Immune deposits at this site and elsewhere (e.g. the
choroid plexus) could result in inflammatory reactions
resulting in tissue damage. IgG and IgM antibodies may also
contribute to tissue damage by their participation with
complement, K cells and monocyte-macrophage cells in cytotoxic
reactions directed against infected cells.
Other aspects of humoral immunity are also elevated in
congenitally infected infants by comparison with normal immune
adults (Stagno et al„ 1975b). CF antibody titres are high at
birth and often remain so, particularly in those with symptoms.
Fluorescent antibody titres against early and late antigens are
both high in titre initially; the former remain elevated during
the first two years then decline while the latter show only a
slight drop over the next five years. Despite this vigourous
production of antibody, there is evidence that the humoral
response to infection may be qualitatively deficient as Pereira
et al. (1983) found that sera from symptomatically infected
infants failed to precipitate many polypeptides precipitated by
other sera in an RIP assay during the first year of life. An
alternative explanation of these results is that antibody to
these antigens was present, but was involved in complexes
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formed in vivo and was therefore not free to react with
radioactive precursor-labelled proteins in the RIP assay. After
the first year sera from these infants precipitated CMV
polypeptides for longer than sera from asymptomatic infants and
also precipitated additional polypeptides. This elevated
humoral response to infection argues strongly against the
hypothesis that the inability of these infants to limit
infection results from induction of immunological tolerance
following exposure during foetal life.
In comparison, the lymphocyte proliferation response to
CMV antigens is markedly deficient in such infants. The
response is usually entirely absent during most of the first
year; an increasing proportion become responsive with
increasing age thereafter although the response remains low
compared with that of immune adults and many remain
unresponsive for five years or more (Gerhz et al., 1977; 1982;
Okabe et al., 1983; Pass et al., 1983c; Reynolds & Dean, 1978;
Reynolds et al„ 1979; Starr et al.. 1979). Lymphokine
production in response to CMV antigens is also impaired
(Fiorilli et al.. 1978; Starr et al., 1979). This however is
not due to a generalised suppression of cell-mediated immunity
as occurs in CMV-mononucleosis in adults. Lymphocyte responses
to mitogens and recall antigens are comparable to those of
age-matched controls (Gehrz et al.. 1982; Pass et al., 1983c;
Reynolds et al., 1979; Starr et al., 1979) and the uptake of
live vaccines is normal in these infants (Reynolds et al..
1978). Although some immunological and haematological features
are reminiscent of mononucleosis, such as elevated total IgG
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and IgM levels (Griffiths et al., 1982a; Pass et al.. 1980a;
Reynolds et al.. 1974). lymphocytosis (Pass et al., 1980a) with
an increased proportion of T cells (Schauf et al., 1976) and
elevated numbers of suppressor T cells resulting in a low
helper/suppressor phenotype ratio (Pass et al.. 1983b), these
findings are not consistently observed and are far less
striking than findings in CMV-mononucleosis.
Immunosuppression associated with congenital CMV
infection, then is substantially different from that observed
in CMV-mononucleosis as it is CMV-specific and is frequently of
considerably longer duration in the former. The mechanism(s)
whereby this immune suppression is effected are not apparent.
The immunological immaturity of the foetus and neonate cannot
account entirely for the defect as lymphocyte responses to HSV
in infants with perinatal HSV infection, although low, are
usually detectable in the newborn period. (Pass et al., 1981a).
Unresponsiveness is not due to an inability to synthesise
IL-2 as the addition of exogenous IL-2 has no effect on the in
vitro proliferation response, suggesting that few antigen
responsive cells are present or that antigen presentation to
antigen-primed lymphocytes is defective (Pass et al., 1984).
The frequency of lymphocytes in peripheral blood capable of
proliferating in response to CMV is low in congenitally
infected infants compared to adult controls as shown by Hayward
et al. (1984) using a limiting dilution lymphocyte
proliferation assay. Low responder frequencies were also
observed in infants perinatally infected with HSV compared to
immune adults, however, suggesting that this may be an age
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related deficiency. Those infants with congenital CMV
infection may have even fewer responder cells resulting in
the complete absence of the proliferation response.
A low frequency of responder cells may be due to defective
generation or functional capacity of these cells, or to
defective accessory cell function. With regard to this last
possibility Hayward et al. (198!) found that monocytes from
infected infants presented antigen normally to maternal
lymphocytes, however others have reported that monocyte-derived
macrophages from such infants inhibited the proliferation of
lymphocytes from control donors in a CMV-specific fashion
(Coleman et al., 1982). Other factors which have been
implicated in suppressing lymphocyte proliferation are
unidentified soluble serum components (Reynolds & Dean, 1978;
Coleman et al., 1982). It is difficult to envisage how soluble
factors, with the exception of specific antibody, could mediate
antigen specific suppression of lymphocyte reactivity however.
Another possible mechanism of suppression of CMV-specific
lymphocyte proliferation is the induction of specific
suppressor T cells. Lymphocytes with such properties have been
identified in other pathological conditions; lymphocytes from
patients with chronic hepatitis B virus infection give low
proliferative responses in general, but the response to
hepatitis B surface antigen (HBs Ag) is further suppressed or
completely absent (Barnaba et al., 1985). This response can be
improved by eliminating T8+ cells, suggesting that activated
suppressor cells are present. When lymphocytes from low
responders are stimulated with HBs Ag and irradiated they
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significantly inhibit the response of fresh autologous
lymphocytes to HBs Ag but not to other antigens.
The presence of activated, specific suppressor cells in
CMV-infected infants may account for the lack of proliferation
following stimulation in some infants, and in most under one
year of age. Others with low responses may have high numbers of
circulating suppressor precursors which are rapidly activated
following antigen stimulation. This could be decided by
experiments similar to those described above. Viral infection
of specific subgroups of lymphocytes may also result in
CMV-specific immune suppression. Until these possibilities are
addressed using sensitive biochemical, molecular and
immunological techniques the precise mechanism of this immune
suppression remains enigmatic.
The corresponding age-related increases in the proportion
of congenitally infected infants who develop a positive
CMV-specific proliferative response and the proportion who
cease to excrete virus, taken together with the observation
that the lymphocyte response defect is most pronounced in those
with symptomatic infection (Pass et al., 1983c; Reynolds et
al„ 1979) suggests that the absence of the proliferative
response is related to the persistence of infection and its
pathological consequence. This does not however establish that
immune unresponsiveness is causally related to the duration or
extent of infection. Certainly this cannot be the sole factor
in determining outcome as there is no absolute correlation
between the two. Unresponsiveness may persist long after the
cessation of excretion and may equally be resolved despite
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continuing excretion.
Immune and innate cytotoxic responses may be of greater
importance in containing infection but are poorly studied in
this patient group. The number of circulating NK and K cells
are very low (0.5% of mononuclear cells) during the newborn
period and increase in number slowly thereafter for at least
30 years (Abo et al., 1982). The ability of peripheral blood
lymphocytes to mediate natural and antibody-dependent
cytotoxicity against HSV-infected targets is markedly reduced
for at least the first year of life in comparison with adults
(Kohl, 1983). Although absolute numbers of T4+ and T8+
lymphocytes are elevated at birth (Thomas & Linch, 1983).
there is evidence that some T cell-mediated cytotoxic
functions are deficient (Campbell et al., 197^).
Curtailment of CMV infection in infants may then be
achieved through the combined effects of various immune
functions including the DTH response and cytotoxic responses
mediated by T, NK and K cells as well as phagocytic cells.
The slow rate of acquisition of some of these functions
during infancy may explain the prolonged periods of shedding.
CMV infection in infancy
As shown in seroepidemiological surveys CMV infection is
common during infancy especially in poorer nations. Infection
can only be confidently diagnosed as perinatal or postnatal
when virus excretion is shown to be absent during the first
week of life but present at a later date. Most information on
this type of infection relates to infants who become infected
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shortly after- birth. The more limited information that exists
regarding infection in older children indicates that this
situation is more similar to infection in younger infants than
in adolescents or older children. Infection in the neonatal
period is usually subclinical (Pass et al., 1981a; Stagno et
al„ 1975b). Infection acquired later in infancy, although also
subclinical in most, is more often clinically apparent. The
most common manifestations are hepatosplenomegaly, liver
dysfunction, pneumonitis and haemolytic anaemia (Gehrz et al.,
1982; Hanshaw et al., 1965). This may argue for a protective
role for maternal antibody in modifying the outcome of
infection, as some have observed in neonatal HSV Infection
(Yeager et al.. 1980). No long-term sequelae have been reported
in otherwise healthy infants infected after birth (Pass et al.,
1981a).
Infected infants excrete virus in saliva and urine (Pass
et al., 1982a; Tamura et al., 1980*). The amount of virus shed
in urine is similar to the amount shed by congenitally infected
infants older than three months old and is generally persistent
for at least three years (Stagno et al., 1975b).
The humoral immune response to infection appears to be
intact in these infants. Specific IgM is present and this
response is of similar duration to the IgM response in
CMV-mononucleosis (Chiba et al., 198O). Secretory IgA with in
vitro virus-neutralizing capacity is present in saliva (Tamura
et al., 1980b). Serum IgG has complement fixing activity and is
directed against various groups of viral antigens including
PENA, EA and LA including viral glycoproteins, although the
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response to the first of these groups of antigens may be
relatively delayed in onset (Chiba et al., 1980; Pereira et
al.. 1983; Stagno et al.. 1975b). These IgG responses generally
persist at moderate to high titre throughout the first year
following infection and at lower titres thereafter, despite the
persistence of viruria (Stagno et al., 1975b).
Infection acquired early in life is not accompanied by the
haematological abnormalities or general cell-mediated
immunosuppression observed in CMV-mononucleosis. Circulating T
cell numbers are normal (Gehrz et al., 1982) as are lymphocyte
proliferative responses to mitogens and recall antigens (Gehrz
et al., 1982; Okabe et al., 1983; Pass et al., 1981a; Reynolds
et al.. 1979). CMV-specific cell-mediated immunity however is
markedly suppressed. Lymphocyte proliferation and lymphokine
production in response to CMV is absent in most and low in the
remainder (Fiorilli et al.. 1982; Gehrz et al.. 19S2; Pass et
al., 198la). Only one group (Okabe et al., 1983) has reported
positive responses in postnatally infected infants under one
year of age. The proportion of infected infants who respond
increases with age; a significant proportion are still
unresponsive at four years of age or older however (Pass et
al., 1981a).
This response to infection is similar to that in
congenital infection and may result from similar or identical
mechanisms. Although both the cessation of excretion and the
development of a proliferative response to CMV are associated
with increasing age, one is not always predictive of the other
(Pass et al., 1981a). This is also similar to congenital
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infection and suggests that the activity of several antiviral
functions is responsible for the eventual elimination of
infection in postnatally infected infants also.
The virus carrier state
During convalescence from primary CMV infection in healthy
adults the haematological picture normalises, immunological
responsiveness gradually returns and virus excretion falls and
is eventually terminated although this may not be achieved for
many months. These events are accompanied by changes in the
virus-specific immune response; some immune functions are lost
during convalescence while others remain and still others only
become fully developed during this period.
That CMV is not completely eradicated from the host
following infection in most if not all cases is undoubtable in
view of the evidence discussed in Chapter 2 that replication of
the virus which caused the original infection may resume and
cause a re-emergence of infection, and that infection can be
acquired from immune individuals and transfusions and
transplanted organs derived from immune donors. It is not known
however, in what state virus persists, nor how it escapes
immune destruction during the interim period. Low grade viral
replication may continue in tissues protected from the immune
system; for example, persistence of virusemenia may be
explained on this basis. However in most immune individuals
infectious virus cannot be detected for most of the time.
Moreover, in vitro studies of CMV replication considered in
Chapter 1 have shown that the replicative cycle can be
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reversibly blocked at various stages. One or more of such
mechanisms may operate in vivo and allow the persistence of
virus in a non-replicative state.
Latency is usually defined as an ongoing virus-host
relationship in which infectious virus is undetectable (Jack,
197^). As a working definition latency is often regarded as a
state of infection where infectious virus is not released from
infected cells and cannot be detected in cell-free homogenates,
but can be rescued in vitro by explant culture or cocultivation
(Openshaw, 1983). CMV infection in immune individuals fits the
first of these definitions but this may be due to the
inadequacy of current detection methods. Whether CMV can remain
truly latent or can only persist by replicating at undetectable
levels cannot be readily ascertained at present as it is not
known with any degree of precision where the virus is
harboured.
The site of latency in some other herpesvirus infections
is known and consequently more is understood regarding the
level of viral expression in these instances. The demonstration
of HSV 1 in the spinal ganglia of mice which could only be
rescued by organ explant culture (Stevens & Cook, 1971) was
rapidly followed up with similar observations in man (Baringer
& Swoveland, 1973; Bastian et al.. 1972). Subsequent
experiments in mice have shown that the neuron is the latently
infected cell-type (Cook et al., 1974; Kennedy et al., 1983:
McLennan & Darby, 1980). Even with this knowledge, and the
availability of animal models the molecular mechanism of
latency has not been elucidated. Stevens & Cook (1971)
79
failed to detect viral particles in latently infected ganglia.
The virus may not be completely dormant however as virus-
specified thymidine Kinase is expressed at detectable levels up
to 60 days after initiation of infection and possibly for
longer at undetectable levels (Yamamoto et al., 1977) whereas
infectious virus cannot be recovered from homogenised ganglia
beyond two weeks after infection (Stevens & Cook, 1971; Walz et
al., 197^). In addition, Baringer & Swoveland (1973) found
occasional viral particles during detailed examination of
ganglial cells. Such attempts to determine the extent of viral
expression in latently infected cells are of course limited by
the methods available. DNA replication or antigen production
which proceeds slowly or only occurs in a few cells may well
escape detection.
There is also evidence that HSV may persist in other
tissues and cell types including trigeminal nerve roots in man
(Warren et al., 1982), the sciatic nerve and the footpad in
guinea pigs (Scriba, 1977) and in mice the footpad (Al-Saadi et
al., 1983) and the eye (Openshaw, 1983).
The ability of EBV to persist in the host is well
recognised and the B cell is known to harbour virus. Tonsillar
lymphocytes from immune donors contain low amounts of viral DNA
(Gerber et al., 1972) and a proportion express EBNA but not
early antigens or viral capsid antigen (Veltri et al., 1976), a
level of viral expression consistent with latency (Epstein &
Achong, 1977). The EBNA-positive cells have since been shown to
be B cells (Veltri et al., 1977). In addition peripheral blood
lymphocytes from immune donors are capable of giving rise to
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EBV-transformed lymphoblastoid lines in culture (Chans et al.t
1971; Gerber & Monroe, 1968; Nillson et al., 1971)- These in
vitro transformants do not arise directly from the outgrowth of
latently infected lymphocytes; activation of lytic infection in
the latter gives rise to free virus which subsequently
transforms uninfected B cells in vitro (Rickinson et al., 1975;
1977b). The physical state in which the viral genome persists
in latently infected lymphocytes has not been demonstrated but
is possibly the same as that in in vitro transformed and in
vivo derived lines, namely multicopy episomes possibly with
some copies integrated into host cell chromosomes.
Latency in murine CMV infection has also been studied in
some depth. Latent virus can be rescued from spleen cells by
explant culture or cocultivation with permissive mouse cells
(Olding et al., 1975; 1976; Wise et al., 1979) and can be
detected by DNA hybridisation in spleen cells at a level of 3-/1
genome copies per 100 cells (Olding et al., 1976). By
cocultivation of fractionated spleen cell populations B cells
have been found to be one site of latency (Olding et al., 1975)
however latent CMV has also been detected in peritoneal
macrophages by cocultivation and by DNA hybridisation at a
level of H-7 genome copies per 100 cells (Brautigam et al.,
1979). Latent virus has also been detected by explant culture
in the salivary gland and prostate gland (Cheung & Lang, 1977)
and by DNA hybridisation in salivary gland cells (Olding et
al., 1976) and spermatogenic cells (Dutko & Oldstone, 1979).
The situation with regard to latency in human CMV
infection is far less clear. The epidemiology of infection in
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recipients of blood or blood product transfusions and in renal
and cardiac allograft recipients indicates that some cells in
the transferred tissues are harbouring potentially infectious
virus. The particular implication of leukocytes in
transfusion-acquired infection is consistent with the known
involvement of these cells in active infection. Most attempts
to demonstrate latent virus directly have proved unsuccessful
however. With rare exception (Diosi et al., 1969) CMV cannot be
cultured from the buffy coat cells of blood from immune donors,
even when the donor was implicated in a transfusion-acquired
infection (Bayer & Tegtmeier, 1976; Kane et al., 1975)* Viral
DNA has occasionally been detected in low amounts, however in
leukocytes of non-viraemic donors (Pagano,1975) although this
finding has not been repeated by others.
Attempts to reactivate latent CMV infection in renal
tissue by explant culture with or without cocultivation have
proved uniformly negative (Naraqi et al., 1978). This may not
be surprising however as these techniques also failed to reveal
virus in kidneys actively infected as shown by the presence of
infectious virus in cell-free homogenated tissue. It may be
argued that the risk of infection acquired from renal and
cardiac allografts is due to latently infected donor leukocytes
perfusing the organ at the time of transplantation. The
increased frequency of infection in these patients over other
transfusion recipients may result from their immunosuppressed
state which in turn may result in a reduced ability to
eliminate virus-infected cells.
The difficulty in demonstrating the presence of latent CMV
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in humans may indicate that the mechanisms responsible for
restricting viral expression are different from those in the
herpesvirus infections described above. Alternatively, latent
CMV may reside in a smaller number of cells, or in a cell type
which has a short lifespan when cultured in vitro. Another
possible reason arises from the fact that only fibroblasts are
fully permissive for CMV replication in culture whereas latency
may well involve another cell type. This could result in
inefficient in vitro reactivation. The ability to induce a
permissive state in other cell types using hormones (Tanaka et
al., 1984b) and base nucleotide analogues (St. Jeor & Rapp,
1973) may thus aid in the search for sites of CMV latency.
In the absence of overt viral infection virus-specific
immune functions are the only readily demonstrable indications
of past infection with herpesviruses. Both humoral and
cell-mediated immune functions may be present and will now be
described. Certain aspects of innate immunty are also
discussed. Although not CMV-specific, these functions may be of
Importance in maintaining the latent state.
During convalescence from primary infection the CF
antibody titre to CMV falls (Andersen, 1970; Medearis, 1964)
although this decline may not become apparent for at least
several months after resolution of infection (Carlstrom et al.,
1968). CF antibody persists indefinitely in most individuals
(Betts et al., 1976; Griffiths et al.. 1978) but some workers
have observed fluctuation of titres with time (Waner et al.,
1973). Similarly, neutralizing antibody titres also persist at
detectable levels in all or most of the immune population and
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correlate well with CF titres (Plummer & Benyesh-Melnick, 1964;
Stalder & Ehrensberger, 1980).
CF and neutralizing antibodies are directed primarily
against late, structural viral antigens (Pereira et al.,
1982b). A large proportion of the antibody measured in the
indirect immunofluorescence, ELISA and RIA IgG assays is also
reactive with these antigens (Forghani & Schmidt, 198O; Sarov
et al., 1980; Torfason et al., 1981).
Antibodies to immediate early, pre-early nuclear and early
antigens are often present at high titre during active CMV
infection and may decline during convalescence. Because of this
many have regarded these antibody reactivities as markers of
acute or recent infection (Musiani et al., 1984; The et al„
1974) as was proposed for antibody to early antigen in EBV
infections (Henle et al., 1971). It is now known however that
the decline of these antibody titres during convalescence is
not consistently observed and many individuals without evidence
of current or recent active infection have detectable, and
often high IgG titres to these antigens (Friedman et al.,
1982a; b; Gartner & Orstavik, 1984; Griffiths et al., 1980a;
Landini et al., 1984). The reason why particular antibody
reactivities persist after infection in some cases but not
others is not known.
The significance of serum IgA antibody to CMV has not been
fully evaluated in this respect. Initial studies have shown
that most healthy immune adults do not have detectable IgA
titres (Levy & Sarov, 198O; Pinku et al., 19&2; Strand &
Hoddevik, 1984) but it was noted in one study (Levy & Sarov,
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1980) that IgA may persist considerably longer than IgM
following primary infection. Further studies are required to
clarify the relationship of CMV-IgA to active and latent
infection.
Investigations of specific DTH responses in healthy
individuals of longstanding immunity have produced variable
findings. Many have found that lymphocytes from all or most of
such individuals proliferate in response to CMV antigens
(Pollard et al., 1978; Schirm et al„ 1980; Starr et al.t 1979;
1980; Waner & Budnick, 1977). In contrast, others have found
that lymphocytes from approximately half of seropositives are
unresponsive in this assay (Ten Napel & The, 1980a; Ten Napel
et al., 1977)- Still others have found that while most immune
adults give a positive response, the response may be absent in
a proportion of adolescents (Faix et al., 1983a) and children
(Beutner et al., 1978). In these last two studies negative
responses in seropositive persons could be explained by
fluctuations in responsiveness with time in the former and, in
the latter, greater strain specificity of the response in the
children studied than has been observed in adults (Starr et
al., 1980; 1981). Ten Napel and colleagues (Ten Napel & The,
1980a; Ten Napel et al., 1977) found that immune individuals
who also had antibodies to early antigens were more
consistently responsive and gave responses which were generally
greater in magnitude than did seropositives without antibody to
early antigens. Most others, however have found that the
presence or magnitude of the response correlates neither with
the magnitude of antibody titres nor with the presence of any
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specific antibody reactivities (Beutner et al., 1978; Faix et
al., 1983a; Schirm et al., 1980; Starr et al., 1979; Waner a
Budnick, 1977). In older immune individuals (60 years and over)
there may be a diminishing of the proliferative response while
antibody titres remain high (Ten Napel a The 1980a).
The lymphocyte proliferation assay systems used by the
investigators cited above vary in detail with respect to
culture conditions, cell density, the source of serum or
plasma, the strain of virus and the antigen preparation used.
While no single factor appears to account for the discrepant
results obtained by different groups, it is clear that
standardisation of the assay and identification of those
variables which bear upon the response are necessary in order
to assess the value of this test as an indicator of
cell-mediated immunity.
Other assessments of DTH responses based on measuring
lymphokine production in response to CMV antigen have also been
used. Production of migration inhibition factor as measured by
a leukocyte migration inhibition test has been reported to
occur with lymphocytes from immune donors but only a few
individuals were tested (Fiorilli et al., 1978; 1982). Gamma
IFN production has also been used to assess CMV-specific DTH
responses (Starr et al., 1980). While lymphocytes from most
immunocompetent seropositive individuals are responsive, the
amount of IFN produced in response to antigen does not
correlate with the magnitude of the proliferative response and
maximal IFN titres are obtained with different antigen
concentrations from those which induce optimal proliferation.
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These two assays may therefore be assaying different
populations or maturational stages of immune lymphocytes.
Activated HLA-restricted CTL's are not present in the
peripheral blood of latently infected individuals (Kirmani et
al„ 1981). This is analogous to the situation in latently
infected mice (Ho, 1980; Quinnan et al„ 1978; 1980).
Lymphocytes from individuals latently infected with EBV on the
other hand are capable of mediating regression of EBV-induced
transformation in vitro, and HLA-restricted T cells are
responsible for this effect (Moss et al., 1978). These however
are secondary CTL's generated from memory T cells following
prolonged contact with target cells as regression does not take
place until 1-2 weeks after initiation of transformation. By
presensitising splenic lymphocytes from CMV-immune mice using
UV-irradiated target cells as stimulator cells Ho & Ashman
(1979) were able to demonstrate secondary CTL's which had been
generated in vitro. The generation of secondary CTL's from
peripheral blood lymphocytes from immune human donors has also
been demonstrated using CMV-infected autologous fibroblasts as
stimulator cells (Borysiewicz et al., 1983).
A proportion of circulating lymphocytes are the null cells
which include NK and K cells. Under appropriate conditions,
both these cell types can lyse CMV-infected target cells in
vitro and their combined activity accounts for most if not all
of the cytotoxicity of lymphocytes against infected cells
(Kirmani et al., 1981). It was concluded in this study that
both NK and K cells from immune persons were cytotoxic for
cells expressing CMV antigens and that the responsible
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effectors from non-immune lymphoctes were NK cells. However the
results clearly showed that specific antibody enhanced the
cytotoxicity of both immune and non-immune lymphocytes. This is
to be expected as K cells themselves have no immune specificty;
the specificity of antibody-dependent cellular cytotoxicity
(ADCC) is determined entirely by the specificity of the
antibody coating the target.
Cytotoxic lymphocytes such as these which do not require
to be presensitised with antigen for their activation may
provide an early means of eliminating lytically infected cells
before virus is released. Their presence may therefore
contribute to the maintenance of the latent state.
Reactivation of CMV Infection and reinfection
Much of our current information regarding CMV reactivation
and reinfection is based on findings in pregnant women and in
immunosuppressed allograft recipients and is discussed in those
contexts. The remaining information is derived in the main from
studies on patients attending STD clinics and much of this
pertains to male homosexuals. As sexual activity may be an
important determinant of both reinfection and reactivation
extrapolation from this data to the general population may not
always be valid.
Reactivation and reinfection are considered together here
as they cannot normally be distinguished in practice. The
events which precede and ensue from these two types of
infection may however be different. This is perhaps more likely
to be the case if reinfection is caused by a strain of virus
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which is substantially different in antigenic composition from
that to which pre-existing immunity is directed. Under these
circumstances exposure to exogenous virus without any local or
systemic changes in the immune or physiological status of the
host may be sufficient for reinfection to occur. In reality
however, these events may occur simultaneously, particularly if
exogenous virus is associated with immunomodulating agents such
as blood products (Goeken et al.. 1982) or seminal plasma
(James & Hargreave, 1984).
While evidence in pregnant women and immunosuppressed
patients discussed below indicates that reactivation of
infection is clearly influenced by the host immune status and
possibly by hormonal factors, it is not known whether subtle
changes in these parameters are necessary for subclinical
reactivation in healthy individuals. Reactivation of a
productive viral replication cycle at the molecular level may
conceivably occur in response to fluctuations in cellular
physiology which are independent of gross physiological
parameters. Whether such an event could lead to sufficient
viral replication to result in a detectable reactivation of
infection without concurrent changes in host physiology is nigh
impossible to ascertain.
Following infection an antigenically foreign virus may be
expected to elicit a greater immune response than a
reactivation of the original strain or a reinfection with a
similar strain. The timing and nature of this immune response
may determine the subsequent course of infection. The site of
initial infection may or may not be different in reinfections
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and reactivations and this too may bear upon the course of
infection.
Frequencies of excretion reported vary widely depending on
patient demography and the number of anatomical sites from
which viral culture was attempted. Where necessary, excretion
rates given below have been adjusted from the original
publications to give percentages which relate to the number of
immune persons rather than to the total number studied.
In the only study of non-pregnant women where cervical,
urinary and salivary excretion of virus were all considered,
33% of seroimmune women shed virus from at least one site, and
24%, 10% and 4% from the cervix, urine and saliva respectively
(Faix et al., 1983a). This study was conducted among adolescent
women who are known to have the highest excretion rates; in
studying an older age group Stagno et al. (1975a) and Knox et
al. (1979) reported cervical and urinary excretion rates of 10%
and 4% respectively. A higher cervical excretion rate (16%) has
also been observed in seroimmune women attending STD clinics
(Jordan et al., 1973).
Most of this excretion cannot be due to primary infection,
even assuming a high seroconversion rate and prolonged
persistence of excretion in many of these women. The relative
extents to which reactivation and reinfection contribute to
this excretion cannot however be determined.
Among male homosexuals reported frequencies of viruria in
the seropositive majority range from 8-9% (Drew et al., 198I;
Mintz et al., 1983) to 20% (Greenberg et al., 1984; Lange et
al., 1984). Virusemenia is reported to occur in 20% (Biggar et
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al., 1983; Lange et al., 1984) to 40% (Mintz et al., 1983).
Again these figures cannot be explained by high primary attack
rates as many of the men studied had been practising
homosexuals for 10 years or more and would presumably have
seroconverted in the distant past. The frequency of virusemenia
in a cohort of males not selected for homosexuality or
promiscuity by contrast was 2% (Lang & Kummer, 1975). a figure
consistent with the probable primary infection rate. (This
figure relates to the total number studied as no serology was
performed.)
All this evidence suggests that the genital tract is a
common site of reactivation and/or reinfection in both sexes
and that some of these infections may be restricted to this
site. In the only one of these studies where viraemia was
sought none was detected (Faix et al., 1983a). These infections
are almost always asymptomatic, however two cases of
non-primary infection associated with hepatitis or a
mononucleosis-like illness in male homosexuals have been
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reported (Coutinho et al., 1984).
The immune response to reactivation and reinfection has
been studied little. Coutinho et al. (1984) found that 4-5% of
seropositive male homosexuals per annum showed four-fold or
greater increases in CMV-IgG titres and Lange et al. (1984)
found that 66% had elevated IgG titres and that 30% had
specific IgM. This latter parameter correlated strongly with
the presence of viruria. On the other hand, Mintz et al. (1983)
studying a different homosexual population found that IgM
titres fluctuated with time but were positive in 95% of those
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with IgG on at least one occasion and did not correlate with
with virus excretion. Although antibody responses to
non-primary infection in the general population have not been
studied, these findings are unexpected as studies in healthy
pregnant women with asymptomatic non-primary infections show
that rises in antibody titre are uncommon (Stagno et al.,
1975a) and IgM responses are absent (Griffiths et al., 1982b).
Low or inverted TL+/T8+ lymphocyte subset ratios similar
to those observed in CMV-mononucleosis have been reported in
CMV-excreting homosexuals (Greenberg et al., 198I) but these
abnormalities are common in promiscuous homosexuals, at least
in the USA (Wallace et al., 1982) and others have found no
correlation with CMV excretion (Lange et al., 1984-). All this
raises the question as to whether these individuals are fully
immunocompetent, and this matter will be discussed
subsequently.
Only one group (Faix et al., 1983a) has studied
CMV-specific cell-mediated immunity in healthy, non-pregnant
women with non-primary infections. In this study (which was
conducted among adolescents with a high excretion rate)
CMV-specific lymphocyte proliferation was absent in over 30% of
seropositive women, however this bore no relationship to viral
excretion. Lymphocyte responses were found to fluctuate with
time, whereas mitogen responses were normal throughout. In
these individuals the specific lymphocyte response may
partially reflect some other immune function(s) which may be a
more important determinant of immunity to infection and which
may be defective or reduced in excreting women. This is
92
suggested by the correlation between increasing age and reduced
virus excretion and by the increased number of adults who give
positive lymphocyte proliferation to CMV, despite no
correlation between excretion and lymphocyte reactivity. An
age-related decrease in the prevalence of CMV excretion is also
observed in homosexual men (Biggar et al., 1983; Drew et al.,
1981). Other immune responses have not been studied in these
groups.
CMV infection during pregnancy
CMV infection in the pregnant woman has received much
research with the aim of identifying factors important in
facilitating transplacental transmission of infection. It is
not known however to what extent infection in this setting
resembles or differs from infection in other healthy adults.
Physiological changes occurring during pregnancy may alter the
frequency of reactivation or modify the course of infection.
Pregnancy hormones may influence viral replication directly by
their effects on infected cells (Chong & Mims, 1984.; Koment,
1985: Tanaka et al., 1984a; b) or indirectly by modifying
aspects of immune responsiveness (Kasakura, 1971; Stimson et
al.. 1980). While some modification of maternal immunity may be
necessary to prevent rejection of the histo-incompatible
foetus, this alteration may be very subtle or specific. The
virtual absence of MHC class I and II antigen expression on the
syncytiotrophoblast which forms the materno-foetal interface
(Faulk & Temple, 1976; Goodfellow et al., 1976) may preclude
the necessity for generalised suppression of MHC-restricted
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immune responses. At least some blocking factors present in
pregnancy plasma specifically inhibit the one-way MLR of
maternal lymphocytes against paternal lymphocytes only
(Mclntyre & Faulk, 1979).
In view of this it is perhaps not surprising that many
have found no generalised impairment of cellular immunity as
detectable in total T cell numbers and proliferation responses
to mitogens and recall antigens (Faix et al„ 1983b; Gehrz et
al.. 1977; Reynolds et al.. 1979; Starr et al., 1979). There is
no general agreement on this matter however (Birkeland &
Kristoffersen, 1980; Blecher & Thompson, 1976; Finn et al.,
1972) and other aspects of immunity such as the MLR are
reported to be increasingly suppressed during the course of
gestation (Kasakura, 1971). Other evidence of selective immune
suppression is the observation of spontaneous remission of some
autoimmune phenomena such as rheumatoid arthritis during
pregnancy (Ostensen & Husby, 1983) and the altered pathogenesis
of certain viral infections during pregnancy. This may be
manifested as an increased rate of infection or reactivation of
infection, increased severity or mortality of infection, or
deficient in vitro immune responses to viral antigens. This is
true of infection during pregnancy with hepatitis viruses
(Christie et al., 1976; D'Cruz et al., 1968), influenza virus
(Greenberg et al., 1958), poliovirus (Siegal & Greenberg,
1955). rubella virus (Thong et al., 1973), polyoma viruses
(Coleman et al., 1983). VZV (Mendelow & Lewis, 1969), and
occasionally with HSV (Peacock & Sarubbi, 1983).
Reported CMV excretion rates in pregnant women range from
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around 10% (Knox et al., 1979." Montgomery et al., 1972; Stagno
et al.. 1975a) to 20% (Faix et al., 1983b; Nankervis et al.,
1984). The higher prevalence in these last two reports is due
to the restriction of the study populations to adolescent
women; increasing age is associated with lower excretion, as is
increasing parity. Viral shedding from the cervix is more
common than urinary shedding [rates of 8-10% versus 3-5%
respectively were reported by Knox et al. (1979), Montgomery et
al. (1972) and Stagno et al. (1975a)]. Higher excretion
prevalences are observed during the third trimester and
postpartum period than during early pregnancy. Stagno et al.
(1975a) and Knox et al. (1979) found that excretion rates
during the third trimester and post partum were not
substantially different from those in nonpregnant women.
Knowles et al. (1982) however found a higher incidence of
cervical excretion in post partum women when compared to
nonpregant women. Further study is required to clarify the
relative frequencies of excretion in pregnant and nonpregnant
women, taking into account age race, parity and gestational
age.
CMV infection during pregnancy, whether primary or not is
usually asymptomatic; primary infection is rarely associated
with a mononucleosis syndrome (Faix et al., 1983b; Griffiths et
al., 1978; Kumar et al., 1984; Stagno et al., 1982b). Virus is
usually excreted in low amounts only but excretion may be
persistent, continuing for three years or more following
delivery (Nankervis et al., 1984). Viraemia is not usually
detectable (Kumar et al., 1984; Pass et al., 1982b).
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Infection of the placenta is probably necessary for
intrauterine transmission to occur. While it is Known for
congenitally infected infants to be delivered from mothers
whose placentae were free of infection (Nankervis et al., 1984)
this may be due to resolution of placental infection some time
between transmission and delivery. If the placenta is infected
at term, it is likely but not inevitable that foetal infection
will have resulted. Transmission is more likely to occur and
possibly to be of greater clinical consequence to the foetus if
maternal infection is primary as discussed in Chapter 2.
Transmission is also more likely in those women who excrete
higher titres of virus in urine and in those nonprimary
infections associated with significant rises in antibody titre
during gestation (Nankervis et al., 1984). Excretion of virus
from the cervix or oropharynx only may represent localised
reactivation of infection resulting in little Immune
stimulation and with low risk to the foetus, at least during
intrauterine life. Those women who transmit CMV infection in
utero are also those who excrete virus in higher titre and for
longer periods in the post partum (Pass et al., 1982b). In the
study of Pass et al. (1982b), two of these risk factors, namely
primary infection and urinary viral excretion, were related;
women with primary infection more frequently excreted virus in
higher titre and for longer periods than those with nonprimary
infection. In the study of Nankervis et al. (1984) however,
these factors were unrelated as most infections were
nonprimary. This suggests that there may be other factors in
addition to primary infection which are responsible for
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increased viral excretion and increased immune stimulation in
some women. Some women may be susceptible to reactivation with
a greater degree of viral replication, reflected in increased
urinary excretion of virus and increased risk of transmission.
This cannot be the sole determinant of risk to the foetus
however as transmission does not necessarily result even when
viraemia is present during gestation or when the placenta
becomes infected (Faix et al„ 1983b; Kumar et al„ 1984). That
some women may have a propensity to transmit infection to the
foetus is suggested by two observations. Firstly, immune women
from poorer communities transmit CMV infection more often than
women from more affluent communities (1.5% versus 0.5%
respectively; Stagno et al., 1982b). Secondly, in a recent
study in London (Griffiths & Baboonian, 1984a) the only case of
congenital infection among infants born to immune women
occurred in an infant whose older sibling was also congenitally
infected despite pre-existing maternal immunity. In view of
these observations the authors speculate with Stern (1977) that
some women are at increased risk of transmitting infection in
utero and that infection occurring in early life, which is the
norm in developing nations may be one cause of this maternal
defect. Other maternal factors which appear to affect the
frequency and duration of excretion are age and parity, as
already mentioned (Montgomery et al., 1972; Pass et al., 1982b;
Stagno et al., 1975a)* The finding that transmission is more
likely to occur when maternal infection takes place during the
final trimester (Griffiths & Baboonian, 1984b; Nankervis et
al., 1984) may be due to greater suppression of immunty to CMV
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at this stage (see below) or may be due to changes in the
structure of the placenta, as proposed by Nankervis et al.
(1984).
Humoral immune responses to CMV infection during pregnancy
are well delineated. Primary infection elicits seroconversion
and an IgM response of up to four months duration (Griffiths et
al., 1982b). Reactivated infection may be associated with a
rise in antibody titre but most are not (Nankervis et al.,
1984; Stagno et al., 1975a) and no IgM response is present
(Griffiths et al., 1982b).
Current knowledge regarding cellular immunity to CMV
infection during pregnancy is incomplete as most studies have
been limited to the post partum period, and primary and
nonprimary infections are generally not distinguished. Gehrz et
al. (1981a; b) followed seroimmune women throughout pregnancy
and found that CMV-specific proliferative responses became
increasingly depressed with increasing gestational age.
Responses to PHA were normal throughout; responses to recall
antigens however also became depressed, but not to the same
extent as CMV responses. The responses to CMV and other recall
antigens reappeared around four months and three months
respectively after delivery although the former remained low
for longer periods. It was suggested that this may allow
reactivation and transmission of infection to the foetus.
Although this is consistent with the findings of increased
frequency of CMV excretion towards the end of pregnancy, none
of the women in this study actually excreted virus, and Faix et
al. (1983b) found that while proliferative responses to CMV
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were frequently low or absent during pregnancy, this did not
correlate with the presence or absence of viral excretion.
Suppression of the CMV- specific proliferation response during
pregnancy, then, is not necessarily related to active
infection.
This complicates the interpretation of lymphocyte
proliferation results in post partum women. As expected from
the above studies, women who were excreting late in pregnancy
or who gave birth to infected infants showed a marked
depression of this response post partum (Gehrz et al„ 1977;
Reynolds et al„ 1979; Starr et al., 1979). however these women
were not compared with post partum women without recent
infection. Presence or absence of the response did not
correlate with a history of transplacental transmission or with
current virological status, but in women with congenitally
infected infants the response was on average lower in those
with symptomatic infants than in those with asymptomatic
infants. It cannot be determined whether this reduced response
was causal or consequential to the type of congenital
infection, or a reflection of some other immune defect. It is
possible that reduced proliferative responses and symptomatic
congenital infection are both more likely when maternal
infection is primary.
Mechanisms whereby lymphocyte proliferative responses are
suppressed during pregnancy are not apparent. It is not clear
whether suppression of the CMV-specific response is a
reflection of a more generalised immune defect associated with
pregnancy or is the result of a specific defect as observed in
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congenitally and postnatally infected infants. Limited evidence
indicates that serum factors and monocyte-derived macrophages
may suppress CMV-specific lymphocyte proliferation in an
antigen specific manner as described in congenitally infected
infants (Coleman et al., 1982).
It is clear from all this that lymphocyte proliferation
studies alone give little or no indication as to why CMV
infection reactivates in some pregnant women and results in
intrauterine infection in a proportion of these women.
Investigation of other cellular immune parameters may reveal
specific defects in immunity. Such studies are virtually absent
in the literature. Rola-Pleszczynski et al. (1977) found that
lymphocyte-mediated cytotoxicity was on average lower in
mothers of congenitally infected infants. Comparison of these
findings with results in other pregnant and post partum women
would be necessary to establish any relationship to infection
or transmission. The nature of the cytotoxic cell type
participating in this assay was not determined. The specificity
of cytotoxicity is most consistent with an NK-like function.
In summary, the CMV-immune pregnant woman may be
susceptible to reactivated infection. This susceptibility is
greatest in the period before and after delivery but how this
compares with excretion rates in other women is not entirely
clear. Pregnancy is associated with a decreased lymphocyte
proliferation response to CMV which may be partly or entirely
CMV-specific. This defect is of unknown cause and bears little
or no apparent relationship to reactivation of infection or
transmission to the foetus. Immune, hormonal and other factors
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which influence these events have not been elucidated. Primary
infection is associated with a higher incidence of
transmission, however other virological and immunological
aspects may be similar to those in other adults with primary
infection.
CMV infection in the immunocompromised host
Several patient groups fall within the category of
immunocompromised patients. Those discussed here are mainly
those patients iatrogenically immunosuppressed in connection
with renal, cardiac or bone marrow transplantation. Many
features of CMV infection in these patients are also true of
infection in other compromised hosts, such as those receiving
radiation or chemotherapy for malignant disease (Agatsuma et
al., 1979). Patients with acquired immune deficiency syndrome
(AIDS) are discussed in the following chapter.
a) Renal and cardiac allograft recipients.
Renal and cardiac transplant patients are susceptible to
infection with a variety of viruses including all four human
herpesviruses (Cheeseman et al., 1980; Gallagher & Merigan,
1979: Kanich & Craighead, 1966: Lopez et al., 1974a). Of these,
CMV infection is the most important, both numerically and
clinically (Fiala et al.. 1975). As discussed in Chapter 2, CMV
infection occurs in up to 100% of initially seropositive and in
4.0-60% of initially seronegative renal and cardiac recipients.
CMV infection is detectable by isolating virus from urine,
throat washings, leukocytes or bronchial washings, or by
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demonstrating specific IgM or rising antibody titres. Viral
excretion or viraemia begins on average around five weeks post
transplant when infection is primary and around eight weeks
post transplant in other types of infection (Pass et al.,
1983c) however a significant proportion of patients with
serological evidence of secondary infection do not become
viruric (Sarov et al., 1984). Most infections are due to
reactivations of latent virus either from the donor organ or
from the recipient, although some may be transfusion
associated. The shorter interval between grafting and excretion
in primary infections indicates that reactivation from the
donor organ may occur more easily or may lead to a detectable
viral infection more readily in the non-immune host. Viral
excretion is prolonged; half of long-term survivors are still
shedding two to five years post transplant and although the
frequency of shedding falls thereafter, excretion has been
documented as long as 14 years after transplantation (Cheeseman
et al., 1979b).
The most common presenting symptom of CMV infection in
these patients is fever. This is frequently accompanied by
other signs and symptoms however, the most important being
pneumonia, leukopenia, hepatitis and, in renal transplant
recipients graft failure (Fiala et al., 1975; Marker et al.,
1981; Rubin et al., 1977; Simmons et al., 1974). Symptoms are
more likely to occur in those with primary infection; 80% of
primary infections are accompanied by clinical manifestations
compared to only 30% of nonprimary infections (Betts et al.,
1975; Ho et al., 1975: Whelchel et al., 1979). Clinically
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apparent infection is also strongly associated with viraemia
which is demonstrable in 10-60% of infected patients (Cheeseman
et al.. 1979a; Fiala et al.. 1975)- The incidence of CMV
reactivation, viraemia and symptomatology are all greater in
those patients who receive antithymocyte globulin (ATG) as part
of their immunosuppressive regime (Cheeseman et al., 1979a;
Pass et al., 1980b; 1981b; Preiksaitis et al., 1983; Schooley
et al., 1983). ATG results in a greater reduction in T cell
numbers and suppression of T cell function than other
immunosuppressive agents (Thomas et al., 1977). Viraemic
infection would thus appear to be favoured when infection is
primary and when immunosuppression is greater and this in turn
results in greater dissemination of infection.
The frequency and severity of CMV-pneumonia in transplant
patients (Hill et al., 196U) may be due to the extreme
permissiveness of alveolar macrophages for CMV replication
(Drew et al., 1979). An inflammatory response to infection in
the lungs may then result not in viral clearance but in
amplified viral replication.
The pathogenesis of renal graft dysfunction is less clear.
Rejection episodes occur more frequently in patients with
primary infection and with secondary infections where an IgM
response is present. IgM titres are also temporally associated
to rejection episodes in a proportion of cases (Sutherland &
Briggs, 1983). Some have postulated that CMV may cause or
enhance rejection (David et al., 1972). It is also possible
that allogeneic reactions occurring during rejection may
enhance CMV reactivation or replication as has been
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demonstrated in a murine model (Wu et al., 1975)- Of relevance
in this respect is the finding that CMV infection is more
common and occurs after a shorter interval in recipients of
cadaveric organs which are less likely to be as well matched to
the recipient as allografts from living related donors (Pass et
al., 1978; 1980b). Defining the association between CMV
infection and rejection is further complicated by the fact that
not all renal graft dysfunction is due to classical rejection.
Glomerulopathy is more common in symptomatic and viraemic CMV
infections (Richardson et al., 1981; Schooley et al., 1983) and
may be due to viral replication in the kidney or to circulating
immune complexes. While this condition may be clinically
indistinguishable from rejection in the absence of biopsy
evidence, resolution of glomerulopathy, unlike rejection
follows a decrease in immunosuppressive therapy. This
highlights the necessity of close virological monitoring of
these patients to enable allograft dysfunction due to viral
infection to be distinguished from rejection when considering
therapeutic measures.
The cause of leukopenia in association with CMV infection
is also unclear. While leukopenia due to immunosuppression may
predispose to CMV infection, onset of CMV infection is often
closely associated with a further reduction in leukocyte count
which remains low even when immunosuppresive therapy is
discontinued (Rubin et al., 1977). In this situation the risk
of superinfection is high and prognosis is poor. Lytic
infection of leukocytes is unlikely to be directly responsible
for leukopenia as only a small proportion of cells are
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infected. Virus is isolated mainly from the PMNL-rich fraction
although also to a lesser extent from mononuclear cells (Fiala
et al„ 1975); a single report documents the presence of CMV in
a very low percentage (0.00003°=) of T cells (Garnett, 1982).
IgM lymphocytotoxic antibody is produced in varying amounts in
response to CMV infection (Baldwin et al„ 1983) and this may
contribute to leukopenia. In many of these patients CMV and
other herpesvirus infections are associated with reduced
numbers of circulating T4+ lymphocytes, increased numbers of
T8+ lymphocytes and inverted T cell subset ratios (Schooley et
al„ 1983) which may result from events similar to those
occurring in the mononucleosis syndrome. In recipients of
allografts from living related donors where lower dose
immunosuppression is often used these alterations have only
been observed in CMV infections (Schooley et al., 1983). This
can occur without resulting in absolute lymphopenia but this
may not be true of the more severely immunosuppressed patients.
The immune response to CMV infection has been well studied
in renal and cardiac transplant recipients. A vigourous humoral
response to infection is observed in most patients which may be
due to elimination of regulatory T cells or, more likely, to
the reduced ability to restrict viral replication resulting in
greater antigenic stimulation of B cells as suggested by Lopez
et al. (1974b). In some patients the antibody response to
infection is poor. Fatal dissemination of infection is common
in such patients (Pass et al., 1983c; Rasmussen et al., 1982;
Simmons et al., 1974). This may indicate a protective role for
antibody in modifying infection in transplant patients or may
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reflect a more profound cellular immune dysfunction with little
helper T cell function in those who do not mount a humoral
response. That antibody itself may contribute to protection or
recovery from infection is suggested by the reports that some
CMV infections appear to resolve following administration of
hyperimmune globulin (Nicholls et al., 1983). This finding
parallels that in a murine model (Shanley et al., 1981).
Primary CMV infection in renal and cardiac transplant
recipients is usually accompanied by a specific IgM response
(Pass et al., 1983a; Rasmussen et al.. 1982; Sutherland &
Briggs, 1983). Peak IgM titres coincide with the onset of viral
excretion and with symptoms when present, but unlike patients
with mononucleosis or pregnant women with asymptomatic
infection, IgM titres frequently persist for a year or longer.
The IgA response has not been studied in transplant recipients
with primary CMV infection. Since humoral immunity is generally
intact, this is likely to be present early in infection also.
The IgG response takes place concomitantly with the IgM
response in primary infections (Pass et al., 1983a). This
response is directed against similar targets as the response in
other primary infections. CF titres and antibody titres to
early and late antigens rise sharply following the onset of
viral shedding (Pass et al., 1983a). The response to pre-early
nuclear antigens however may lag behind other responses in
these patients (Gartner & Orstavik, 1984). IgG titres generally
peak at around 20 weeks after transplant and remain stable
throughout follow-up (Pass et al., 1983c).
In patients with nonprimary CMV infection, the timing and
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nature of the immune response is less predictable. Serological
evidence of infection precedes viruria in about two thirds of
patients and the appearance of specific serum IgA is often the
first serological response to infection detectable (Sarov et
al., 1981; 1982; 198&). In other patients the appearance of
serum IgA coincides with a rise in IgG titres and overall over
90% of patients with recurrent infection produce IgA.
IgM is also produced in around 1X0% of nonprimary infection
(Pass et al., 1983a; Sarov et al., 198^-; Sutherland & Briggs,
1983). It has been speculated that an IgM response may be more
common in reinfections acquired from the donor organ than in
reactivations of virus latent in the recipient. The appearance
of IgM is temporally related to a rise in IgG titres in most
cases and to the appearance of IgA in some cases. The IgM
response postdates the appearance of IgA in many however (Sarov
et al., I98U). IgG titres do not generally approach those seen
in primary infection (Pass et al., 1983b) but remain relatively
high for long periods (Roenhorst et al., 1985). IgM and IgA
titres frequently persist for a year or more.
Cell-mediated immunity has also been thoroughly
investigated in renal and cardiac transplant patients. The aim
of immunosuppressive therapy in these patients is to suppress
cell-mediated immune functions specifically, which include
those responsible for graft rejection. This treatment may
result in a reduction of the proliferative response of PBL to
mitogens (Agatsuma et al., 1979: Lopez et al.. 197&b) but this
is usually only demonstrable in those receiving ATG at the time
of testing (Pass et al., 1981; Rand et al., 1976). The defect
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can be overcome In vitro by culturing PBL in pooled plasma
instead of autologous plasma (Lopez et al., 197^b) indicating
that some immunosuppressive agents may act by suppressing
lymphocyte activation or proliferation. As will be seen however
these agents also act by blocking the maturation of functional
effector cells from thymic precursors. Lymphocyte reactivity is
maximally depressed during the first three months after
transplantation and gradually returns to normal or near normal
levels as immunosuppression is reduced to maintenance levels.
The development of antigen-specific reactivity following
transplantation follows a similar time course to that described
above for mitogen responsiveness. In one study (Rand et al.,
1976) HSV-specific responses were maximally depressed during
the first three months - the period when HSV reactivations are
most common - and normalised thereafter. In contrast the return
of VZV-specific responsiveness was delayed beyond this early
period. Reactivated VZV infections were uncommon in this
patient cohort, suggesting that return of immune responsiveness
may be dependent on active infection and immune stimulation.
This is consistent with the results of Haahr et al. (1979) who
found that HSV-specific responses were actually elevated during
the first year in comparison with healthy controls and fell
thereafter in parallel with the declining frequency of HSV
infections.
This pattern of returning immune reactivity does not
extend to CMV-specific immunity however. Although most CMV
infections occur during the early months after transplantation,
specific lymphocyte proliferative responses do not return to
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normal for- at least two years, irrespective of whether
infection is primary or not (Agatsuma et al., 1979; Haahr et
al.. 1979: Pollard et al., 1978; Roenhorst et al., 1985). Pass
et al. (1981b) found that persistence of unresponsiveness was
more pronounced in those receiving ATG. Immunosuppressive
therapy may then aggravate lymphocyte unreactivity to CMV but
would not seem to be the sole cause as the return of the CMV-
specific response is delayed beyond the recovery of other
responses, even in those receiving ATG. The development of a
lymphocyte response to CMV bears some temporal relationship to
the cessation of viral excretion in these patients suggesting
that this may be one effector function responsible for
curtailing residual viral replication. In particular the
proliferative response to CMV-infected cells has been found to
be lower in those who had experienced secondary infections
during the first six months post transplant compared with those
who had not become infected during this period and this
parameter only returned to normal in long term survivors
(Roenhorst et al.. 1985). The response to CMV virion antigens
was low in both groups of long term survivors in this study.
This may suggest that reduced responsiveness to infected cell
antigens is more likely to result in reactivated infection than
reduced responsiveness to virion antigens only, but induction
of a long-term suppression of the reponse to the former
following reactivation may also be possible.
Prolonged suppression of the proliferation response to CMV
appears from these results to occur following active CMV
infection and may be partly CMV-speclfic although admittedly
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this is difficult to ascertain in these patients. A general
impairment of immunity is likely to occur in those infections
associated with leukopenia and this may not be apparent in
proliferation assays using standardised lymphocyte numbers. The
frequency of superinfections in those with CMV infection
testifies to such an impairment.
In contrast to the delay in the development of the DTH
response to CMV infection, cytotoxic responses are elicited
early in infection in most cases. These responses have been
studied in renal transplant patients by Rook et al. (1984).
Serious or fatal CMV infections were confined to those who did
not mount a cytotoxic response. This response was mediated by
CTL's and/or NK and K cells. NK and K cell activity was
depressed throughout the first three weeks after transplant
compared to pretransplant levels in most patients. (Activated
CTL's were also absent prior to transplantation as in most
latently infected individuals.) Following infection activated
cytotoxic cells developed rapidly - prior to excretion and to
the rise in antibody titres in the majority, even when
infection occurred early after transplantation. Patients with
CTL responses also showed generally higher levels of NK and K
cell activity although in some patients these latter responses
developed in the absence of a CTL response.
The absence of a cytotoxic response was associated with
large dose methylprednisoline administration between five and
14 days previously to treat rejection episodes. The five day
delay before this treatment suppressed cytotoxic function
indicates that this drug acts primarily on cytotoxic
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precursors. (ATG was not used in these patients.) Patients with
cytotoxic responses did not suffer prolonged viraemia,
pneumonitis or superinfections and had a significantly lower
incidence of leukopenia and graft dysfunction. These responses
therefore appear to be effective in restricting viral
replication and curtailing viraemia, although not prolonged
viral excretion. Far from resulting in graft rejection as has
been speculated, these responses protect against it.
Cytotoxic responses were not the only protective
mechanisms operative in these patients as most of those without
them eventually recovered, despite complications. The only
patient who died in this study was one of the two who failed to
mount both cytotoxic and humoral responses to infection.
Cheeseman et al. (1979a) reported that administration of
human-leukocyte IFN prolonged the interval between
transplantation and onset of virus excretion and reduced the
incidence of viraemia. This beneficial effect may have been due
to potentiation of cytotoxicity mediated by NK and K cells
(Herberman et al., 1979) and CTL's (Zarling et al., 1978),
however the diverse functions of IFN may also have resulted in
other protective mechanisms.
b) Bone marrow allograft recipients.
The plight of bone marrow transplant patients is in some
ways similar to that of other transplant patients, only
greater. In addition to chemotherapy in order to suppress graft
versus host (gvh) disease, these patients receive total body
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irradiation prior to transplantation aimed at eliminating bone
marrow haematopoeic precursor cells. This results in a state of
profound immunodeficiency in the initial period after
transplant (Gale et al., 1978), followed by a gradual return of
immunocompetence as the donor marrow establishes and assumes
functional capacity. During marrow regeneration T8+ cells
reconstitute more rapidly than Tl+ cells resulting in a low
TU+/T8+ ratio (Schroff et al., 19S2; Singer et al., 19S3).
During the first few months after transplant, IL 2 production
by lymphocytes is very low, probably due to a lack of
functional IL 2-producing lymphocytes. IL 2 production remains
lower than normal after this period for at least two years, due
in part to the excess numbers of suppressor cells which inhibit
IL 2 production (Azogui et al., 1983).
During this period infectious complications are common and
CMV emerges as a major pathogen. Interstitial pneumonitis is
frequently associated with CMV infection, however pulmonary
cytotoxicity due to gvh disease, chemotherapy, irradiation and
other infections, particularly Pneumocystis carinii are also
implicated in this condition (Meyers et al., 1975) and it is
often difficult to identify a primary etiology even when
pulmonary CMV infection is present. Interestingly in one study
of 100 syngeneic transplant recipients (Appelbaum et al.. 1982)
no instances of CMV associated pneumonia were recorded, despite
similar excretion rates to recipients of allogeneic marrow
transplants. This may have been due to differences in the incidence
of gvh disease, in the degree of immunosuppressive therapy used
for its treatment or prevention, or in the rate of
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immunological reconstitution between these two groups.
There is no difference in the incidence or severity of
infection between those who were immune prior to transplant and
those who were not (Meyers et al„ 1980c). All infections in
these patients are primary-like and this is also evident in
the serological response to infection. Skinho;) et al. (1984)
showed that most infections during the first five months were
associated with both seroconversion or rising IgG titres and
specific IgM production. It was not clear from this study
whether the serological response coincided with the onset of
CMV infection or the return of immunocompetence however,
particularly those infections during the very early post
transplant period. Failure to mount this response was recorded
in five of 16 patients and was associated with high dose
chemotherapy at the time of infection. All these patients
succumbed to CMV-associated pneumonia.
CMV infection is associated with particularly low mitogen
responsiveness in comparison with uninfected patients (Meyers
et al., 1980c; Quinnan et al., 1981; 1982a). This may be
related to the similar situation in CMV-mononueleosis, but it
is also possible that emergence of CMV infection and mitogen
unresponsiveness have a common cause, such as gvh disease or
its treatment. CMV-specific lymphocyte proliferation responses
are absent or significantly depressed after transplant and
usually do not develop until CMV infection occurs irrespective
of the pretransplant immune status of the recipient or the
donor Meyers et al., 1980c). Even when infection does occur the
response is usually delayed for three weeks or more in relation
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to the serological response (Quinnan et al., 1981). This is
still more rapid than the appearance of the response reported
in renal transplant recipients however it is not known if the
assays used are comparable. The delay in the response may be
due to suppression of proliferative responses in general
induced by CMV infection or may be due to the relatively low
numbers of helper T cells. While this latter possibility is
likely to contribute to the unresponsive state, CMV infection
may also exert an additional immunosuppressive influence as a
limited study of patients with active VZV infection indicates
that VZV-specific proliferation responses are elicited rapidly
following infection (Meyers et al., 1980a). In marrow
transplant recipients surviving over 200 days proliferative
responses to VZV, HSV and CMV are similar to those of normal
individuals (Meyers et al., 1980a; b; c).
As with other transplant recipients, the generation of
cytotoxic responses occurs rapidly in marrow transplant
recipients following active CMV infection and has been studied
by Quinnan et al. (198I; 1982a). The HLA-restricted CTL
response is often detectable prior to seroconversion and is
transient, declining after recovery. This response is rapidly
followed by NK and I< cell responses in most patients. In some
patients these are the only cytotoxic responses demonstrable.
These responses persist for longer than the CTL response and
may be important in maintaining the infection-free state.
Unlike renal transplant recipients, failure to elicit a
cytotoxic response is uniformly associated with a fatal outcome
in these patients. Low NK and K cell activity is also evident
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prior to the onset of fatal infection.
These results indicate that cytotoxic responses are
important in promoting recovery from CMV infection in marrow
transplant recipients also. Protective roles for other immune
responses cannot however be discounted. Winston et al. (1982)
has reported that administration of immune plasma throughout
the period of greatest susceptibility to CMV infection does not
reduce the frequency of Infection but does reduce the incidence




THE ACQUIRED IMMUNE DEFICIENCY SYNDROME
The outbreak of opportunistic infections and Kaposi's
sarcoma (KS) in 1978 among male homosexuals in certain American
cities has presented one of the greatest challenges of our
times to all branches of medical science. Numerous speculations
on the etiology of this acquired immune deficiency syndrome
(AIDS) have been put forward in an attempt to explain its
apparent sudden onset in epidemic proportions and its frequency
amongst particular population groups. Many of these theories
have envisaged a multifactorial etiology and most Include one
or more infectious agents as important factors.
The prominence of CMV infection in the syndrome was
recognised in the earliest observations. A description of the
epidemiology, microbiology and immunology of AIDS is necessary
to establish the background against which this CMV infection is
set. Although the primary etiology of AIDS is now known to be
the retrovirus human T-lymphotropic virus type III (HTLV III;
also known as lymphadenopathy-associated virus [LAV]), a
consideration of previous hypotheses of etiology is also
beneficial as it underlines the complex interactions that occur
in AIDS. Furthermore the identification of the primary
causative factor does not rule out the possibility that other
factors may also be important or even essential to the
pathogenesis of AIDS following the initial retrovirus
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infection. In the present context, such a discussion also
emphasizes the prominence of CMV infection, both prior to and
during the evolution of the syndrome.
AIDS was first identified in promiscuous male homosexuals
(Follansbee et al., 1982; Gottlieb et al.. 1981; Mildvan
et al., 1982; Masur et al., 1981; Siegal et al., 1981) and most
cases in the west have arisen among this group. Other groups at
risk are intravenous drug abusers (Gold et al., 1982; Masur
et al., 1981; 1982), recipients of blood transfusions (Curran
et al.. 1984) and blood products, in particular factor VIII
(Evatt et al., 1984), Haitian immigrants to the USA (Pitchenik
et al., 1983; Vieira et al., 1983). sexual contacts of
individuals in these groups (Masur et al.. 1982; Pitchenik
et al., 1984) and Infants born to women at risk (Oleske et al.,
1983; Scott et al., 1984). An increasing number of cases are
being identified outside the USA and the disease is now known
to be endemic in several central African countries (Piot
et al.. 1984; Van de Perre et al.. 1984) with an estimated
frequency of up to eight cases per 10 000 of the population per
annum in one city and a female to male ratio approaching unity.
Transmission appears to be predominantly among promiscuous
heterosexuals in Africa. This is suggestive of an epidemic at a
more advanced stage even than that observed in the USA and is
consistent with an African origin for AIDS. The common
denominators in most of these groups are intimate or parental
contact with blood and its derivatives, semen or other body
fluids. The apparent exception of the Haitian group may be due
to difficulties in evaluating this group for risk factors.
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Cases may present with a range of opportunistic
infections. AIDS was initially recognised by the unusually high
frequency of Pneumocystis carinll in previously healthy
homosexual men (Gottlieb et al.. 1981; Masur et al.. 1981).
Other protozoan, fungal and bacterial infections seen include
Toxoplasma gondii, Entamoeba histolytica, Cryptococus
neoformans, Isospora belli. Candida albicans. Nocardia species,
Mycobacterium tuberculosis and M. avium intracellulars,
Pseudomonas aeruginosa and Staphylococcus species (Gottlieb
et al., 1981; Greene et al., 1982; Follansbee et al., 1982;
Masur et al.. 1981; Mildvan et al., 1982; Ng et al.. 1984).
Viral infection and reactivation is extremely common; CMV
infection is almost universal (Gottlieb et al., 198I; Quinnan
et al., 1984) as is EBV infection (Quinnan et al., 1984). HSV
and VZV infections are also common, and are a cause of
significant morbidity (Quinnan et al., 1984; Siegal et al.,
1981). Polyoma virus (England et al.. 1984; Miller et al..
1982) and adenovirus infections (Brodie et al.. 1984) have also
been described.
KS is the most common malignancy encountered in AIDS (Drew
et al., 1982; Friedman-Kien et al., 1982; Urmacher et al.,
1982). This is unlike the classical KS seen in elderly or
iatrogenically immunosuppressed individuals which usually runs
a slow, indolent course, and is more similar to the aggressive,
often lymphadenopathic form seen most commonly in young male
and less commonly female Individuals in parts of central Africa
(Slavin et al., 1970; Taylor et al.. 1971) which is also
associated with immunosuppression (Master et al., 1970). The
development of KS has been confined mainly to male homosexuals
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with AIDS where it is observed in a third of cases (Guinan
et al.. 1984). 10-20% of African cases have KS (Piot et al„
1984; Van de Perre et al.. 1984) but few cases have been
reported in drug addicts and Haitians (Guinan et al.. 1984) and
none in haemophiliacs (Evatt et al.. 1984). The likelihood of
KS occurring may then be Influenced by other factors more
prevalent among homosexuals, as well as by genetic factors
(Friedman-Kien et al.. 1982). Non-Hodgkins lymphoma has also
been documented less frequently in AIDS patients (Ziegler
et al., 1984).
Death in the AIDS patient most commonly results from
pneumonia caused by opportunistic infections, notably
P. carinli (Centers for Disease Control, 1983) and CMV (Macher
et al., 1983). These two infections often occur together
(Follansbee et al., 1982; Gottlieb et al., 1981).
The occurrence of these opportunistic infections and
neoplasms is highly suggestive of an impaired immune system
and immunological investigation of AIDS patients bears this
out. Patients show varying degrees of anergy in the DTH test
reactions (Friedman-Kien et al.. 1982) and in vitro
proliferative responses to T cell mitogens and recall antigens
are significantly depressed (Gottlieb et al., 1981; Masur et
al., 1981). Leukocytes function poorly both as responders and
stimulators in the allogeneic and autologous MLR (Gupta &
Safai, 1983; Masur et al., 198l;1982). These in vivo and
in vitro tests of immune function are dependent largely on T4+
lymphocyte function. Analysis of leukocyte populations reveals
a reduction in total lymphocyte numbers and total T cell
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numbers (Masur et al., 1981) and an inversion of the normal
T//+/T8+ lymphocyte numbers ratio which is due mainly to a
selective, sometimes almost complete elimination of Tk+
lymphocytes (Friedman-Kien et al.. 1982; Gottlieb et al., 198I;
Mildvan et al., 1982). The percentage of T8+ lymphocytes is
increased as a result but absolute numbers are normal or
somewhat depressed. This is not due to sequestration of T//+
lymphocytes in lymphoid tissue as analysis of lymph node
lymphocyte populations reveals the same selective depletion of
T//+ lymphocytes (Modlin et al., 1983). Low or inverted T/I+/T8+
lymphocyte ratios of a less striking nature have also been
observed in those with ARC1 (Cavaille-Coll et al.. 1985; Hersch
et al„ 1984; Mathur-Wagh et al., 198/1), in healthy homosexuals
(Detels et al., 1983; Fahey et al.. 1983; Kornfeld et al..
1982; Wallace et al„ 1982), promiscuous women (Wallace et al.,
1983) and in treated haemophiliacs (Menitove et al., 1983) but
except in those with ARC, this is due mainly to elevation of
T8+ lymphocyte numbers in most cases. These changes may be
related to the incubation phase of AIDS or may be due to
other causes.
The extent of the reduction in T4+ lymphocyte numbers is
generally reflected in the degree to which immune function is
impaired in these groups. In vitro and in vivo DTH responses
and mitogen-induced proliferative responses are maximally
suppressed in those with fulminant AIDS, intermediate in those
with ARC and least affected but still significantly lower than
normal in healthy homosexuals (Cavaille-Coll et al.. 198//;
1 ARC = AIDS related complex.
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Gluckman et al.t 1985: Hersch et al., 1984; Kalish et al.,
1984; Mathur-Wagh et al., 1984; Stahl et al., 1982). This
results from low IL 2 production following antigenic or
mitogenic stimulation of lymphocytes (Alcocer-Varela et al..
1985; Gluckman et al., 1985: Tsang et al., 1984).
In healthy homosexuals this may be due to the presence of
high numbers of T8+ suppressor cells, however in patients with
AIDS an intrinsic defect in the function of the remaining T4+
cells appears to be responsible as the response of purified T4+
lymphocytes in the autologous MLR is very low (Gupta & Safai,
1983). In addition there is no absolute correlation between
T4+/T8+ lymphocyte ratios and IL 2 production capacity
(Gluckman et al., 1985).
There is also an abnormal response to IL 2 of lymphocytes
from patients with AIDS or ARC, as addition of exogenous IL 2
results in only a partial restoration of proliferative
responses (Gupta et al., 1984; Lifson et al., 1984; Murray
et al., 1985). This is due to deficient expression of IL 2
receptors on lymphocytes following activation (Gluckman et al.,
1985; Prince et al., 1984; Tsang et al., 1984). This may be due
to the presence of suppressive factors in the sera of AIDS
patients which appear to act directly on stimulated
lymphocytes, possibly by masking the IL 2 receptor (Hennig &
Tomar, 1984). Reduced antigen-presenting capacity may also
contribute to poor DTH responses, and reduced class II MHC
antigen expression on antigen-presenting cells has been
reported (Belsito et al., 1984; Heagy et al., 1984).
The reduction in the number and functional capacity of T4+
lymphocytes would seem to be the major cause of immune
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dysfunction in AIDS and ARC however. In view of the central
role of this cell in immune responses, it is not surprising
that a variety of other immune and non-immune functions are
impaired. Lymphokine production by stimulated lymphocytes is
low (Murray et al., 1984) and this is likely to be related to
the reduced NK cell activity (Reddy et al., 1984; Rook et al„
1983), the absence of CTL responses to viral infections (Rook
et al., 1983). reduced monocyte adherence (Hersch et al., 1984)
reduced class II MHC antigen expression on accessory cells and
possibly to reduced PMNL function (Valone et al., 1984).
The observation that B cell numbers were approximately
normal in AIDS (Mildvan et al., 1982) and that serum
immunoglobulin levels were elevated (Mathur-Wagh et al., 1984;
Stahl et al., 1982) initially led to the conclusion that B cell
function was relatively unimpaired in AIDS. Closer
investigation indicates otherwise however. PWM-driven
immunoglobulin synthesis by B cells is defective and this is
not solely due to lack of helper functions as T-independent
mitogens such as EBV also fall to induce a normal response and
coculture of B cells with normal T cells only occa s ionally
corrects the defect (Lane et al.. 1893; Pahwa et al., 1984).
Primary B cell responses cannot be generated in vivo or
in vitro following immunisation (Lane et al., 1983) and
frequently no IgM response to CMV is demonstrable despite
disseminated infection (Dylewski et al., 1983).
This B cell defect may be due to suppression by T8+ cells,
and infiltration of the latter into the follicular centre (B
cell zone) of lymph node follicles has been observed (Modlin
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et al., 1983). It is perhaps more likely however that the
defect is intrinsic and may result from non-specific in vivo
activation of B cells. This would result in prior commitment
and inability to respond to further in vitro stimulation. That
B cells are activated in AIDS is shown by the high rate of
spontaneous immunoglobulin secretion in vitro (Lane et al..
1983). and this is the probable cause of the
hypergammaglobulinaemia. This of course places serious limits
on the value of serology in diagnosing infection in AIDS
patients. B cell activation is perhaps an important cause of
the lymph node hyperplasia which characterises the prodromal,
lymphadenopathic phase (Mathur-Wagh et al., 1984) and frank
lymphoma is often preceded by this condition (Levine et al.,
1984).
There are also signs of profound dysregulation of other
immune control functions and of haematopoiesis in AIDS. Thymic
dysplasia is often evident at autopsy (Elie et al., 1983) and
anaemia and thrombocytopenia are common (Kalish et al., 1984).
Levels of the thymic hormone alpha 1-thymosin are elevated
perhaps due to lack of feedback inhibition from functional T4+
lymphocytes (Hersch et al., 1983; 1984). Serum levels of beta-2
microglobulin are also elevated (Zolla-Pazner et al., 1984) and
an unusual, acid-labile alpha IFN is often present at high
concentration in AIDS and ARC (De Stefano et al., 1982; Eyster
et al., 1983). This may be due to antigenic stimulation
(Balkwill et al., 1983) but acid-labile IFN has also been found
in patients with systemic lupus erythematosis (Preble et al.,
1982) and may be related to the occurrence of autoimmune
phenomena in AIDS also (Morris et al.. 1982).
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Most of the features of AIDS and related conditions
described above were elucidated without identifying their root
cause(s), although numerous speculations were offered in this
area. Attempts to answer the question of etiology had to
account for certain features of the syndrome. Firstly, the
evidence pointed strongly towards the involvement of an
infectious agent, as clustering of cases was noticed and there
were clear examples of cases which could be linked by sexual or
parenteral contact to other cases (Auerbach et al., 1984). The
initial geographic restriction to North American cities was
also suggestive of a transmissible cause and the high frequency
of occurrence in homosexuals and drug addicts was very
reminiscent of HBV epidemiology.
The wide spectrum of sexually transmitted diseases
prevalent among homosexuals allowed much speculation over the
etiology of AIDS, however the second factor which had to be
accounted for was the apparent sudden onset of the epidemic.
The question arose of whether a new pathogen or a virulent
strain of a known pathogen had appeared, or whether changes in
the lifestyle of those at risk were responsible, perhaps in
concert with other common infectious agents. While the search
for new pathogens continued others addressed the second of
these possibilities.
AIDS was initially recognised in the male homosexual
population and it was probable that its occurrence in other
groups resulted from contact with this group. The appearance of
AIDS is set against a background of rapidly changing lifesyle
among homosexual groups, particularly in the USA, with
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increased promiscuity and mobility between communities in North
American cities. This was accompanied by an increase in sexually
transmitted diseases (Darrow et al„ 1981) and it was thought
possible that multiple infections may act in combination or
synergism to produce the immunological changes seen in AIDS.
Some infections common in homosexuals are known to have
immunosuppressive effects, most notably CMV and EBV (Chapter 3)
and CMV was considered by many to be a prime candidate (Durack,
1981; Gottlieb et al., 1981). Evidence of past CMV infection is
very common in male homosexuals (Chapter 2), particularly in
the USA where over 90% are seropositive (Drew et al., 1981).
Amongst those who are seronegative on initial testing over 80%
become infected per annum (Mintz et al., 1983). Such a high
prevalence made it difficult to establish a causative role,
however the high frequency of viruria (7-8%) and even higher
frequency of virusemenia (35%; Drew et al.. 1981; Mintz et al.,
1983) suggested that CMV immunity was diminished in this group.
This would result in frequent reactivation of infection which
may induce further immunosuppression and susceptibility to
opportunistic infection. The development of KS in which a role
for CMV has been proposed on virological and epidemiological
grounds (Boldogh et al., 1981; Drew et al., 1982; Giraldo
et al., 1975; 1978) and the near universality of active CMV
infection in patients with advanced AIDS supported this view.
A role for EBV in the induction of AIDS was not considered
to the same extent initially. This may have been because
information on active EBV infection in those with AIDS or in
those at risk was lacking, or because the occurrence of B cell
lymphoma which has been linked with EBV infection in other
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immunocompromised individuals (Hanto et al.. 1981) and other
pathology attributable to EBV infection was seen less often
than KS or disseminated CMV infection. However, it has since
been shown that active EBV infection, like CMV infection is
virtually universal in AIDS and ARC (Quinnan et al„ 1984).
Perhaps surprisingly, excretion was also almost universal in
healthy homosexuals in this study. In addition the finding of
polyclonal B cell activation (Lane et al.. 1983). "the
recognition of the prodromal syndrome characterised by lymph
node hyperplasia (Mathur-Wagh et al., 1984) and the
demonstration of EBV DNA at high copy number (Lipscomb et al.,
1983) and EBV antigens (Quinnan et al.. 1984) in lymph node
cells is also strongly suggestive of active, morbid EBV
infection.
While CMV and EBV infections may result in an immune
suppression of considerable duration, they are however normally
self-limiting in otherwise healthy persons. Although T4+/T8+
lymphocyte ratios in AIDS and ARC are superficially similar to
those in the mononucleosis syndrome, this is due to reduced T4+
cell numbers in the first two conditions and mainly to elevated
T8+ cell numbers in the last. Furthermore the intrinsic defect
in T4+ lymphocyte function is not observed in CMV or EBV
infections. This would suggest that the immunosuppression seen
in AIDS is not primarily due to infection with these viruses.
CMV or EBV infection may predispose to some other immunological
assault or may reactivate or gain fuller pathogenic expression
subsequent to such an event, but additional factors seemed
necessary to explain the progressive and permanent immune
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dysfunction in AIDS.
Multiple CMV infections are likely to occur in
promiscuous homosexuals and have been demonstrated in
patients with AIDS (Drew et al.. 1984; Spector et al.. 1984).
Repeated CMV infections or concurrent infection with EBV or
other agents may cause a greater Immune suppression than is
normally seen in the mononucleosis syndrome. It would be
predicted that this too however would result from stimulation
of T8+ suppressor cells rather than an intrinsic T4+ cell
defect.
An abnormal immune response may result when infectious
agents are encountered via an unusual route. The rectal mucosa
is fragile and easily breached during rectal intercourse when
agents present in faeces or semen may be directly introduced
into the circulation (Detels et al, 1983). Exposure to semen by
itself may be a significant cause of immunosuppression.
Spermatozoa are capable of suppressing mitogen — induced
lymphocyte proliferation in vitro, possibly due to the presence
of mitogen receptors on spermatozoa resulting in absorption of
mitogen and reduction of the proliferative signal to
lymphocytes (Marcus et al.. 1978). As the interaction of
mitogen with lymphocytes can mimic the interaction of MHC
products with lymphocytes during an immune response this effect
may be operative in vivo. Seminal plasma also contains a
variety of immunomodulating agents which are probably important
in suppressing immune responses against spermatozoa that would
result in infertility. When encountered outside the
reproductive system these components may suppress the function
of lymphocytes and macrophages (James & Hargreave, 1984).
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Immunosuppression may also follow immunisation against
antigens on spermatozoa which cross-react with lymphocyte
membrane antigens (Sonnabend et al., 198*0 and it has been
suggested that the introduction of allogeneic leukocytes during
rectal intercourse may induce local graft versus host (gvh)
reactions if, on account of semen- or virus infection-induced
immunosuppression they were not immediately rejected (Shearer
et al., 1983). Comparable events have been demonstrated in mice
injected with parental lymphocytes and immunosuppression is the
end result in this model (Shearer & Polisson, 1980). In support
of these theories it has been reported that healthy homosexuals
with a history of frequent passive (receptive) rectal
intercourse frequently have anti-sperm antibody, have high MLR
activity against lymphocytes from regular active partners
compared to lymphocytes from other individuals, but low
activity in a xenogeneic MLR which measures the ability of
lymphocytes to induce a local gvh reaction in an
immunosuppressed animal, and are more likely to have low
T4+/T8+ lymphocyte ratios (Detels et al., 1983; Mavligit
et al., 198*1). Repeated occurrences of this nature may induce
cycles of immunosuppression resulting in reactivation of CMV
and EBV infection, which would themselves contribute to
immunosuppression and result in a self-sustaining, irreversible
phase (Sonnabend et al., 198*0.
Other factors considered of relevance to the etiology of
AIDS in male homosexuals were the use of amyl and butyl nitrite
drugs (Goedert et al., 1982), oestrogens (Couthino, 1982) and
steroids (Neumann, 1982). The susceptibility of other groups to
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AIDS was thought to be due to other predisposing factors acting
in synergy with viral or other infections, giving an end result
similar to that in homosexuals. Drug addicts are known to be
immunocompromised frequently (Brown et al., 197*1-) and the
immunological immaturity of the neonate may increase
susceptibility. Investigation of immune parameters in
haemophiliacs reveals abnormal T cell subset ratios in a
proportion (Lederman et al.. 1983; Menitove et al., 1983)
which have been attributed to the presence of potentially
immunosuppressive components in factor VIII preparations (Ablin
& Gonder, 198*1-; Lee et al.. 198*1).
A major shortcoming of these hypotheses which favoured a
multifactorial etiology was their inability to explain the
sudden onset of the AIDS epidemic in different groups at around
the same time, and its occassional occurrence in individuals
outwith recognised high risk groups where an isolated contact
with an affected or at risk person appears to have resulted in
transmission. It became increasingly clear that a common
denominator, probably an infectious agent, was likely to be
present in every case.
Several observations suggested a retroviral etiology.
Although animal retroviruses have been studied mainly with a
view to understanding their role in oncogenesis it was
frequently noticed that retroviral infections resulted in
immunosuppression and degenerative disease as well as malignant
disease. The incubation phase of experimental leukemia in
inbred mice is characterised by suppression of both humoral
(Peterson et al., 1963) and cellular immune mechanisms (Dent
et al., 1965). Infection of cats with feline leukemia virus
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(FeLV), which is a naturally occurring, horizontally
transmissible virus (Hardy et al., 1976) is frequently followed
by viral persistence associated with lymphopenia (Essex et al.,
1975; 1976), anaemia (Onions et al., 1982), suppression of
humoral immune responses (Trainin et al.. 1983) and a marked
susceptibility to other infections (Essex et al.. 1975; 1976).
Virion components of FeLV and other retroviruses are known
to suppress mitogen-induced proliferation directly (Hebebrand
et al.. 1977; Weislow et al., 1981). This may cause an initial,
local immunosuppression preventing viral clearance, followed by
a systemic immunosuppression with the onset of viraemia (Mathes
et al„ 1979). Alternatively, immunosuppression may result from
infection of lymphoid tissue or of bone marrow precursor cells.
Experimental infection of kittens with FeLV results in bone
marrow and lymph node lesions (Hoover et al., 1973). severe
thymic atrophy (Anderson et al., 1971; Perryman et al.. 1972)
and suppression of cellular immune responses (Perryman et al.,
1972).
The human T cell leukaemia viruses (HTLV I and HTLV II)
are recently discovered human retroviruses (Kalyanaraman
et al.. 1982; Poiesz et al., 1980) which infect and transform
TH+ lymphocytes specifically (Essex et al., 1982; Hattori
et al., 1981). Evidence of sexual transmission exists
(Schupbach et al., 1983) and serological evidence of infection
is common in parts of Africa (Hunsmann et al., 1983; Saxinger
et al., 1984) where aggressive KS is also found, and in the
Caribbean (Schupbach et al., 1983). The cell tropism and
geographical distribution of HTLV I suggested a possible
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involvement in AIDS and a search for HTLV I infection in AIDS
patients and in high risk groups was initiated. Proviral DNA
sequences were detected in fresh T cells from two of 33 AIDS
patients (Gelmann et al., 1983) and antibodies to HTLV I
membrane antigens were found in 25% of AIDS cases, 26% of ARC
cases, up to 19% of haemophiliacs at risk and only 1% of
controls (Essex et al„ 1983a; b). The difference in antibody
prevalence among those with, or at risk of AIDS compared to
controls was greater than that observed for any other viral
infection. The failure to demonstrate antibody in all AIDS
cases may have been due to waining of the humoral immune
response as infected T4+ cells became depleted resulting in
reduced antigenic challenge and impaired antibody production.
An HTLV I etiology for AIDS was not consistent with all
the information however. The low frequency of HTLV I detection
or isolation, the absence of antibody to virus core proteins
and the virtual absence of AIDS in southern Japan despite the
high prevalence of HTLV I exposure in that region (Hinuma
et al., 198I) suggested that HTLV I was not the cause of AIDS,
but that another antigenically related virus may be
responsible. Subsequently, similar but serologically distinct
retroviruses were isolated from a patient with ARC
(Barre-Sinoussi et al., 1983) and from two sibling
haemophiliacs, one of whom had AIDS (Vilmer et al., 1984-).
Characterisation of these isolates was initially hampered by
the lack of a permissive cell line as isolation attempts in
primary human lymphocyte culture resulted in accelerated
terminal differentiation of infected cells, cell death and loss
of virus (Gallo et al., 198U). A permissive T cell line has now
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been found, allowing viral detection and isolation from the
concentrated supernate of primary T cell cultures on a more
reproducible basis (Popovic et_al., 1984) and initial isolation
attempts were positive in 86% of ARC cases, 36% of AIDS cases,
5% of healthy homosexuals considered to be at low risk, three
of four mothers of infants with AIDS and none of over 100
heterosexuals (Gallo et al.. 1984). Such a correlation between
the virus carrier state and the presence of or capacity to
transmit AIDS or ARC is strong evidence that theses
retroviruses, collectively known as HTLV III or LAV were
causative of these two conditions, and were not merely
opportunists. The less than 100% isolation rate was considered
due to the low numbers of T4+ cells in many specimens,
particularly those from patients with advanced AIDS.
HTLV III membrane antigens were found to be cross-reactive
with those of HTLV I and HTLV II whereas the core proteins were
antigenically distinct (Barre-Sinoussi et al., 1983; Schupbach
et al., 1984) which may explain the earlier findings of
antibodies to HTLV I membrane antigens in patients with AIDS or
ARC or in those at risk. Analysis of the HTLV III antibody
prevalence in patients and high risk groups strengthened the
case for an HTLV III etiology for AIDS. Antibody was present in
7b% of AIDS cases, over 90% of ARC cases and none of controls
(Brun-Vezinet et al., 1984a; Sarngadharan et al., 1984). The
less than 100% detection rate may have been due to test
insensitivity or to drops in antibody titres following the
depletion of infected cells or to B cell malfunction. Antibody
has also been demonstrated in AIDS patients from the UK
(Cheingsong-Popov et al., 1984) and Africa (Brun-Vezinet
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et al.. 1984b), in blood donors implicated in transmission by
transfusion (Jaffe et al., 1984), in other persons suspected as
a resevoir of infection (Laurence et al., 1984), and in the UK,
in 59% of homosexuals with symptoms other than those which
constitute AIDS or ARC, 42% of case contacts, 17% of
homosexuals at risk, 34% of factor VIII recipients, 15% of drug
addicts but in no heterosexuals or random blood donors
(Cheingsong-Popov et al.. 1984).
A surprisingly high seropositivity rate of 67% has been
found in sera collected from Ugandan children in 1973 (Saxinger
et al., 1985) indicating that HTLV III or a similar virus
existed some time before the recognition of AIDS. It is highly
possible that AIDS was present in Africa before 1978 and
probable Instances have been diagnosed retrospectively from
1976 and 1977 (Bygbjerg, 1983; Brun-Vezinet et al., 1984b;
Vandepitte et al., 1983). Antibody was present in 5% of healthy
mothers in Zaire in 1980, in 7% of hospitalised patients in
1983 (Brun-Vezinet et al.. 1984b) and in 2% of healthy Zambians
in 1984 (Bayley et al.. 1985) but in 20% of healthy Ugandans in
1984 (Bayley et al., 1985). This would indicate that HTLV III
has been established for some time in Uganda and has recently
spread into other African countries.
The status of aggressive KS in Africa with respect to HTLV
III infection has recently been clarified. Antibody has been
demonstrated in 92% of cases from Uganda and Zambia compared to
only 17% of classical KS cases (Bayley et al., 1985).
Consistent with the view that HTLV III infection has only
recently been introduced to Zambia is the observation that
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aggressive KS was first recognised in that country in 1983
(Bayley, 1984).
These results present a strong case for considering HTLV
III as etiologic in the development AIDS (including aggressive
KS) and ARC. An understanding of the pathogenesis of HTLV III
infection in these conditions and in those who remain
asymptomatic can only be partial at the present time. Primary
infection is associated with an acute glandular fever-like
illness in some cases (Cooper et al., 1985; Lancet, 1984;
Tucker et al., 1985). The initial infection is frequently or
always followed by viral persistence (Laurence et al.. 1984).
The virus shows a strong T4+ lymphocyte tropism (Gallo et al.,
1984; Klatzmann et al., 1984a) and the T4 antigen is a
component of the virus receptor (Dalgleish et al., 1984;
Klatzmann et al., 1984b). The low numbers and functional
capacity of T4+ lymphocytes in AIDS and ARC may then be
directly due to viral infection and elimination. Low numbers of
T4+ cell numbers may also occur in the asymptomatic carrier
state (Goedert et al., 1984) although this is not always the
case (Laurence et al., 1984). Initial findings indicate that
low T4+ numbers and the presence of additional constitutional
symptoms in patients with lymphadenopathy is more likely in
those with detectable HTLV III viraemia (Kaplan et al.. 1985).
Virus has also been demonstrated in semen (Ho et al., 1984;
Zagury et al., 1984) as might be expected from epidemiological
considerations, and also in saliva, both cell-free and
cell-associated (Groopman et al., 1984). The importance of
saliva as a vehicle of transmission is not known but clearly
cannot be discounted in view of this finding. Retroviral
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particles have also been visualised by EM in macrophages
(Gyorkey et al.t 1985) and follicular dendritic cells
(Armstrong et al., 1985). The presence of viral particles in
macrophages probably resulted from phagocytosis as complete
particles were present in phagocytic vacuoles but budding of
virus from dendritic cells was clearly discernable. Productive
infection of macrophages may also occur following phagocytosis
and these cell populations may be a reservoir for viral
persistence and dissemination to lymphocytes (Armstrong &
Home, 198/1).
It is estimated that approximately 7% of healthy
seropositive individuals will develop AIDS each year, and that
around 13% will develop ARC (Goedert et al., 1984). The factors
which influence the likelihood of developing AIDS or associated
conditions following HTLV III infection are unknown at present.
It is possible that many of those factors previously considered
as possible causes of AIDS will be found to be important as
cofactors which influence the expression of HTLV III infection.
The identification of the causative agent and the development
of diagnostic assays allows such issues to be addressed.
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INTRODUCTION
OBJECTIVES AND SCOPE OF PROJECT
This project was initiated at a time when the cause of
AIDS and associated conditions was unknown. Some considered the
characteristic immune abnormalities to be the net result of
several forces acting together while others suspected a single
agent to be pre-eminently responsible, although the presence of
other cofactors was generally agreed to be important. In order
to test these hypotheses it was considered necessary to
establish the prevalence of possible causative or contributory
factors in populations at risk for AIDS, but prior to its
onset. It was therefore decided to investigate CMV infection
and immunity in healthy male homosexuals in what may be
considered an "AIDS-free" region. While several surveys of a
similar nature have been undertaken elsewhere since the
appearance of AIDS (Biggar et al., 1983; Couthino et al.. 1984;
Drew et al., 1981; Lange et al., 1984; Mintz et al.. 1983;
Quinnan et al., 1984) these studies have been conducted among
populations where AIDS or its prodromal stages was known or
strongly suspected to be present. Consequently it is unknown
how many of those regarded as healthy homosexuals were actually
in early, asymptomatic stages of the syndrome, in the absence
of any definitive diagnostic test for AIDS or its putative
agent(s).
The present study was conducted during the period before
any case of AIDS was reported in Scotland. It was therefore
thought probable that at least most of the homosexual
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population would not be in the incubation phase of AIDS. This
population then, provided an opportunity to assess the
prevalence and effects of factors suspected of contributing to
AIDS in individuals, many of whom in different geographical
circumstances might be considered to be at high risk for AIDS.
In determining which factors should be assessed in this
project, consideration was given to those parameters which were
suitable for studying in large numbers of individuals. It was
decided to study CMV infection and immunity for the following
reasons:
a) CMV was considered by many to be important in the etiology
and/or pathogenesis of AIDS.
b) In view of the influence of immune mechanisms on the
expression of CMV infection, studying the latter may give an
indirect indication of the functional capacity of the former.
c) Methods for determining the prevalence of previous and
current CMV infection, and for assessing CMV-specific immune
responses are suitable for studying the numbers anticipated.
d) Immune responses to CMV have been characterised in other
groups, allowing comparisons with the group under study to be
drawn.
CMV excretion from the throat and in the urine was
assessed as isolation specimens from these sites are readily
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available. Serological investigations included screening for
CMV-IgG antibodies as an indication of past infection,
screening for CMV-IgM as an indication of current or recent
infection, and screening for antibodies to CMV IEA and CMV EA.
The significance of these last two antibody reactivities has
not been fully clarified (Chapter 3) but they have been found
at increased frequency or in greater titres among patient
groups where CMV infection is more prevalent, namely renal
transplant patients (The et al.. 1977) and patients with
rheumatoid arthritis (Male et al., 1982). Thus, although not of
diagnostic significance, they may provide information of
epidemiological value.
Cellular immune parameters were also studied in this
project. Lymphocyte proliferation responses to CMV antigens
were determined as this measurement of immunity has been shown
to be low in some groups of CMV-infected or CMV-susceptible
patients. Mitogen-induced proliferation responses were also
considered to be of interest. If active CMV infection
contributes to the pathogenesis of AIDS, either by causing an
initial depression of cellular immunity or by exacerbating a
pre-existing immune dysfunction in individuals at risk for
other reasons, then this may be detectable as reduced
proliferative responses to mitogens in those with active CMV
infection, or in those who are active homosexuals, (if
homosexuality is, in itself associated with reduced immune
capacity).
In view of the fact that the pathogenesis of ARC and AIDS
is likely to be complex, the identification of the primary
etiologic agent does not nullify the value of such
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investigations. It does however provide a means of testing the
original assumption that the population under study was
relatively AIDS-free, and may enable comparisons to be made
between those with and without HTLV III infection.
It is anticipated that this work will be of relevance when
considered in relation to other investigations into the
pathogenesis of AIDS. Such studies may eventually permit the
identification of prognostic indicators which would have an
impact on the management of and advice given to those in whom
HTLV III infection has been diagnosed. An understanding of the
pathogenesis of AIDS may also give insight into the processes
by which opportunistic infections arise, and procedures by
which they may be managed in other immunocompromised patients.
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MATERIALS, METHODS AND STUDY POPULATIONS
Study population and conduct of survey
The population under study consisted of homosexual and
heterosexual males who attended the STD clinic at the
Department of Genitourinary Medicine, Edinburgh Royal
Infirmary as outpatients between May 1983 and May 1984.
Whenever possible both homosexuals and heterosexuals were
enrolled into the survey on each clinic session. Individuals
who were known to be hepatitis B virus surface antigenaemic
at the time were excluded. In other respects individuals were
approached and enrolled for study on a random basis.
Consenting volunteers were studied under code, without
knowledge of sexual preference or other particulars until the
completion of the majority of laboratory investigations,
except the serological analysis of HTLV III infection which
was only performed on specimens from homosexuals.
A throat swab, clean-catch urine specimen and peripheral
venous blood sample was sought from each volunteer. Throat
swabs were immediately placed in viral transport medium and
blood samples were immediately heparinised (10-15 IU heparin
per ml of blood). All specimens were placed in sterile
containers and were processed in the laboratory on the day of
collection.
Miscellaneous specimens
Other heparinised blood specimens were obtained from
healthy laboratory personnel. This group was used in the
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initial characterisation of some of the assays. Some were
also studied longitudinally on two or more occasions in order
to assess time-dependent fluctuations in some of the
parameters under study.
Serum specimens from patients in whom acute viral and
other infections had been diagnosed were from the Virus
Diagnostic Laboratory, Bacteriology Department, Edinburgh
University, provided by Dr. E. Edmond and from the Regional
Virus Laboratory, City Hospital, Edinburgh, provided by H.
Cubie. Retrospective serum specimens from some of the study
population were from the Hepatitis Reference Laboratory,
Bacteriology Department, Edinburgh University, provided by
Dr. J.F. Peutherer.
Cell culture
Human embryo fibroblasts (HEF) were propagated at 37C in
glass or plastic Roux flasks. Growth medium (GM) consisted of
Eagles minimal essential medium (EMEM; Flow Laboratories,
Irvine, Scotland) supplemented with 6% heat-inactivated
newborn calf serum (NBCS; Flow Laboratories), 2 mM
L-glutamine (Gibco, Paisley, Scotland), 300 IU/ml benzyl
penicillin (Glaxo), 0.3 mg/ml streptomycin sulphate (Evans)
and 1-2 ml/100ml 8% sodium bicarbonate solution to give the
correct pH. Maintenance medium (MM) was the same as GM in all
respects but contained only 2% NBCS. HEF monolayers were
allowed to grow to confluence in 100 ml GM and were then
passaged by briefly exposing the washed monolayer to a
solution of 1% trypsin and 0.02% versene in Dulbecco medium
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(DM) at 37C. The detached monolayer was resuspended in GM and
reseeded Into two or three Roux flasks.
For cryopreservation of HEF's trypsinised cells were
pelletted and resuspended in 50% NBCS, 40% GM and 10% dimethyl
sulphoxide (DMSO), 1 ml per contents of each Roux flask. The
suspension was cooled slowly to -70C in 1 ml aliquots then
transferred into liquid nitrogen the following day. To retrieve
cryopreserved HEF's, 1 ml aliquots were rapidly warmed to 37C
and seeded into Roux flasks with 100 ml GM. GM was changed the
following day.
Tube cultures were prepared by seeding tissue culture
tubes with 2 x 10s HEF's in 1 ml GM and incubated in stationary
racks until confluent. GM was then replaced with MM and tubes
were transferred to a roller drum. Medium was changed every 2-3
days.
HEF's were checked periodically for mycoplasmal
contamination by incubation in solid, semi-solid and diphasic
pleuro-pneumonia-like organism (PPLO) agar at 37C under
anaerobic conditions. Cultures were subcultured and examined
twice weekly for two weeks.
Virus and antigens
The Adl69 strain of human CMV (Rowe et al., 1956) was
used in all experiments. Virus was propagated in HEF's.
Monolayers were infected while subconfluent as this favours
productive infection in most cells with optimum antigen
production and progeny virus release (Chapter 1). Monolayers
were infected with virus in a small volume at a multiplicity
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of infection (moi) of approximately one. After a one hour
adsorption period at 37C monolayers were washed with DM
before adding 100 ml MM. Control cultures were prepared in an
analogous manner, omitting the exposure to virus. MM was
changed after no more than seven days.
When infected cultures showed 100% cytopathic effect
(CPE) and disintegration of the monolayer was evident
(usually 8-10 days post infection) the culture supernatant
was removed, clarified by low speed centrifugation (2000 rpm,
15 min in a bench centrifuge), aliquoted and stored at -70C.
Stock virus was also checked for mycoplasmal contamination.
Virus was titrated in tube culture. Tubes showing >50% CPE
after seven days culture were scored positive and the 50%
tissue culture infective dose (TCIDso) was estimated by the
method of Reed & Muench.
Glycine extract (GE) antigen was prepared by infecting
cells as described above. When infected cultures showed 100%
CPE with disintegration of the monolayer, cells from infected
and control cultures were dislodged with glass beads, without
aspirating the culture medium. Cells were pelleted from the
resulting suspension by centrifugation at 2500 rpm for 30 min
in a Mistral 6L centrifuge (MSE), washed three times in 0.01M
phosphate-buffered saline (PBS; prepared by mixing 28 ml 0.2M
Na H2PO4. 2HiO with 72 ml 0.2M Na2HPO*. dissolving 17g NaCl
in this, adjusting the pH to 7-2 then making up to 21 with
distilled water). After the final wash, cells were
resuspended in glycine buffer, pH 9 (GB), 1 ml per contents
of each Roux flask. GB was prepared on the day of use by
143
mixing three parts of 0.1M NaOH with five parts of 0.1M
glycine. The cell suspension was then sonicated vig o r ously
for 15s using an ultrasonic probe (MSE), allowed to stand at
4C for 4-6h then centrlfuged at 3000 rpm for 15 min in a
bench centrifuge. The suspension was aliquoted in 1 ml
amounts and stored at -70C.
Polyethylene glycol (PEG)-precipitate antigen was
prepared in a manner similar to that used by Hamelin & Lussler
(1979). Cells were infected with virus as described above.
3-4 days prior to 100% CPE with monolayer disintegration,
infected and control cell supernates were harvested and
stored at 4C. Culture medium was replaced with 50 ml MM. This
was repeated on each day following until the infected
monolayer had collapsed. The pooled supernates from infected
and control cultures were then clarified by centrifugation.
PEG 6000 (Fisons) was then added to give a final
concentration of 5%• Supernates were held overnight at 4C and
the precipitate was pelleted by centrifugation at 5000 rpm
for 30 min at 5C in a Sorvall RC2-B centrifuge. The pellet
was resuspended in PBS, 1ml per contents of each Roux flask,
and held at 4C for 4-6h to allow the precipitated virus to
resuspend. The suspension was then stored in 1 ml aliquots at
-70C.
Lymphocyte proliferation assays
Up to 12 ml heparinised peripheral venous blood was
carefully layered on to 6 ml Ficoll-Hypaque lymphocyte
separation medium (Flow Laboratories) and centrifuged at 2000
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rpm for 15 min in a bench centrifuge. The uppermost layer of
plasma from the centrifuged sample was harvested and used to
supplement lymphocyte culture medium. The remainder was
stored at -20C for serological analyses. The mononuclear
leukocyte-rich layer from the Ficoll-Hypaque/plasma interface
was harvested and washed three times in RPMI 1640 (Dutch
Modification) medium (Flow Laboratories) by centrifugation as
above. After the final wash the cell pellet was resuspended
in lymphocyte culture medium which consisted of RPMI 1640
(Dutch Modification) medium supplemented with glutamine,
penicillin and streptomycin at the same final concentrations
as in GM and MM, and 15% autologous plasma. In some experiments
as detailed under Results, autologous plasma was replaced by
pooled homologous plasma. The cell density was adjusted to
10® viable mononuclear cells per ml with lymphocyte culture
medium. Cell viability in most experiments was estimated at
95-100% on the basis of trypan blue exclusion. The resulting
cell suspension was dispensed in 200 pi volumes into wells of
U-bottomed tissue culture grade 96-well microtitre plates
(Sterilin).
Stimulants used in the assay were phytohaemagglutlnin
(PHA; Miles-Yeda), concanavalin A (Con A; Sigma), pokeweed
mitogen (PWM; Gibco) and CMV and control GE antigens.
Dilutions of mitogens and antigens were added in 10 pi
volumes to quadruplicate culture wells where lymphocyte yield
permitted. In other cases stimulants were added to wells in
triplicate or occasionally in duplicate. Some wells were left
without stimulant as controls. Microtitre plates were covered
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and incubated at 37C in a humidified atmosphere of 95% &if
and 5% CO2. PHA-stlmulated and respective control cultures
were maintained for four days. Other mitogen- and antigen-
stimulated and control cultures were maintained for six days.
24h before the end of the culture period, each culture well
was pulsed with 5 pCi methyl-sH thymidine (40-60 Ci/mmol;
Amersham). At the end of the culture period, lymphocyte
cultures were harvested on to glass-fibre filter paper
(Whatman 934- AH) and washed 20x with tap water using a semi-
automated cell harvester (Xlacon). Filter papers were dried
at 37C. Individual filter paper discs were removed and placed
in scintillation vials with 3 ml scintillation fluid which
consisted of toluene ("Fisons AR") with 12.5% 2,5-diphenyl-
oxazole (Fisons) and 0.5% l,4-di(2-methlystyryl)-benzene
(Fisons). Scintillation vials were counted for 60s in a
Packard Tri-carb liquid scintillation spectrometer.
In calculating results the 3H-thymidine incorporation
for each treatment was taken as the mean cpm for all
replicate cultures. Mitogen- or antigen-induced proliferation
was determined by comparing the 3H-thymidine incorporation of
stimulated cultures with that of the appropriate control
cultures (unstimulated and control antigen-stimulated
cultures respectively). Results for mitogen-induced
proliferation were recorded both as stimulation indices (SI =
mean cpm of stimulated cultures / mean cpm of control
cultures) and as net stimulation (the difference in mean cpm
between stimulated and control cultures). Results for CMV-
specific stimulation were recorded as SI values.
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Virus Isolation-
To attempt virus isolation from clinical specimens, 0.2
ml of fresh urine or transport medium bathing throat swabs
was inoculated into HEF tube cultures. Tubes were examined
twice weekly for the development of CPE characteristic of




A range of CMV-reactive monoclonal antibody (McAb)
preparations were gifted by Dr. H. Hart, Inveresk Research
International Ltd, Musselburgh, Scotland (Hart & Wilkinson,
unpublished). McAbs were provided as ascitic fluid, hybridoma
culture supernatant or sodium sulphate-precipitated IgG (see
below) and stored at -70C. McAbs were raised by immunising
eight-week-old Balb/c mice intraperitoneally with HEF's
infected with CMV Adl69 nine days previously in Freund's
incomplete adjuvant. Immunised mice were boosted
intravenously with sucrose gradient (20-70%) purified CMV
virions four weeks later and spleen cells were removed three
days later. Spleen cells were fused with cells of the mouse
myeloma line P3 x 63.Ag8/NS-l using PEG and grown in RPMI 1640
medium supplemented with glutamine, penicillin, streptomycin,
100 pg/ml pyruvate and 10% foetal calf serum (FCS). Hybrids
were selected in HAT medium and culture supernatants were
screened for CMV reactivity by indirect ELISA and indirect
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immunofluorescence (IIF) as described below. Clones from
colonies which gave CMV-IgG positive supernatants were
selected by limiting dilution.
The following McAb preparations were received:
HCMV 19, HCMV 23, HCMV 2k. HCMV 25 and 96D3. all reactive with
immediate early antigens (IEA) by IIF; HCMV 3, reactive with
a nuclear early antigen (EA) by IIF; HCMV 1, HCMV 22, HCMV
29. AB3. 91D11, 92E9. 93F2 and 9^H3, reactive with other CMV
antigens of undetermined class.
McAbs CH 12, CH 16 and CH 28, reactive with late
glycoprotein antigens, were gifted by Dr. L. Pereira, Viral and
Rickettsial Disease Laboratory, Department of Health Services,
Berkeley, California. Their production and characterisation
has been described (Pereira et al„ 1982b).
IgG was precipitated from ascitic fluid by adding 205
mg Na2SO*. 10 H20 (finely ground for rapid dissolution) to
0.5 ml ascitic fluid. The suspension was incubated for lh at
room temperature (RT) with agitation. The precipitated IgG
was then pelleted by centrifugation at 3000 rpm for 20 min in
a bench centrifuge and washed twice with 18% Na2S04 in 0.1M
Na HCO3, then dissolved in 0.1M Na HCOj and dialysed overnight
against three changes of 0.1M Na HCO3. The protein
concentration was determined from the absorbance at 280 nm
(based on an absorbance value of 13-8 for a 10 mg/ml IgG
solution).
Rabbit antisera
Antisera 37 and 39, raised in rabbits against CMV virion
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membrane and whole virion antigens respectively, were gifted
by G. Farrar, Molecular Genetics Laboratory, PHLS, Porton.
Virions were pelleted from 50 ml infected cell culture
supernatant, purified on tartrate/glycerol gradients (Talbot
& Almeida, 1977) and resuspended in 0.5 ml PBS. Virion
membrane antigens were prepared from pelleted virions by
resuspending in 1% Triton, incubating on ice for 20 min then
centrifuging at 100 000 g for 2h at 1C to remove nucleocapsids.
Rabbits were immunised with 0.5 ml doses of these preparations
in Freund's complete adjuvant and boosted at three weekly
intervals with the same preparation in Freund's incomplete
adjuvant. Rabbits were bled periodically and serum was assayed
for CMV-IgG.
CMV-specific IgG ELISA
Sera and plasmas were screened for CMV-specific IgG
(CMV-IgG) by indirect ELISA. 96-well immunoplates (Nunclon)
were coated overnight at 4C with GE test and control antigen
diluted in coating buffer (1.50 g Na2 CO3. 10 H2Of 2.93 £
Na HCO3, 0.2 g Na N3 in 11 double distilled water, pH 9.6).
All reagents were added in 300 pi volumes per well. An
antigen dilution was chosen such that a reference positive
control serum gave an ELISA reading within the range 0.90-
1.00. Most batches of antigen were used at a dilution of
1:800-1:3200. Every third column of wells was coated with
control antigen and the remainder were coated with test
antigen. After coating plates were washed three times with
washing fluid (PBS plus 0.1% bovine serum albumin (BSA;
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Sigma), 0.05% Tween 20 (Biorad) and 0.02% Na N3) using an
automated plate washer (Organon-Teknika). Serum was diluted
1:100 in PBS containing 1% BSA and 0.05% Tween 20 (PBSAT).
Diluted serum was added to triplicate wells (two wells coated
with test antigen and one coated with control antigen).
A control positive and negative serum was included on each
plate. Plates were incubated for three hours at RT then washed
as above. Alkaline phosphatase-conjugated swine anti-human IgG
(Northumbria Biologicals Ltd.) diluted 1:4-00 in PBSAT was then
added to each well and plates were incubated at RT for two
hours, then washed as before. Alkaline phosphatase substrate
solution was prepared by dissolving 5 mg substrate tablets
(Sigma) in 10% diethanolamine-HCl buffer pH 9-8 to give a
lmg/ml solution. This was added to each well and plates were
incubated at RT for 30 min. The enzyme reaction was stopped by
adding 50 pi 3M NaOH to each well. Optical density (OD)
measurements at 405 nm were determined for each well using an
automated spectro-photometer (Dynatech MR 580). Sera were
considered to be CMV-IgG positive when the mean OD reading of
the two test antigen wells was greater than two standard
deviations above the mean OD reading of test antigen wells of
the negative control serum, unless nonspecificity was indicated
by an equivalent OD reading in the control antigen well.
A similar protocol was used for testing rabbit antisera
and McAb preparations for ELISA reactivity. A range of
dilutions of antiserum, ascitic fluid, hybridoma culture
supernatant or sodium sulphate-precipitated IgG were reacted
with antigen-coated plates. Alkaline phosphatase-conjugated
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goat anti-rabbit IgG (Sigma) or rabbit anti-mouse IgG (Miles)
diluted 1:4-00 were then added as appropriate. The assay was
the same in other respects.
IgM capture ELISA (MACELISA)
Biotin labelled McAbs were prepared according to Guedson
et al. (1979)- Sodium sulphate-precipitated IgG was mixed with
varying amounts of 0.1M (34.1 mg/ml) N-hydroxysuccinimido
(NHS)-biotin (Sigma) dissolved in dry dimethyl formamide
(Pierce; silylation grade) such that the ratio of NHS-biotin :
free IgG amino groups was either 1:1 or 4:1, based on a figure
of 90 free amino groups per IgG molecule at pH values over
8.5 (Habeeb, 1966). The reaction was allowed to proceed for
lh at RT. The mixture was then made up to 0.5 ml with PBS and
dialysed overnight at 4C against three changes of PBS. An
equal volume of glycerol was then added and the label was
stored at -20C. Biotinylation was found to proceed
efficiently irrespective of the original IgG concentration or
the volume of the reaction mixture. Biotin labels were
assayed for CMV reactivity using a modification of the
indirect ELISA in which 200 jil rather than 300 ^Jl volumes of
all reactants were used. Dilutions of biotinylated McAb were
used in the first incubation and a 1:1600 dilution of avidin-
peroxidase conjugate (Sigma) was used in the second
incubation. The peroxidase substrate solution consisted of
0.4 mg/ml o-phenylenediamine (Sigma) in phosphate citrate
buffer (22.5 g Na2 HPO« and 5.6 g citric acid in 11 distilled
water, pH 6) with 0.2 pl/ml 30% hydrogen peroxide added
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immediately prior to use. The substrate reaction was stopped
with 100 pi /4-M HZS04 per well after 30 min. OD values were
determined at li90 nm.
In the MACELISA 300 pi volumes of all reactants were
added to each well when using McAbs or rabbit antisera as
detector antibody, and in 200 pi volumes per well when using
biotinylated McAbs as detector antibody.
96-well immunoplates were coated with various dilutions
of a 1 mg/ml stock solution of affinity-purified goat anti-
human p chain antibody (TAGO, Burllngame, USA). Plates were
coated overnight at RT and then washed three times as
described for indirect ELISA. Triplicate wells were then
treated with dilutions of test serum in PBSAT and incubated
at 37C for 3h. After washing, test and control antigens,
diluted in PBS plus 0.05% Tween 20 (PBST) and 5% CMV-
seronegative human serum were added; test antigen to two of
each triplicate set of wells and control antigen to the third
well. Plates were incubated overnight at HC then washed five
times. To detect IgM-bound CMV antigen wells were then
treated with dilutions of McAb preparations, rabbit antiserum
or biotinylated McAb in PBSAT, incubated for 3h at RT and
washed three times. The appropriate enzyme conjugate was then
added to each well at the same respective dilutions as used
above. Plates were incubated a further 2h and washed three
times. Bound conjugate was detected with the appropriate
substrate as detailed above. Modifications to this
generalised protocol were introduced as described under
Results.
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The VirEnz M - CMV kit (Northumbria Biologicals Ltd.) was
used according to the manufacturer's instructions. Test and
control sera were diluted 1:50 in PBST and 100 pi volumes were
added in duplicate to anti-human p chain antibody coated wells.
Plates were incubated for lh at RT and then washed three
times with rinse solution. Wells were then incubated overnight
at RT with 100 pi diluted test antigen or antigen diluent
(control), then washed as above. 100 pi peroxidase conjugated
McAb was added to each well and incubated at RT for 3h. Plates
were then washed and treated with 100 pi tetramethyl benzidine
substrate solution for 30 min at RT. The enzyme reaction was
stopped with 100 pi 5N H2 S04 and OD values were determined at
450 nm. Specimens which gave net OD readings (test antigen OD
minus antigen diluent OD) greater than that of the weak
positive control were considered positve. Those that gave net
OD readings between 70% and 99% of that of the weak positive
control were considered as doubtful positives. Other
specimens were considered negative.
Radio-lodination of antibody preparations
a) Chloramlne T method
20 pi of a 1 mg/ml solution of sodium sulphate-
precipitated or affinity purified IgG was drawn into the
tip of a glass pipette. 20 pi of a 2.5 mg/ml solution of
chloramine T in double strength PBS was then drawn into the
same pipette, leaving an air space between this solution and
the IgG solution. The contents of the pipette were then
expelled into a glass tube containing 200 pCi Na [12°I]
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(Amersham). The mixture was incubated for 30s on ice then the
reaction was stopped by adding 20 pi of a 6 mg/ml solution of
sodium metabisulphite in PBS. After 2-3 min 0.5 ml carrier
buffer (DM plus 0.5% BSA and 0.02% Na N3) was added. The
iodinated protein was separated from unbound Isotope by
fractionation on a 30 cm x 7mm diameter column of Sephadex G100
(Pharmacia) equilibrated with carrier buffer. 30x1 ml fractions
were collected. 10 pi of each fraction was counted for 60s in
an LKB Wallac 80 000 gamma counter. Fractions containing the
first peak of radioactivity were pooled and stored at 4C for
use in RIA. The percentage incorporation of iodine into
antibody was estimated by comparing the sum of cpm of fractions
containing the first peak of (incorporated) radioactivity with
that of the second peak of (unincorporated) radioactivity.
b) Iodogen method
50 pi of a 1 mg/ml solution of sodium sulphate-
precipitated or affinity purified IgG was mixed with 1 mCi
Na [l2eI] in an Iodogen-coated tube. These tubes were
gifted by Dr. R.S. Tedder, Middlesex Hospital and were
prepared by coating glass tubes with 50 pi of a 40 pg/ml
solution of Iodogen (Pierce) in dichloromethane and drying at
50C in nitrogen. Tubes were stored at 4C. The reaction was
allowed to proceed for 30 min at RT and was stopped by
aspirating the reaction mixture from the Iodogen tube.
Radiolabelled preparations were fractionated as described
above.
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Indirect RIA for CMV-IgM
The method of Kangro (1980) was used, except that
radiolabel was prepared by the Iodogen method. PVC U-well
microtitre plates (Dynatech) were coated with dilutions of GE
test and control antigen in PBS. 50 pi volumes were dessicated
on to the wells under a cold air stream and fixed with 10%
formalin in PBS (pH 6.2), 150 jil/well for 20 min at RT. Plates
were washed once with 0.2% gelatin in PBS, 200 pl/well and
blocked overnight at 4C with 5% normal rabbit serum (NRS;
Scottish Antibody Production Unit [SAPU]) in PBS, 100
pl/well. The blocking solution was then shaken off and plates
were drained of excess moisture before use. 1:400 and 1:1600
dilutions of test and control sera in PBS plus 5% NRS and 1%
Dextran T10 (Pharmacia) were tested on duplicate test and
control antigen-coated wells. 50 pi of diluted serum was
added to each well and plates were incubated for 3h at 37C.
Some test and control antigen-coated wells were treated with
serum diluent only, as controls. Plates were then washed
three times with 0.2% gelatin and 50 pi of iodinated
affinity-purified goat anti-human p chain antibody was added
to each well. Radiolabel was used four days to three weeks
after preparation. Label diluent consisted of EMEM plus 3%
NBCS, 0.5% lactalbumin hydrolysate (Sigma) and 10% NRS,
adjusted to pH 7.2 with 8% Na HCOs. Label was added to give
30 000 cpm per 50 pi. Plates were incubated for 2h at 37C,
washed ten times with tap water and dried. Individual wells
were cut from the plate and bound radioactivity was counted
for 60s. Results were calculated by dividing the mean cpm of
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test antigen wells treated with test or control serum by the
mean cpm of test antigen wells treated with serum diluent, and
repeatlmg this for control antigen wells. The two values thus
obtained were expressed as a ratio, with the test antigen
value as the numerator (the specific binding index [SBI]).
Sera which gave SBI values equal to or greater than two were
considered positive.
All sera giving positive results were absorbed against
IgG-coated latex to remove any false reactivity due to
rheumatoid factor, and retested. To prepare IgG-coated latex,
0.5 ml of a 13% w/v suspension of latex beads (Yarsley
Research Laboratories, The Street, Ashstead, Surrey) was
added to 1.5 ml distilled water and filtered through ashless
filter paper (Whatman No. tlO). 0.5 ml filtered latex was
added dropwise to 27-5 ml glycine buffer, pH 8.2 (5 S Na CI,
3-7 S glycine and 1.2 g Na N3 in 500 ml distilled water).
3 mg normal human IgG in the form of a 150 mg/ml solution
(Scottish National Blood Transfusion Service) was then added
dropwise to the latex suspension with constant agitation and
the resulting suspension was agitated at RT for 20 min then
centrifuged at 3500 rpm in a bench centrifuge for 20 min at
UC. The latex pellet was resuspended in 0.75 ml PBS and
stored at HC. To absorb test sera, 10 pi test serum was mixed
with 25 pi IgG-coated latex and serum diluent was added to
give the required test dilution. Sera were incubated at 37C
for lh and centrifuged as above. The supernantant was used
for testing. A false positive-generating rheumatoid factor
positive control serum was included in each series of
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absorptions. The preparation of IgG-coated latex and the
absorptions were all carried out in plastic containers.
Initial studies indicated that an antigen dilution of
1:20 was sufficient to give positive SBI values with all
positive control sera. Higher dilutions than this often
resulted in lower binding of radiolabel. This was probably
due to overloading of the wells, resulting in uncoating of
solid phase-bound antigen during the test serum incubation
and competition between bound and unbound antigen for IgM.
Indirect RIA with monoclonal antibodies
This assay was a modification of the indirect RIA for
CMV-IgM. Test serum dilutions were replaced with dilutions of
McAb preparations and the radiolabel was rabbit anti-mouse
IgG (Miles) labelled by the Iodogen method. Serum diluent
control wells were omitted in this assay and results were
calculated by dividing the mean cpm of test antigen-coated
wells by that of control antigen-coated wells.
IgM antibody capture RIA (MACRIA)
Anti-human }j chain antibody-coated etched polystyrene
beads (Northumbria Biologicals Ltd.) were incubated with test
serum dilutions in PBSAT for 3h at 37C. Dilutions of serum and
all other reactants were added in 200 fil volumes. Beads were
then washed three times with PBST using a Pentawash bead
washing device (Abbot). Beads were then incubated overnight at
UC with dilutions of GE test and control antigen in PBST.
Beads were washed five times as above and then incubated for
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2h at 37C with radiolabelled McAb diluted in PBSAT plus 15%
NBCS and 5% CMV-seronegative human serum. Beads were then
washed five times and bound radioactivity was counted for
60s. Modifications to this basic procedure were used as
described under Results.
Indirect Immunofluorescence for CMV-lgM (CMV-IgM IIF)
Slides for IIF were prepared from HEF's infected with
CMV as described previously. When infected cells showed 100%
CPE, but before the monolayer had collapsed, infected and
control cells were harvested by brief trypsinlsation. An
equal volume of NBCS was then added to quench trypsin
activity. Cells were washed three times in PBS then
resuspended in PBS at a concentration of 106 cells/ml. 10 pi
aliquots were placed on the wells of PTFE-coated multispot
slides (Hendley Essex; 6 mm diameter wells) such that each
slide consisted of a row of infected cell spots opposite a
row of control cell spots. Slides were dried at RT in a
moving air stream, fixed in acetone for 5 min then stored at
-20C.
In the test, sera were diluted 1:10 in DM plus 2% NBCS.
HO pi was spotted on to an infected cell and a control cell
spot. Slides were incubated in a humid atmosphere for 3h at
37C. Excess serum dilution was then shaken off and the slides
were washed twice, each time for 10 min, in PBS stirred
continuously by a magnetic stirrer. Slides were then allowed
to dry at room temperature before applying 30 pi fluorescein
isothiocyanate (FITC)-conjugated sheep anti-human IgM (SAPU)
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diluted 1:20 in DM plus 2% NBCS. Slides were incubated as
above but for lh only, then washed and dried as above. Slides
were mounted in 33% glycerol in 0.1M Na HCOs (pH 8.2) and
examined at a magnification of 400 X with a Leitz Ortholux
ultraviolet microscope. IgM-positive sera resulted in diffuse
membrane and cytoplasmic fluorescence in infected cells only.
All positive sera were retested after absorption with IgG-
coated latex or sucrose density centrifugation. Only sera
which remained positive after either of these steps were
considered IgM positive.
Sucrose density gradient centrifugation was performed on 5
ml preformed and equilibrated 12.5-37% sucrose gradients. 0.9
ml volumes of 37%. 31%. 25%. 18.75% and 12.5% sucrose in DM
plus 0.02% Na N3 were layered successively into 2.5 in x 0.5 in
diameter polyallomer centrifuge tubes (Beckman) and allowed to
stand for at least 4h at 4C before use. 150 pi test serum mixed
with an equal volume of DM was then layered on top of the
gradient. Gradients were centrifuged at 35 000 rpm for l8h at
4C in a Beckman L.8-55 ultracentrifuge using an SW 50 rotor. 0.4
ml fractions were collected from the bottom of the gradient by
piercing the base of the tube and fractions were tested for the
presence of IgG and IgM by Ouchterlony gel diffusion in 0.9%
agarose (Miles) against sheep anti-human IgG and IgM (SAPU).
IgM containing fractions (usually fractions 2-5) were tested by
IIF.
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Indirect immunofluorescence for IgG to CMV early Immediate
early antigens (CMV IEA-IgG IIF)
Cells were infected with CMV as described previously, lh
after the replacement of culture medium following the
adsorption period, infected and control cells were harvested
and used to make CMV IEA slides for IIF in an Identical
manner to that described above for CMV-IgM IIF. In the test,
sera were diluted 1:10, spotted on to prepared slides and
incubated as in the CMV-IgM IIF, but for U5 min only. Slides
were then washed, dried and treated with 30 pi FITC-
coniugated sheep anti-human IgG (SAPU) diluted 1:80 in DM
plus 2% NBCS. Slides were incubated a further &5 min as
above, then were washed and prepared for examination in the
same way as in the CMV-IgM IIF. Slides were examined at a
magnification of 630 X. This facilitated detection of CMV IEA
fluorescence which was present as discrete intranuclear
inclusion fluorescence (Plate 1) and/or fine speckled
cytoplasmic fluorescence which did not give good photographic
reproduction.
Indirect Immunofluorescence for IgG to CMV early antigens
(CMV EA-IgG IIF)
HEF's were infected with CMV as described previously.
After the absorption period, infected and control cell
cultures were Incubated for three days in MM containing 80
pg/ml cytosine arabinoside (Ara C; Sigma), then harvested as
described above. The preparation of slides and the IIF
procedure was the same as described for CMV IEA-IgG IIF,
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Plate 1: CMV Immediate early antigens stained by indirect
Immunofluorescence with monoclonal antibody 96D3.
except that sera were tested at dilutions of 1:16 and 1:32.
CMV EA fluorescence was present as discrete inclusion
fluorescence (Plate 2) and/or fine speckled nuclear
fluorescence which did not give good photographic
reproduction.
Indirect immunofluorescence with MoAbs
Slides prepared for the detection of CMV-IgM, CMV IEA-
IgG and CMV EA-IgG were also used in the characterisation of
McAbs. Incubation conditions used were as described for the
CMV IEA-IIF. A range of McAb dilutions were used in the first
incubation. FITC-conjugated rabbit anti-mouse IgG (Miles)
diluted 1:100 in DM plus 2% NBCS was used in the second
incubation. McAbs characterised by Dr. Hart were also tested
on slides of unfixed cells.
Indirect Immunofluorescence for EBV-IgM and EBV-IgG
Slides of acetone-fixed EB3 cells were gifted by Dr. E.
Edmond, Bacteriology Department, Edinburgh University. The
IIF procedures used were the same as IgM and IgG IIF
procedures described above, using 1:10 dilutions of test sera.
EBV-IgM and -IgG fluorescence was present as diffuse membrane
and cytoplasmic fluorescence.
Indirect immunofluorescence for HTLV IlI-IgG (HTLV III-IgG
IIF)
Multispot slides (8 mm spots) of acetone-fixed HTLV III-
infected H9 cells were gifted by Dr. J.F. Peutherer. The IIF
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Plate 2: CMV early antigens stained by indirect
V
immunofluorescence wltfi' plasma from laboratory personnel WN.
procedure was similar to that of other IgG IIF assays
described above. 100 pi of test serum diluted 1:10 was used
in the first incubation and 50 pi of conjugate dilution was
used in the second incubation. IgG positive specimens
resulted in diffuse membrane fluorescence.
Indirect ELISA for HTLV III-IgG (HTLV III-IgG ELISA)
The Abbott HTLV III EIA kit was used according to the
manufacturer's instructions. Antigen-coated beads were
incubated with 210 pi test or control serum diluted 1:440 in
specimen diluent for lh at 40C. Beads were then washed three
times with distilled water and Incubated with 200 pi anti-human
IgG peroxidase conjugate preparation for 2h at 40C. Beads were
washed as above and transferred to assay tubes. 300 pi
o-phenylene diamime substrate solution was then dispensed into
two empty assay tubes and to each bead-containing tube. Tubes
were incubated at RT for 30 min before stopping the enzyme
reaction with 1 ml 0.5M H2SO«. OD values at 492 nm were
determined in a dual wavelength analyser (Abbott) using one of
the control assay tubes as a blank. The cutoff was determined
as the mean OD value of two negative control specimens plus
one tenth of the mean OD value of three positive control
specimens. The results were only accepted if the difference
between positive and negative control mean OD values was
equal to or greater than 0.4.
Western blot immunostainlng for HTLV III-IgG
Polyacrylamide gel electrophoresis and electrophoretic
162
transfer of HTLV III polypeptides on to nitrocellulose was
performed by Dr. P. Simmonds, Bacteriology Department,
Edinburgh University.
Sodium dodecyl sulphate (SDS)-solublised HTLV III
proteins were separated by discontinuous polyacrylamide gel
electrophoresis (PAGE) according to the method of Laemmli
(1970). A 12% acrylamide separating gel was prepared by
mixing 20.25 ml stock acrylamide solution (25.65% acrylamide
[BDH] with 0.72% N, N'-methylene bisacrylamide [acrylamide
cross-linking agent; BDH] in double distilled water) with
22.5 ml separating gel buffer (0.75M Tris-HCl, pH 8.8 plus
0.2% SDS [BDH]) and degassing the mixture under vacuum for 10
min. A 15 mg/ml solution of ammonium persulphate (BDH) was
prepared freshly and 2.25 ml of this plus 62.5 pi NNN "N"
tetramethylene diamine (TEMED; BDH) were then added to the
acrylamide solution (polymerisation catalysts). A vertical
slab gel was prepared by pouring this solution between two
glass plates, one of which was 20 x 21 cm and the other 20 x
23 cm. The glass plates were separated by 2 mm spacers on
three sides, held together with bulldog clips and sealed with
molten Vaseline. The gel was covered with a layer of butanol
and allowed to polymerise for U5 min.
A 5-3% acrylamide stacking gel was prepared by mixing 2
ml stock acrylamide solution with 5 ml stacking gel buffer
(0.25M Tris-HCl, pH 6.8 plus 0.2% SDS) and 2.5 ml distilled
water, and degassing as above. 0.5 ml ammonium persulphate
solution and 20 pi TEMED were then added. The butanol layer
was aspirated from the top of the polymerised separating gel
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and the stacking gel was layered on top to give a depth of 1
cm, layered over with butanol and allowed to polymerise for
45 min. The butanol layer was then aspirated, the bottom
spacer removed and the gel was mounted with bulldog clips in
a homemade perspex gel tank with platinum electrodes. The
bottom reservoir was filled with 200 ml electrode buffer
(0.025M Tris plus 0.192M glycine and 0.1% SDS, pH 8.3).
excluding air spaces from the bottom of the gel.
The antigen preparation was a 1% Triton extract of HTLV
Ill-infected H9 cells containing 1 mg/ml protein and was
gifted by Dr. Peutherer. The antigen was prepared for PAGE by
boiling a 200 pi sample mixed with 200 pi sample buffer
(0.125M Tris-HCl, pH 6.8 plus 4% SDS, 20% glycerol. 2%
2-mercaptoethanol and 0.002 % bromophenol blue) for 4 min.
The sample was layered evenly on top of the stacking gel and
the upper reservoir was filled with 200 ml electrode buffer.
The tank was connected to a VOKAM V500-500 power pack (lower
reservoir to positive terminal). The gel and gel tank, prepared
for electrophoresis, are illustrated in Figure 1. The gel was
subjected to 60V at 10mA for approximately 1.5h (until the dye
front reached the stacking gel/separating gel interface), and
then to 160V at 25mA for approximately 4h (until the dye front
had travelled 10 cm through the separating gel. The power was
disconnected and the gel removed from the tank and from
between the glass plates. The stacking gel and the remainder
of the separating gel below the dye front were removed.
The electrophoretically separated polypeptides were
blotted on to nitrocellulose according to the method of
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Figure 1: Cross-sectional view of gel tank used for
polyacrylamide gel electrophoresis.
Towbin et al. (1979). A 16 x 10 cm sheet of nitrocellulose
(0.45 pm pore size; Schleicher & Schull) was placed over the
gel, excludine air bubbles. The eel and nitrocellulose were
placed between two sheets of Whatman 3M filter paper and then
between two sheets of Scotchbrite. This was placed in a
notched perspex cassette and placed in a 20 x 15 x 15 cm
homemade perspex blotting tank with stainless steel grid
electrodes (20 x 15 cm) such that the nitrocellulose sheet
was nearer the positive electrode. The tank was filled with
5 1 0.025M Tris buffer plus 0.192M glycine and 20% methanol,
pH 8.3. The gel was blotted overnight at 4C under 22V at 40mA
using a homemade 0-25V, 500mA power pack. The nitrocellulose
was then removed and immersed in blocking buffer which
consisted of Tris-buffered saline (TBS; 20mM Tris, 0.5M NaCl,
brought to pH 7-5 with 1M HC1) plus 3% gelatin (Sigma). The
nitrocellulose was incubated in blocking buffer for 30 min at
RT with agitation, then drained and stored at -20C.
For immunostaining of PAGE-separated, nitrocellulose-
bound antigens, 3mm strips were cut from the nitrocellulose
sheet and used as the solid phase in an indirect ELISA.
Strips were incubated in stoppered test tubes containing 2 ml
test or control serum diluted 1:50 in TBS plus 0.025% Tween
20 (TBST) and 1% gelatin. Test tubes were incubated for 2h at
RT with agitation. Strips were then rinsed with distilled
water and washed twice with TBST, each time for 5 min, with
agitation. Strips were then treated with peroxidase-
conjugated goat anti-human IgG (Sigma) diluted 1:250 in TBST
plus 1% gelatin, 8 ml per test tube with up to seven strips
per test tube, and incubated for 2h as above. Strips were
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then rinsed and washed three times. To develop the strips 10
ml ice cold methanol containing 3 mg/ml //-chloro-l-naphthol-
containing substrate (Biorad) was mixed with 50 ml TBS
containing 30 pi of 30% hydrogen peroxide immediately before
use. Strips were incubated in this mixture for 20 min. The
enzyme reaction was stopped by washing the strips several
times in tap water. Strips were then dried and examined for
staining of HTLV III antigens. Staining of the p25 and gp/J-1
bands (Sarngadharan et al., 198/1) was most commonly observed
and sera which resulted in staining of either or both of
these bands were considered positive.
Safety precautions
The risk of HTLV III infection to health care and
laboratory personnel appears to be low (Hirsch et al.. 198/1).
This is dependent on the malntainance of recognised safety
regulations however. Moreover the risk of infection from
laboratory specimens was unknown at the outset of this work.
All specimens from homosexual and heterosexual volunteers
were therefore handled as recommended by the National
Insitutes of Health (1982). Disposable gloves were worn when
handling specimens and all manipulations were performed in
still-air cabinets, except the harvesting of lymphocyte
cultures. The cell harvester, centrifuge buckets and all other
laboratory apparatus used was rinsed with activated
glutaraldehyde solution after use, which has been shown to
inactive HTLV III efficiently (Spire et al.,198ZQ. All sera
were inactivated at 56c for 30 min when it became known that
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this too eliminated infectivity. Disposable plastics were used
for all manipulations and containments. These were disposed of
by chloros treatment followed by autoclaving. These precautions
were approved by Edinburgh University Safety Committee.
Statistical analysis
Population means were compared using the simple
significance test based on the normal distribution when
numbers were sufficient (both populations >30). Student's
t-test was used in other cases. Differences in the frequency
of a given event between populations were compared using the X.2
formula with Yates correction when numbers were sufficient
(when the occurrence of each possible event was >U). In other
cases the exact test for 2x2 contingency tables was used.




A summary of demographic features and results of
virological and serological investigation in homosexuals and
heterosexuals is given in the Appendix.
Demographic features of study populations
Specimens were received from a total of 84 male
homosexuals and from 140 male heterosexuals. Information
regarding age, sexual preference and any current infections was
obtained for all volunteers. Information on the reported number
of sexual partners in the previous three months was also
available for most volunteers. Information on the reported
duration of sexual activity was available for most homosexuals
but only for a limited number of heterosexuals.
The age distribution of these two study populations is
shown in Figure 2. The mean age of the homosexuals was 26.2
years, and the age range was 17-45- The mean age of the
heterosexuals was 22.4 years with an age range of 16-48. The
difference in mean age was highly significant (p <0.001).
Homosexuals also reported longer histories of sexual activity
and greater numbers of sexual partners than heterosexuals.
The former reported a mean duration of sexual activity of 7.6
years and a mean partner number of 2.9 in the previous three
months. For the heterosexual group the mean duration of
sexual activity was 3.2 years and the mean partner number was
1-25 (p <0.001 for both differences). 73% of homosexuals and























FIGURE 2: AGE DISTRIBUTION OF a) HOMOSEXUAL AND
b) HETEROSEXUAL VOLUNTEERS UIMOER STUDY.
partner in the previous quarter (p <0.001).
Current infection was diagnosed in 55% of the
homosexuals and in 64% of the heterosexuals (not significant
[NS]). Infections most commonly diagnosed were gonorrhoea (in
15% of homosexuals and 20% of heterosexuals), non-gonococcal
urethritis (NGU; in 11% of homosexuals and 24% of
heterosexuals), and warts (in 13% of homosexuals and 17% of
heterosexuals). Only the difference in incidence of NGU
between the two study groups was significant (p <0.05).
Gonococcal infections were predominantly rectal in
homosexuals and predominantly urethral in heterosexuals.
Warts were frequently anal in homosexuals and usually penile
in heterosexuals. Infections other than these were diagnosed
more commonly in homosexuals (15% compared to 4%; p <0.01) and
included HSV, scabies, giardiasis, amoebiasis, molluscum
contagiosum, enterobiasis and chlamydial infection. Rectal or
anal infections (gonorrhoea, warts or HSV) were diagnosed in
19% of homosexuals.
CMV-IgG antibody prevalence in study groups
Antibody to CMV was detected by indirect ELISA in 63/84
homosexuals (75%) and in 36/140 heterosexuals (26%). This
difference is extremely significant (p «0.001; X? = ^9*7).
To account for the possible influence of age on this
difference, age-matched sub-groups of the two populations
were compared for the prevalence of CMV-IgG (Table 1). The
rate of seropositivity among homosexuals under 26 years of
age is significantly higher than that of age-matched
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Age Number seropositive / Total number (%) p value
(years) Homosexuals Heterosexuals
16-19 6/9 (73%) 5/38 (13%) p = 0.002
20-22 16/20 (80%) 13/46 (28%) p = 0.0001
23-25 15/21 (71%) 4/23 (17%) p = 0.0001
>25 32/4a (73%) 20/36 (56%) NS
Table 1; The CMV-IgG antibody prevalence of male homosexuals
and heterosexuals of different ages.
heterosexuals. In older age groups the prevalence of antibody
in heterosexuals approaches that of homosexuals.
Comparison of sub-groups of the two populations after
matching for the number of recent sexual partners reported
similarly reveals a greater antibody prevalence among
homosexuals in both sub-groups where numbers were sufficient
for comparison (Table 2).
Finally, comparison of subgroups matched for reported
duration of sexual activity indicates that significantly more
homosexuals with less than five years of sexual experience are
seropositve than are heterosexuals with a similar history of
sexual activity. Heterosexuals with longer sexual experience
than this however are seropositive as frequently as homosexuals
(Table 3).
Within the homosexual cohort antibody was detected in
22/29 (76%) of those under 23 years old, in 19/29 (66%) of
those from 23-28 years old and in 22/26 (85%) of those over
28 years old. None of these differences were statistically
significant. Of those reporting only one recent partner,
14/22 (64%) were seropositive, compared to 48/60 (80%) of
those who reported more than one recent partner and 20/23
(87%) of those who reported more than two recent partners.
None of these differences acheived statistical significance.
A small but significant difference in antibody prevalence was
observed in homosexuals with a history of sexual activity
greater than seven years compared to other homosexuals (29/33
[88%] compared to 29/43 [67%] respectively; p = 0.026) however
no other subdivision of this group with respect to sexual
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No. of Number seropositive / Total (%) P value
Partners
(last 3 mo. ) Homosexuals Heterosexuals
1 14/22 (64%) 26/104 (25%) P rlooV
2 28/37 (76%) 7/30 (23%) P < 0.001
Table 2: The CMV-IgG antibody prevalence of male homosexuals




Number seropositive / Total (%) p value
Homosexuals Heterosexuals
<3 8/11 (73%) 3/23 (13%) p = 10_l*
3-4 13/19 (68%) 2/12 (17%) p = 0.006
>4 37/46 (80%) 4/5 (80%) NS
Table 3' The CMV-IgG antibody prevalence of male homosexuals
and heterosexuals of different sexual histories.
history revealed significant differences.
Within the heterosexual cohort, 19/97 (20%) of those
under 24 years of age, 9/33 (27%) of those between 2k and 28
years old inclusive, and 8/10 (80%) of those over 28 years
old were seropositive. Antibody prevalence was significantly
higher in the oldest age group (p = 0.0003). Antibody was
present in 26/104 (25%) of those who reported only one recent
partner and in the same proportion (8/32) of those reporting
more partners. Those who had been sexually active for longer
than four years were seropositive significantly more
frequently than those with shorter a history of sexual
activity (4/5 [80%] compared to 5/35 [14%]; p = 0.006).
Virus excretion in study populations
Results of virus excretion were obtained for urine
specimens from 48 homosexuals and from 91 heterosexuals.
Specimens from the remaining volunteers were either not
obtained or were unsuitable for virus isolation due to
microbial contamination or cytotoxicity in cell culture.
Throat swab specimens from 62 homosexuals and 114 heterosexuals
were also successfully cultured however CMV was isolated from
these specimens in only one case (homosexual volunteer P7473).
The corresponding urine specimen from this volunteer also
yielded CMV, therefore only urinary virus excretion is
considered in this analysis. Viruria was detected in 7/48 (15%)
of homosexuals and in 1/91 (1%) of heterosexuals. This
difference was significant (p = 0.002) however when specimens
from only those who were seropositive were included in the
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analysis, the difference was not significant, probably due to
lack of numbers. (7/37 [19%] of seropositive homosexuals and
1/20 [5%] of seropositive heterosexuals were viruric; p =
0.125*) No CMV excretion in seronegative individuals was
observed.
Within the homosexual cohort viruria was predominantly
confined to those under 22 years old (6/12 [50%] compared to
1/35 [3%] of the older age group; p = 0.0005) and was
confined entirely to those under 26 years old (7/28 [25%]
compared to 0/19; P = 0.019). Viruria was also confined to
those with a history of sexual activity of less than eight
years (7/23 [30%] compared to 0/19 of those with a longer
history; p = 0.009). Viruria was highly prevalent in those
with a history of sexual activity of one year or less; three
of five were excreting, a significantly greater proportion
compaired to the remainder of the cohort (/]•/36 [11%]; p =
0.028). The two virus negative specimens from this group were
from seronegative individuals. Viruria was also confined to
those who reported fewer than three recent sexual partners
(7/2^i [29%] compared to 0/8) however this association was not
significant (p = 0.105). This possibly reflected an
association between recent partner number and the duration of
sexual activity.
Repeat isolation specimens were available for three of
those who were viruric on initial testing. One homosexual
(P7&73) was still viruric (but was no longer excreting virus
in saliva) three weeks after initial testing. Two homosexuals
(P&331 and P789i0 were no longer viruric nine and six weeks
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respectively after initial testing.
CMV-IgM antibodies
a) Development of a CMV-IgM assay
A CMV-IgM capture assay was developed for the purpose of
screening plasmas from the study populations for the presence
of IgM antibodies. The usefulness of the assay as an aid to
diagnosis of CMV infection in other groups was also assessed.
The principle of the IgM-capture assay is illustrated in Figure
3. In developing a CMV-IgM capture assay, a range of reagents
and methodologies were assessed. Radioimmunoassay (RIA)
techniques were employed initially, using radiolabelled CMV-
reactive murine monoclonal antibody (McAb) preparations as
detector antibodies. Subsequently, enzyme-linked immunosorbent
assay (ELISA) techniques were assessed with both McAbs and
polyclonal antisera raised against CMV as detector antibodies.
The development of the assay is described below.
IgM antibody capture by RIA (MACRIA)
McAb preparations were assessed for their reactivity
with CMV GE antigen by testing twofold dilutions in an
indirect RIA. The results are shown in Table H. McAb
preparations HCMV 1, HCMV 23 and 96D3 showed greatest
reactivity. Of these HCMV 23 showed strongest reactivity on
dilution and was selected for use in the MACRIA. Precipitated
IgG was iodinated by the Iodogen method, giving a 90%
incorporation of radioisotope. This label was diluted to give





















Test serum is added -
any Igfl binds to
coating antibody
Step 1:







Figure 3: Principle of the IqM-capture assay
using a) labelled or b) unlabelled detector
antibody
Dilution of McAb
McAb 1: 25 1: 50 1: 100 1: 200 1: 400 1: 800
HCMV 1 (1) 14. 7 6. 2 3.4 2.3 NT NT
HCMV 3 (2) 3. 1 4. 1 4.5 5-8 4. 1 2.9
HCMV 23 (3) 8.8 11. 5 8.9 11. 1 10. 9 12. 3
HCMV 25 (3) 3.7 2. 4 2. 8 2. 0 2.3 1. 4
AB3 (1) 2.6 4.4 5.3 5.2 NT NT
91D11 (1) 1.3 1.5 1.3 1.7 NT NT
92E9 (1) 2. 1 2.7 4.3 4. 5 NT NT
93F2 (1) 2.5 3. 7 4.9 4. 0 NT NT
94H3 (1) 1.5 2.3 1.9 1. 7 NT NT
96D3 (1) 5.0 8. 2 9.0 6.0 NT NT
1; Hybridoma culture supernatant
2; Ascitic fluid
3; Sodium sulphate precipitated IgG
NT = not tested
Table 4: Positive : negative binding ratios of McAbs by
indirect RIA
optimal reactant concentrations a range of dilutions of CMV-IgM
positive and negative control sera were tested against a range
of antigen dilutions by chessboard titration. The results are
shown in Table 5- As the radiolabel gave no significant
reaction with control antigen, it would appear that non¬
specific binding of test antigen to the solid phase resulted in
high binding of radiolabel with both IgM positive and IgM
negative sera. This non-specific binding of antigen was not
mediated by non-specifically bound CMV-IgG as CMV-IgG negative
sera gave similar results (not shown).
In an attempt to reduce this non-specific antigen binding,
anti p chain antibody-coated beads were quenched overnight at
room temperature with 0.2% Tween 20 in PBS prior to use (Table
6). In addition, test serum diluent was modified to contain 2%
CMV-seronegative human serum to reduce any nonspecific reaction
of the radiolabel with test antigen (Table 7). Both these
modifications resulted in some reduction of non — specific
binding although the effect of the former was minor.
At this point it became necessary to prepare a fresh
radiolabel. It was considered that a label containing a wider
range of antigenic reactivities may be a more sensitive
detector of bound antigen. A pool of equal concentrations of
McAbs HCMV 1, HCMV 23 and HCMV 24 (also shown to be strongly
reactive to CMV by Dr. Hart) was therefore radiolabelled.
This radiolabel was prepared by Dr. Hart using the chloramine
T method and was also used at a dilution of 40 000 cpm in 200
pi. This was used in a chessboard titration of varying test




a) CMV-IgM positive serum dilution
1: 50 1: 200 1:800 1 : 3200 1:12800
1: 10 3.1 3. 9 3. 1 1. 2 1.3
1: 20 1. 8 3. 5 3. 0 1.6 1.8
1: /J-0 3.7 3- 8 a. 0 1.3 1.5
1: 80 1.5 2.3 3. 2 8.6 3. 2
1: 160 1. 0 1. 0 7.0 5.2 8.6
Antigen
dilution
b) CMV-IgM negative serum dilution
1: 50 1: 200 1:800 1 : 3200 1:12800
1: 10 2. 1 2. 2 3. 0 1. 1 1.9
1: 20 3.6 1.9 5.0 3.1 3.9
1: 10 9.0 2. 8 1.1 2.7 1.9
H CD O 3.5 3.9 5-2 5.1 5-1
1: 160 3. 9 5.1 7.6 5.3 1. 2
Table 5: Positive : negative antigen ratios obtained by MACRIA
on chess board titration of antigen and a) IgM positive








Quenched beads Unquenched beads
IgM 1: 50 1: 20 11. 9 12. 1
+ve 1: 50 1: 80 a.n 11. 5
1: 200 1: 20 in. i 12. 0
1: 200 1: 80 12. 4 7.5
IgM 1: 50 1: 20 n. 2 5-1
-ve 1: 50 1: 80 3.0 5.1
1: 200 1: 20 6. 0 8 .n
1: 200 1: 80 3. 5 5-7
Table 6: The effect of pre-guenchlng anti-p coated beads with












IgM 1: 50 1: 20 12. 1 21. Zl
+ve 1: 50 1: 80 5.3 5.0
1: 200 1: 20 47-7 11. 9
1: 200 1: 80 k. 0 13. 7
IgM 1: 50 1: 20 6.9 til. 9
-ve 1: 50 1: 80 7. 0 COH
1: 200 1: 20 5-5 5.1
1: 200 1: 80 8.5 15. ti
Table 7: The effect of modifying serum diluent to contain 2%
CMV-seronegative serum on the MACRIA reactivity of IgM+ve and
-ve sera.
investigate the relative merits of an assay based on low serum
and antigen dilutions, and an assay based on high dilutions of
both serum and antigen. The effect of adding 20% NBCS to the
antigen diluent as a more effective means of blocking
non-specific antigen binding was also assessed (Table 8). From
these results it is clear that the addition of NBCS to the
antigen diluent had no discernable effect when reactants were
used at low dilution and was too inhibitory at higher dilutions
of reactants. The problem of non-specificity persisted. This
experiment was repeated using intermediate dilutions of serum
and antigen, with NBCS added to the antigen diluent (Table 9).
This resulted in no improvement; reactivity decreased rapidly
with increasing antigen dilution in the presence of NBCS.
An assay system using test serum diluted 1:50 and
antigen diluted 1:10 was capable of distinguishing a panel of
control IgM-positive sera from a panel of IgM-negative sera
(Table 10). Test resolution was low however and
reproducibility proved to be poor. In view of these
shortcomings, an alternative assay system was sought.
IgM antibody capture by ELISA (MACELISA)
The McAb preparations used previously in RIA were
assessed for their suitability as detector antibodies in a
MACELISA. Further McAb preparations were also available for
testing at this stage and two polyclonal rabbit antisera
raised against CMV whole virions and virion envelopes were
also tested. These antisera were shown to be CMV-reactive by












IgM 1: 50 1: 10 yes 11. 8
+ve 1: 50 1: 10 no 11. 1
1:1000 1: 100 yes 3.4
1:1000 1: 100 no NT
1:10000 1: 100 yes 2. 8
1:10000 1:100 no 9.9
l:100000 1: 100 yes 3. 5
1:100000 1: 100 no 7.1
I gM 1: 50 1: 10 yes 2. 4
-ve 1: 50 1: 10 no 2. 8
1:1000 1: 100 yes 1. 8
1:1000 1: 100 no 4. 2
1:10000 1: 100 yes 1.3
1:10000 1: 100 no 3. 1
l:100000 1: 100 yes 1.7
1:100000 1: 100 no 3.1
Table 8: Titration of IgM positive and negative control serum
by MACRIA using pooled McAb radiolabel: investigation of the






1: 10 oCMH 1: 50 1: 100
IgM 1: 50 15- 9 7.3 4.4 3. 5
+ve 1: 100 17- 0 9.6 5.4 3. 4
1: 500 21. 0 8.8 5.4 3. 0
1:1000 14. 1 9. 1 6. 1 3. 4
IgM 1: 50 4. 1 2. 4 2. 8 1-7
-ve 1: 100 4.9 3.7 1.5 1.6
1: 500 7.6 4. 2 2.6 2. 0
1:1000 7-2 4.4 2. 1 1.5
Table 9: Positive : negative antigen ratios obtained on chess¬
board titration of IgM positive and negative serum and
antigen.













Table 10: MACRIA reactivity of a
panel of CMV-IgM +ve and -ve sera.
antigen was observed at low dilution (Table 11). CMV-IgM
positive and negative control sera were used at a dilution of
1:50 and reacted with microtitre plate wells coated with
anti-human p chain antibody at a 1:100 dilution of stock
solution (lmg/ml protein concentration). CMV GE and also PEG
precipitate antigen were used at a dilution of 1:100. (Only
test antigens were used in this initial experiment.) Ascitic
fluids and antisera were tested at three twofold dilutions and
bound antibody was detected with the appropriate anti-species
IgG enzyme conjugate. The results are shown in Table 12.
While some McAbs distinguished between the positive and
negative control sera, the problem of high reactivity with
IgM negative serum encountered in the MACRIA remained.
Although this was also true to some extent of the rabbit
antisera, this reactivity was greatly reduced at higher
antiserum dilutions. Antiserum 39 in particular showed strong
reactivity and good specificity and was selected for further
experiments. PEG precipitate antigen was of inferior
reactivity in the MACELXSA and was no longer used.
This assay system was tested with a range of IgM positive
and negative control sera. The rabbit antiserum was also
tested at higher dilutions as was the coating antibody.
(Table 13). It was decided to use the antiserum at a dilution
of 1:1600 as this gave low readings with IgM negative sera
but was still capable of identifying all IgM positive sera. A
coating antibody dilution of 1:200 was chosen as this gave
little difference in results compared to the lower dilutions




OD (405 nm) readings
Test antigen (mean) Control antigen Net
Antiserum 37
1: 400 1. 411 1. 142 0. 269
1: 800 1. 048 0. 707 0. 311
1:1600 0. 805 0.441 0. 364
1:3200 0. 582 0. 251 0. 331
1:6400 0. 409 0. 140 0. 269
1:12800 0. 275 0. 061 0. 214
1:25600 0. 160 0. 029 0.131
1:51200 0. 090 0 . 010 0. 080
Antiserum 39
1: 400 >1.500 0. 892 -
1: 800 >1.500 0. 511 -
1:1600 1. 161 0. 318 0. 843
1:3200 0. 878 0. 164 0. 714
1:6400 0. 605 0. 078 0. 527
1:12800 0. 403 0. 029 0. 374
1:25600 0. 247 0. 029 0. 218
1:51200 0. 144 0, 004 0. 140
Table 11; Reactivity of rabbit antlsera 37 and 39 by Indirect
ELISA with CMV GE antigen.
Detector GE Ag PEG precipitate Ag
antibody Dilution IgM +ve IgM -ve IgM +ve IgM -ve
serum serum serum serum
HCMV 1 1: 50 1. 027 0. 917 0. 902 0. 876
(1) 1: 100 0. 876 0. 832 0. 907 0. 748
1: 200 1. 157 0. 895 0. 910 0. 845
HCMV 3 1: 50 0. 851 0. 890 0. 841 0. 984
(2) 1: 100 1. 002 1. 087 1. 047 0. 935
1: 200 0. 939 0. 917 0. 939 0. 880
HCMV 19 l:1000 >1.5 1. 157 0. 914 0. 848
(3) 1:2000 >1. 5 1. 151 0. 970 1. 027
l:4000 1. 489 1. 131 0. 862 0. 862
HCMV 22 1: 50 >1. 5 >1.5 1. 318 1. 445
(3) 1: 100 >1. 5 >1.5 1. 245 1. 359
1: 200 1. 395 1. 398 1. Ill 1. 131
HCMV 23 1: 50 >1.5 1. 369 1. 234 1. 252
(3) 1: 100 >1.5 1. 359 1. 245 1. 359
1: 200 >1.5 1. 268 1. 179 1. 027
HCMV 24 1: 50 1. 327 1. 060 0. 923 0. 947
(1) 1: 100 1. 336 1. 145 0. 960 0. 855
1: 200 1. 280 1. 007 0. 960 0. 802
HCMV 25 1: 50 1. 350 1. 038 0. 978 1. 043
(3) l: 100 1. 318 1. 060 0. 978 0. 998
l: 200 1. 268 0. 984 0. 926 0. 779
HCMV 29 1: 50 1. 202 1. 245 1. 095 1.157
(3) 1: 100 1. 106 1. 031 1. 047 0. 956
1: 200 0. 970 0. 917 0. 978 1. 007
AB3 1: 50 1. 007 0. 992 0. 952 0. 943
(2) 1: 100 1. Ill 0. 926 0. 966 0. 956
1: 200 0. 923 0. 926 0. 930 0. 858
Table 12
Continued overleaf
Detector GE Ag PEG precipitate Ag
antibody Dilution IgM +ve IgM -ve IgM +ve IgM -ve
























































































































1: Hybridoma culture supernate
2: Ascitic fluid
3: Sodium sulphate precipitated
4: Rabbit antiserum
Antigens were diluted 1:100 and




the MACELISA using various
detector antibodies.













































GE antigen was diluted 1:100 and
Table 13: The MACELISA - Titration
detector antibody using CMV-IgM
b) IgM +ve serum S5150
Anti¬ Anti-human p chain
serum coating Ab diln.
diln. 1:100 1:200 1:400
1: 200 1.249 1.249 1.186
1: 400 0.974 0.952 0.923
1: 800 0.742 0.704 0.698
1:1600 0.519 0.500 0.498































of coating antibody and
(a-d) and -ve (e-f) sera.
at least two of the four IgM positive sera tested.
This test system was used to determine the optimun test
serum concentration. At this point control antigen was
included in the assay (Table 14). Positive and negative
control sera were readily distinguished at all serum
dilutions tested. OD readings for control antigen wells and
for test antigen wells with IgM negative sera generally
increased with increasing serum dilution. This may be due to
increased non-specific binding of rabbit antibody or anti-
rabbit conjugate to the solid phase at higher test serum
dilutions. Greater non-specific binding of antigen may also
occur under these conditions and may result in increased
background readings in view of the reactivity of the rabbit
antiserum with control antigen. A test serum dilution of 1:50
was retained in further tests.
In order to determine a cutoff point sera were assigned
an IgM value which was calculated by the equation:
NET OD1 (TEST SERUM) - NET OD (—VE CONTROL SERUM)
IgM value =
NET OD (+VE CONTROL)2- NET OD (-VE CONTROL SERUM)
MULTIPLIED TIMES 100
1. NET OD = mean OD reading of two test antigen wells
minus OD reading of one control antigen well.




OD readings (Test antigen/control antigen)
Serum dilution
1: 50 1: 200 1: 500 1:1000
IgM +ve
S6824 1. 36/1/0. 000 1.276/0.003 1.084/0.045 1.056/0.073
S5150 0. 456/0. 000 0.416/0.000 0.422/0.011 0.416/0.011
1937 1.078/0.06l 0.780/0.091 0.820/0.100 0.710/0.214
1861 1.004/0.006 0.926/0.012 0.806/0.037 0.730/0.060
S6004 1.179/0.000 1.174/0.000 1. 157/0.020 1.174/0.034
SB14318 1.217/0.005 1.179/0.048 1.116/0.057 1.122/0.056
IgM -ve
PM 0.217/0.053 0.198/0.008 0.264/0.103 0.271/0.120
PW 0.164/0.008 0.160/0.040 0.202/0.033 0.222/0.101
RF+ve 1 0.195/0.100 0.239/0.057 0.255/0.058 0.272/0.102
RF+ve 2 0.179/0.007 0.079/0.000 0.091/0.000 0.072/0.000
Table 14: The effect of dilution on the MACELISA reactivity
of CMV-IgM +ve and -ve control sera.
The assay was then used to screen a panel of sera from
patients with proven or suspected primary CMV infection and a
panel of potential false positive generating sera. The results
are shown in Table 15. As can be seen seen few sera of the
latter group gave IgM values greater than 20. The one specimen
which did was a rheumatoid factor positive serum which remained
positive after sucrose density gradient fractionation. (See
Figure U) This specimen was therefore considered to be
genuinely CMV-IgM positive. Most of the sera from proven
primary CMV infections gave IgM values much greater than 20,
although some from asymptomatically infected individuals with
unknown types of infection gave low values around 20. An IgM
value of 20 was therefore taken as the cutoff value. The IgM
status of sera giving values under but close to the cutoff
may be considered as doubtful. In view of the fact that
several EBV-IgM positive sera gave IgM values which were
close to the cutoff it was considered prudent to test sera
giving positive results for the presence of EBV-IgM by IIF.
Subsequently it became apparent that incusion of a weak
CMV-IgM positive sample with an IgM value close to cutoff in
each run was necessary. This was because inter-test
fluctuations in the OD readings of weakly positive sera were
greater than those of strongly positive sera, where IgM is
liHely to be present in excess. IgM values were then calculated
using a projected net OD reading equivalent to an IgM value of
100 which was extrapolated from the net OD readings of the weak
positive (IgM value = 21) and negative (IgM value = 0)
control samples.
The sensitivity and specificity of the assay were then
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Serum Diagnosis IgM value
S10622 CMV-mononucleosis >100
S10623 Paired serum >100
S12564 CMV hepatitis 108
S11982 Rash, hepatomegaly 0
S11983 Paired serum 0
sii486 Acute renal failure 4
S11U9U Sequential serum 3
S12080 Sequential serum 19
S12551 Sequential serum 24
S11398 J aundice 5
S11399 Paired serum 6
S12101 Abnormal liver function tests 0
cs 763 Renal transplant patient, 2
CS 779 CMV seroconversion 13
cs 795 Sequential sera 52
cs 496 Renal transplant patient, 6
cs 518 CMV seroconversion 40
cs 528 Sequential sera 50
cs 444 Bone marrow transplant patient, 1
cs ti77 CMV seroconversion 4
cs 503 6
cs 516 Sequential sera 12
RF 17 Rheumatoid factor positive 34
S3697 Monospot positive 6
S5696 Monospot positive 9
S7615 Monospot positive 18
S7639 Monospot positive 18
S8112 Monospot positive 17
S6737 Monospot positive 2
21481 Rubella-IgM positive 2
423 Rubella-IgM positive 0
238 EBV-IgM positive 18
403 Hepatitis A-IgM positive 7
1192 Hepatitis A-IgM positive 7
1169 VZV-IgM positive 1
S2519 HSV-IgM positive 11
SB5058 HSV-IgM positive 3
1709 Mycoplasma CF titre >256 1
797 VZV CF titre 1024 0
31170 HSV seroconversion 0
298 Psittacosis CF titre 512 12
23974 Influenza B CF titre >256 0
Table 15: MACELISA IgM values of sera from various acute
infections.
tested further. To verify that MACELISA reactivity was in
fact due to the presence of IgM in test sera several IgM
positive sera were fractionated by sucrose density
centrifugation and individual fractions were tested in the
MACELISA. Results of representative sera are shown in Figure
4. Maximum IgM values were obtained with fractions containing
most IgM. The positive results obtained with higher fractions
of strongly positive sera are probably due to carry-over of
IgM during fraction collection.
The IgM-specificity of the assay was further confirmed
by inhibition experiments with myeloma sera. When added to
CMV-IgM positive sera, IgM myeloma sera consistently
inhibited the capture of specific IgM by the coating antibody
in a dose-dependent fashion. In contrast, an IgG myeloma
serum, an IgA myeloma serum and a gamma globulin preparation
did not inhibit specific IgM binding any more than observed
with CMV-seronegative serum. Representative results of this
experiment using a strong CMV-IgM positive serum are shown in
Figure 5.
The sensitivity of the MACELISA was assessed by testing
a panel of sera which had previously been tested for CMV-IgM
by indirect RIA. Of 173 sera tested, three were CMV-IgM
positive by indirect RIA. These three sera were also strongly
positive by MACELISA (IgM values were 63-78). A further three
sera which were negative by indirect RIA gave IgM values of
20 by MACELISA. It could not be determined whether this
slight discordance was due to greater specificity of indirect
RIA or greater sensitivity of the MACELISA.
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* Serum RF 17
Figure 4: MACELISfi reactivity of sucrose
density gradient fractions of CfW-IqM
positive specimens.
KEY
• IgM myeloma 1 (16 mg/ml IgM)
• IgPH myeloma 2 (192 mg/ml Igffl)
• IgK| myeloma 3 (87 mg/ml Igffl)
O Igfl myeloma (57 mg/ml Igfl)
O IgG myeloma (50 mg/ml IgG)
A Pooled normal gamma globulin (150 mg/ml protein)
X ClW-seronegative human serum
Figure 5: Inhibition of CMU-IqM capture by different
antibody classes.
The assay was then used to screen plasma samples from
the homosexual and heterosexual volunteers. These results are
discussed below. It became apparent during further use that
the MACELISA may be of selective sensitivity. For example,
several plasmas from individuals who were viruric at the time
of study were found to give IgM values close to but
consistently below the cutoff. This may simply reflect a waning
of IgM titres following acute infection, however it was also
considered possible that the MACELISA detected IgM
specificities which are not representative of those in some
specimens.
In view of this possibility it was decided to develop an
alternative MACELISA system using McAbs directed against
glycoprotein antigens. It was considered that biotinylation of
McAbs may permit their use at higher dilutions than those used
previously in the MACRIA and MACELISA using unlabelled McAbs,
possibly overcoming the problems of nonspecificity encountered
in these assays. McAb HCMV 2k, directed against an immediate
early glycoprotein which is also present at late stages of
infection was selected for biotinylation. Three McAbs, CH 12,
CH 16 and CH 28, reactive with late glycoproteins were also
available at this stage. Of these three, CH 16 showed greatest
reactivity against CMV GE antigen by indirect ELISA (Table 16)
and was also selected for biotinylation. McAb HCMV 3. reactive
with an early nuclear antigen was also biotinylated for
comparison. Each McAb was biotinylated at two different
biotin : free IgG amino group ratios as detailed under




Mean test antigen Control antigen Net
CH 12 1: 200 0 . 104 0 . 001 0. 103
1: 400 0. 124 0.044 0. 080
1: 800 0 . 115 0.049 0. 066
1:1600 0. 130 0. 063 0. 067
1:3200 0. 097 0. 038 0. 059
1:6400 0. 066 0.028 0. 038
1:12800 0. 076 0.010 0. 066
1:25600 0. 017 0. 000 0. 017
CH 16 1: 200 0. 849 0.041 0.808
1: 400 0. 824 0. 008 0. 816
1: 800 0. 832 -0.010 0. 842
1:1600 0. 904 0. 045 0. 859
1:3200 0. 852 0. 004 0. 848
1:6400 0. 838 0 . 091 0. 747
1:12800 0. 851 0. 017 0. 834
1:25600 0. 720 0. 035 0.685
CH 2 8 1: 200 0. 142 0. 050 0. 092
1: 400 0.069 0. 028 0.041
1: 800 0. 040 0. 043 <0
1:1600 0. 034 0. 028 0.006
1:3200 0. 036 0. 080 <0
1:6400 0. 018 0. 008 0. 010
1:12800 -0.044 -0.046 0. 002
1:25600 -0.085 -0.054 <0
Table 16: The reactivity of McAbs from L. Pereira with CMV GE
by Indirect ELISA.
were then tested for their CMV GE reactivity (Table 17). Those
showing greatest specificity (HCMV 24 and CH 16 labelled at a
4:1 molar ratio and HCMV 3 labelled at a 1:1 molar ratio)
were selected for use in the MACELISA.
Initially, biotinylated McAb HCMV 24 (B-HCMV 24) was
used. On testing a selected panel of sera and plasmas it was
evident that this assay detected CMV-IgM relatively more
efficiently in some specimens and less efficiently in others
compared to the MACELISA using rabbit antiserum as detector
antibody (Table 18). Plasma P7473 was initially weakly
positive in the original MACELISA test but had become
negative on repeat testing, probably due to multiple thawing
and refreezing which is known to inactivate IgM. This
specimen was still readily identifiable as IgM positive in
the modified MACELISA however. In contrast the
positive serum S12564 which was strongly positive in the
original MACELISA gave lower IgM values in the modified test.
The MACELISA using B-HCMV 24 was used to test a wider selection
of sera (Table 19). The biotin label was used at a dilution of
1:10 000 as this gave maximal distinction between the positive
and negative control sera. The results of this experiment
reinforced the conclusion of the initial test, namely that the
two MACELISA tests detected IgM in different sera to different
relative extents. It was also noticed that some sera from
patients with other acute infections gave high background IgM
values. An IgM value of 25 was therefore taken as the cutoff.
A MACELISA using B-CH 16 gave similar results to that







Mean test antigen Control antigen Net
B-HCMV 24 1:5120 0. 889 0.166 0. 723
(4: 1) 1:20480 0. 860 0.109 0. 751
1:81920 0. 559 0. 046 0. 513
1:327680 0. 328 0. 102 0. 226
B-HCMV 24 1:5120 <0.900 0. 807 _
(1:1) 1:20480 <0.900 0. 569 -
1:81920 0. 783 0. 283 0. 500
1:327680 0. 495 0 . 181 0. 314
B-HCMV 3 1:5120 0.783 0. 314 0. 469
(4:1) 1:20480 0. 434 0. 133 0. 070
1:81920 0. 173 0.070 0.103
1:327680 0.156 0.169 <0
B-HCMV 3 1:5120 0 . 406 0. 058 0. 348
(1:1) 1:20480 0. 211 0. 005 0. 206
1:81920 0. 084 0. 002 0.082
1:327680 NT NT NT
B-CH 16 1:10000 1. 450 0. 179 1. 271
(4:1) 1:20000 1. 131 0. 119 1. 012
1:40000 0. 737 O.O85 0. 652
1:80000 0. 512 0. 087 0. 425
B-CH 16 1:10000 0. 748 0.189 0. 559
(1:1) 1:20000 0. 550 0.158 0. 392
1:40000 0. 423 0. 181 0. 242
1:80000 0. 394 0.183 0. 211
NT = not tested
Table 17: ELISA reactivity of blotinylated McAbs
a) Detector antibody = rabbit antiserum (1:1600)
Serum
OD readings igM
valueMean test antigen control antigen Net
wk +ve 0. 322 0. 043 0. 279 21
-ve 0. 033 0. 001 0 . 032 0
S12564
(1:200) 1. 187 0. 141 1. 046 86
(1:400) 0. 90k 0. 127 0. 777 63
(1:800) 0. 566 0. 124 0. 442 35
NP 0. 180 0. 118 0. 062 3
PM 0. 355 0. 233 0.133 9
P7473 0. 452 0 . 220 0 . 232 17
b) Detector antibody = B-HCMV 24 (1:5000)
Serum
OD readings IgM
valueMean test antigen control antigen Net
wk +ve 0. 426 0. 190 0. 236 21
-ve 0. 245 0. 264 <0 0
S12564
(1:200) 0. 794 0.209 0. 585 52
(1:400) 0. 629 0. 239 0. 390 35
(1:800) 0. 493 0. 230 0. 263 23
NP 0. 363 0 . 200 0. 163 15
PM 0. 445 0.243 0. 202 18
P7473 0. 928 0. 380 0. 548 49
Table 18
Continued overleaf
c) Detector antibody = B-HCMV 24 (1:10000)
Serum
OD readings igM
valueMean test antigen control antigen Net
wk +ve 0. 286 0. 075 0. 211 21
-ve 0. 124 0. 055 0. 069 0
S12564
(1:200) 0. 583 0.092 0. 491 62
(1:400) 0. 425 0. 089 0. 336 39
(1:800) 0. 311 0. 091 0. 220 22
NP 0. 216 0. 088 0 . 128 9
PM 0. 271 0.095 0. 176 16
P7473 0. 645 0. 147 0. 498 63
d) Detector antibody = B-HCMV 24 (1:20000)
Serum
OD readings IgM
valueMean test antigen control antigen Net
wk +ve 0. 188 0. 004 0. 184 21
-ve 0. 071 0. 017 0. 054 0
S12564
(1:200) 0. 405 0.048 0. 357 49
(1:400) 0. 291 o. 050 0. 241 30
(1:800) 0. 209 0. 053 0. 156 16
NP 0. 103 0. 054 0. 049 0
PM 0. 164 0. 043 0. 121 11
P7473 0. 452 0. 123 0. 329 44
CMV-IgM +ve: S12564, P7473
CMV-IgM -ve: NP, PM
S12564 diluted in NP.
Table 18: Comparison of a) rabbit antiserum and b)-d) B-HCMV
24 as detector antibodies in the MACELISA.
Serum Diagnosis IgM value
S10622 CMV-mononucleosis 92
S10623 Paired serum 73
S14273 Bone marrow transplant recipient, 41
CMV CF titre 512
CS 175 Renal transplant recipient, 9
CS 197 CMV seroconversion 108
CS 212 Sequential sera 84
S3697 Monospot positive 0
S5696 Monospot positive 0
S7615 Monospot positive 11
S8112 Monospot positive 4
21481 Rubella-IgM positive 23
423 Rubella-IgM positive 12
238 EBV-IgM positive 0
285 E8V-IgM positive 25
1192 Hepatitis A-IgM positive 17
1169 VZV-IgM positive 20
1709 Mycoplasma CF titre >256 12
797 VZV CF titre 1024 17
31170 HSV seroconversion 14
298 Psittacosis CF titre 512 8
23974 Influenza B CF titre >256 19
Plasmas positive in original MACELISA







Table 19? Modified MACELISA: IgM values of sera from various
acute Infections and from plasmas characterised In the original
MACELISA.
which were strongly positive by other assays gave detectably
positive results (Table 20). It was initially intended to
employ a MACELISA using a mixture of B-HCMV 2k and B-CH 16
as detector antibody, however it became necessary to stop
using B-CH 16 as high background IgM values were observed
with many sera. This was found to be due to label
deterioration. The final test therefore used B-HCMV 2k only.
The reproducibility of both MACELISA tests proved to be
reasonable. Strongly positive sera gave positive results on
all occasions. Fluctuations in the IgM values of weak
positive specimens were in the order of 0-9 IgM units. This
occasionally resulted in fluctuations around the cutoff value.
All positive or doubtful specimens were therefore confirmed
by repeat testing. After multiple testing several positive
sera gave consistently negative results which was probably
due to multiple freeze-thawing.
During the course of these developments a CMV-IgM
capture assay using peroxidase-labelled McAb as detector
antibody became available commercially. The VirEnz - M CMV
kit was tested with sera and plasmas which had been
characterised by MACELISA. Only results obtained with the
modified MACELISA were compared as considerable deterioration
of MACELISA reactivity had occurred with several specimens
since testing with the original MACELISA. The results are
shown in Table 21. The two tests are comparable although
there are some discrepancies. Some sera which were weakly
positive originally by MACELISA were still positive in the
VirEnz kit. Some EBV-IgM positive sera were also positive or
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Detector antibody
Serum B-HCMV 24 B-CH 16 B-HCMV 3
(1:10000) (1:10000) (1:2000)
S12564
(1:200) 0. 776 0. 541 0. 162
(1:400) 0. 337 0. 245 0. 078
-ve 0. 092 0.171 0. 022
CS 1057 0. 093 0. 095 0. 029
CS 1075 0. 435 0. 381 0. 095
cs 1087 0. 474 0. 383 0. 089
CS 1101 0. 281 0. 253 0. 084
S3697 0. 000 0. 000 0 . 084
S5696 0. 000 0. 000 0. 038
S7629 0. 819 1.418 0.164
PM 0. 124 0.136 0. 035
FC 0.105 0.136 0. 026
P8392 0. 210 0.157 0. 037
S10623 1 . 031 0 . 966 0 . 243
P4710 0.409 0 . 450 0.113
Specimens CS 1057 - CS 1101 were sequential sera
from a bone marrow transplant recipient showing CMV
seroconversion. S3697-S7629 were Monospot positive
specimens. S12564, S10623, P8392 and P4710 were CMV-
IgM positive in the original MACELISA. Other specimens
were CMV-IgM negative.
Table 20: Net OD readings of selected sera in the
modified MACELISA using different detector antibodies.
Serum IgM value VirEnz result
P7775 1H -ve
M9937 HO +ve












P5612 8 - ve
S3697 0 doubtful +ve
S7629 45 +ve
P6592, P7&9H, PU331. P5997 and P7^73 were from
viruric homosexuals. P7775. S3697 and S7629 were
EBV-IgM positive. Other specimens were CMV-IgM
positive in the original MACELISA.
N.B. Discrepancies between IgM values quoted in this
table and those of other tables are probably due
to deterioration of MACELISA reactivity on storage.
Table 21: Comparison of the modified MACELISA with
the VirEnz - M CMV kit.
doubtful in the latter test but negative by MACELISA. It is
likely that both assays could be used on a diagnostic basis
provided EBV-IgM positive sera were excluded.
b) CMV-IgM antibodies in the study populations
All plasmas from the two study populations were tested
for CMV-IgM using the original MACELISA with rabbit antiserum
as detector antibody (MACELISA 1) and with the modified assay
using B-HCMV ZH as detector antibody (MACELISA 2), with a few
exceptions where a specimen had been exhausted. A random
selection was also tested by IIF for CMV-IgM. All other
specimens which were positive in one or both MACELISA's were
also tested by IIF. All specimens which were positive in any of
these three tests were also tested by IIF for EBV-IgM and -IgG.
Any which were EBV-IgM positive were regarded as CMV-IgM
negative.
114. specimens were tested by IIF for CMV-IgM at the same
time as specimens were tested by MACELISA 1. Correlation
between these two sets of results was 98%; 107 were negative
in both tests and five were positive in both tests. Two
specimens were positive by IIF only. One of these specimens was
from an individual who was excreting virus at the time
(P7895). The other specimen was from an individual who had no
other evidence of active infection (M2866).
In all, 200 plasmas from the two study populations were
tested by both MACELISA 1 and MACELISA 2. Correlation between
the results obtained was 98%; 190 were negative in both tests
and six were positive in both tests. There were three which
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were positive only by MACELISA 1 and one which was positive
only by MACELISA 2. It should be noted however that some sera
which were originally positive by MACELISA 1 were no longer
positive in this test at the time of testing by MACELISA 2.
In addition, 17 specimens were tested by MACELISA 1
only, one of which was positive, and six specimens were
tested by MACELISA 2 only, none of which were positive. The
results obtained for sera which were positive by either or
both MACELISA's are shown in Table 22. The single specimen
which was EBV-IgM positive was considered CMV-IgM negative in
the analysis that follows. The remainder were considered
CMV-IgM positive.
7/84 (8.3%) of the homosexual group and 3/140 (2.1%) of
the heterosexual group were CMV-IgM positive. This difference
is statistically significant (p = 0.028). If only
seropositive individuals are considered in the analysis no
significant difference is detectable. (7/63 [11.1%] of
seropositive homosexuals and 3/34 [8.8%] of seropositive
heterosexuals were CMV-IgM positive.) No seronegative
individuals were CMV-IgM positive.
Within the homosexual group, CMV-IgM was only found in
those under 25 years of age; 7/43 (16%) of this age group and
0/4l of the older age group were IgM positive (p = 10 ~6).
CMV-IgM was also restricted to those with under six years of
sexual experience. (7/39 [18%] of this group and 0/37 of the
more sexually experienced group were CMV-IgM positive; p =
0.0007.) There was no significant association between the




CMV-IgM IIF1 EBV-IgM IIF1MACELISA 1 MACELISA 2
M9937 16 HO
PU331 25 17 -f- -
P4710 25 39 + -
P5612 94 17 - -
P6867 31 NT NT1 NT
P7138 27 18 - -
P7202 32 37 + -
P7^73 26 1X2 + -
P7663 23 23 + -
P7775 2U 28 4- 4-
P8392 22 tX3 4- —
'IIF results recorded are those determined after absorption
against latex-bound IgG.
ZNT = not tested
Table 22: MACELISA positive specimens from study populations;
IgM values and IIF results.
Numbers were insufficient for a similar an a lysis within
the heterosexual group.
Retrospective specimens were available for four
homosexuals who were CMV-IgM positive at the time of testing.
One individual (P4331) was IgG negative 17 months prior to
testing. Another (P4710) was IgG negative 13 days prior to
testing. One (M9937) was IgG and IgM positive five months
prior to testing and one (P5612) was IgG positive 7.5 months
prior to testing. The IgM status of this retrospective
specimen was not determined.
CMV IEA-IgG antibodies in the study populations
CMV IEA-IgG antibodies were only detected in plasmas which
were CMV-IgG positive by indirect ELISA. This type of antibody
was detected in 46/63 (73%) of seropositive homosexuals and in
only 16/34 (47%) of seropositive heterosexuals, a significantly
lower prevalence (p <0.05). Within the seropositive homosexual
cohort, no significant trends were apparent when individuals
were grouped according to age (32/41 [78%] of those under 29
years of age and 14/22 [64%] of the older age group were CMV
IEA-IgG positive; p = NS), duration of sexual activity (24/29
[83%] of those with a history of sexual activity shorter than
eight years and 18/29 [62%] of those with a longer history of
sexual activity were CMV IEA-IgG positive; p = NS) or recent
partner number (23/42 [55%] of those reporting fewer than three
recent partners and 11/20 [55%] of those reporting a higher
number of recent partners were CMV IEA-IgG seropositive). No
other breakdown of these figures showed any significant
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differences.
CMV IEA-IgG was present in five of the seven homosexuals
who were excreting virus and in all seven of those who were
CMV-IgM positive. Neither of these associations were
statistically significant when compared to the remainder of the
seropositive homosexual group.
Numbers were insufficient for a similar breakdown within
the heterosexual group.
CMV EA-IgG antibodies in the study populations
Like CMV IEA-IgG, CMV EA-IgG antibodies were only
detected in plasmas which were CMV-IgG positive by indirect
ELISA. Specimens which were positive at either of the two
screening dilutions were regarded as positive.
CMV EA-IgG was detected in 35/63 (56%) of seropositive
homosexuals and in 8/3& (2/1%) of seropositive heterosexuals.
This difference is more striking than that observed with CMV
IEA-IgG (p <0.01). Within the seropositive homosexual group,
the presence of CMV EA-IgG did not correlate with age (22/Ll
[5/|%] of those under 28 years of age and 13/22 [59%] of the
older age group were positive), duration of sexual activity
(16/29 [55%] of those with a history of sexual activity less
than eight years and identical numbers of those with a longer
history were positive) or the number of recent partners (6/1/1
[Z/3%] of those reporting one recent partner, 17/28 [6l%] of
those reporting two partners and 11/20 [55%] of those
reporting more than two recent partners were positive). None of
these differences were significant.
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CMV EA-IgG was present in five of the seven homosexuals
who were viruric at the time of testing and in six of the
seven who were CMV-IgM positive. These associations are not
significant.
The presence of CMV EA-IgG correlated to some extent
with the presence of CMV IEA-IgG (p <0.05) although the
former was detected less frequently. 3&/U3 (79%) of CMV
EA-IgG positive specimens were also CMV IEA-IgG positive.
Persistence of CMV IEA-IgG and CMV EA-IgG
To determine whether or not the presence of these
antibody reactivities fluctuated with time in individuals of
long-standing immunity, repeat plasma specimens from
seropositive, healthy laboratory personnel, collected over
periods ranging from 5-16 months were tested for CMV IEA-IgG
and CMV EA-IgG. The results are shown in Figure 6. As can be
seen, the presence or absence of CMV IEA-IgG was constant in
all individuals. Two individuals however showed a change in
CMV EA-IgG status.
Lymphocyte proliferative responses to mitogens
Initial tests were carried out using lymphocytes from
laboratory personnel. Maximal proliferation in response to
phytohaemagglutinin (PHA) occurred when stock PHA solution
was added to cultures to give a final dilution of either 1:400
or 1:800. Responses to pokeweed mitogen (PWM) were more
variable, and frequently the dose-response curve gave two


























































































lymphocyte populations. In other cases a plateau effect was
observed. Lymphocytes from most individuals save good
responses when the final dilution of stock PWM solution was
1:200-1:800. PHA and PWM were therefore used at dilutions of
1:200, 1:400 and 1:800 wherever lymphocyte yield permitted.
Concanavalin A (Con A) was found to give maximal stimulation
when a 10 mg/ml stock solution was added to give a final
dilution of 1:40 or 1:80. Con A was often inhibitory at
hisher concentrations and was therefore used at dilutions of
l:4o, 1:80 and 1:160 wherever possible. The dilution which
resulted in maximal proliferation was used for statistical
analysis.
Lymphocyte proliferation studies with the above mitogens
were attempted successfully on specimens from 138 study
volunteers, although lymphocyte yield did not permit
investigation with all three mitogens on each specimen. The
test failed on a number of occasions; this was usually
recognised by the absence of significant proliferation in all
cultures initiated at the same time. Test failure appeared to
be due to fluctuations in C02 concentration in most cases.
Results of mitogen-induced proliferation of lymphocytes
from homosexuals and heterosexuals are shown in Table 23.
None of the differences in mean proliferation between the two
study populations were significant. Lymphocytes from
individuals with evidence of current or recent CMV infection
(those who were viruric and/or CMV-IgM positive) did not show
































































'SI = stimulation index
Table 23: Mltogen-induced lymphocyte proliferative responses
of homosexuals and heterosexuals.
Lymphocyte proliferative responses to CMV antigens
CMV-specific proliferative responses were assayed in
parallel with mitogen-induced responses and results were
discarded when the latter tests failed. This test was also
initially characterised using lymphocytes from laboratory
personnel. CMV GE antigen was added to cultures to give a
range of final dilutions while control antigen was used at a
single dilution of 1:80. The results are shown in Table 24.
The antigen dilution which resulted in the maximum stimulation
index (SI) was used in all evaluations. Clearly not all
seropositive individuals gave significant CMV-specific
proliferative responses in this assay. No seronegative
individual gave a response with an SI greater than two. This
value was therefore taken as the cutoff.
CMV-specific lymphocyte proliferation was successfully
studied in 133 homosexual and heterosexual volunteers. These
assays were carried out before the CMV serostatus of the
volunteers was determined. 77 of those studied were CMV-
seronegative. In only four of these cases (5%) were SI values
above the cutoff observed. These values were all low
(2.0-2.7). Of the 56 seropositive volunteers studied 37 were
homosexuals and 19 were heterosexuals. The results of these
assays are shown in Table 25. There was no significant
difference between the study groups, either in the proportion
who gave a positive response or in the mean SI of those who
did respond.








GL (F) 23. 1 IR (F) 1. 2
PM (M) 20. 8 PW ( F) 0.9
AG (F) 6 . 2 IC (F) 0. 9
PR ( F) 1. 1 GO (M) 1. 1
OC (M) 0. 8 MA ( F) 1. 0
BB (F) 1. 8 MB ( F) 1. 1
PN (M) 1. 8
WN (M) 1 . 1
PC (M) 2. 8
AM (M) 0. 8
EE (F) 1.7
Table 21: CMV-speoific lymphocyte proliferative responses of
seropositive and seronegative laboratory personnel.
Homosexuals SI Heterosexuals SI
K5914 6.7 H9499 2. 1
K6561 2 . 0 M6615 3. IX
K7967 1.6 P6685 3.0
M653 1. 2 P6824 17. 3
M946 1. 4 P6867 1. 2
M1968 34 • 3 P6910 1.5
M2244 0.9 P7004 13. 5
M2688 3.0 P7072 1. 8
M4158 2.7 P7097 2. 0
M5058 1.3 P7138 0. 9
M5928 1 . 4 P7181 1.5
M6845 6.3 P7224 5-7
M8018 1.3 P7262 2 . 0
M8092 2.9 P7356 1. 2
M9937 2.5 P7469 2. 3
P34l 1.9 P7775 3-9
P706 ll. 1 P7824 2. IX
P2182 2.7 P7829 0. 8


















Proportion responding Proportion responding
(SI £2) = 20/37 (54%) (SI £2) = 11/19 (58%)
Table 25s CMV-speclfic lymphocyte proliferative responses
of seropositive homosexuals and heterosexuals.
responsiveness to CMV antigens and the presence of CMV
IEA-IgG or CMV EA-IgG. 21/29 (72%) of responders and 13/23
(52%) of non-responders were CMV IEA-IgG positive. 16/31
(52%) of responders and 11/25 (4/1%) of non-responders were
CMV EA-IgG positive.
To determine if unresponsiveness to CMV antigens in
seropositive individuals was due to the presence of soluble
inhibitory factors, or to the absence of necessary growth
factors in autologous plasma, lymphocytes from some
volunteers were tested in the presence of pooled homologous
plasma as well as in autologous plasma. Three plasma pools
were used in these studies. Pool 1 consisted of equal volumes
of plasma from eight seropositive individuals whose
lymphocytes had shown good responsiveness to CMV antigens (SI
= 4.1-34.3). Pool 2 consisted of equal volumes of plasma from
eight seronegative individuals. Pool 3 consisted of equal
volumes of plasma from eight seropositive individuals whose
lymphocytes had been unresponsive to CMV antigens. The
maximal SI values obtained with lymphocytes cultured in these
three pools, and in autologous plasma are shown in Table 26.
No clear pattern emerges from these results. Of the nine
seropositive individuals whose lymphocytes were tested in
this series, some enhancement was observed in four when
lymphocytes were cultured in pooled plasma, but this was only
significant in three cases. Of these three, one (P5997) was
excreting CMV at the time of study and one (P7775) was EBV-
IgM positive. The use of these plasma pools, particularly




Autologous Pool 1 Pool 2 Pool 3
P3007 (sero+ve) 1. 9 1. 2 1. 9 1. 0
P3^55 (sero-ve) 1.7 0. 6 1.6 1.5
P3881 (sero+ve) 3.0 5- 2 k. 2 7.6
P4153 (sero-ve) 2. 1 1.9 2. 0 3. 3
P5278 (sero-ve) 0. 9 2. 5 1. 2 1. 4
P5997 (sero+ve) 1.7 3. 3 k. 6 k. 0
P6097 (sero-ve) 0.9 1. 0 1. 2 0. 6
P6615 (sero-ve) 0. 7 2 . 2 1. 8 NT
P7680 (sero-ve) 0. 9 1. 0 1 . 2 0. 6
P7693 (sero-ve) 1. 3 0. 9 1. 0 1. 6
P7757 (sero+ve) k. 5 6.7 5.0 6.6
P7760 (sero+ve) 2. 3 5.9 2.3 2. 7
P7775 (sero+ve) 3- 9 10. 7 5.0 7.3
P7779 (sero-ve) 1. k 0. 8 0. 7 1. 2
P7821 (sero-ve) 1. 1 0. 9 1. 1 2 . 0
P782/i (sero+ve) 2. k 1. 9 1. k 1. 2
P7829 (sero+ve) 0. 8 1. 3 1. 7 1. k
P7830 (sero-ve) 2. 1 0.7 1. 1 0. 7
P7832 (sero-ve) 0.7 1.7 1.3 1. 1
P78/I2 (sero+ve) 1. 2 NT NT 1. a
P7888 (sero-ve) 0. 9 1. k NT 2 . k
P7890 (sero-ve) 1. 1 1. 6 1.3 0.7
P7892 (sero-ve) 1. 3 1. 2 0 . 8 1. k
Pool 1: Pooled homologous plasma from seropositive individuals
whose lymphocytes responded to CMV antigen.
Pool 2: Pooled homologous plasma from seronegative
individuals.
Pool 3: Pooled homologous plasma from seropositive
individuals whose lymphocytes were unresponsive to
CMV antigen.
NT = not tested
Table 26; Stimulation indices of lymphocytes cultured in
plasma from different sources.
non-specific stimulation in some assays using lymphocytes
from seronegative individuals.
To determine if the presence or absence of the CMV-
specific proliferative response in seropositive individuals
was constant, or fluctuated with time, a number of
seropositive laboratory personnel were tested on a number of
occasions. The results are shown in Figure 7. It is clear
that not only did the presence or absence of the response
vary with time in most individuals, but that the magnitude of
the response when present was variable in all individuals.
Antibodies to HTLV III
Plasmas from the homosexual cohort were screened for
HTLV III by indirect ELISA. A high proportion of specimens
(73%) gave ELISA readings above cutoff, however this was
considered to be largely due to non-specific reactions
perhaps related to the fact that specimens had been thawed
and refrozen frequently. Most specimens gave absorbance
values less than 0.2. (The mean positive control absorbance
value was 0.531 and the mean negative control value was
0.027, giving a recommended cutoff value of 0.080.) Those
specimens which gave absorbance values greater than 0.2 were
retested. All remained positive on retesting and were
therefore tested for HTLV III-IgG by IIF and by Western blot
immunostaining. The results for these specimens are shown in
Table 27. Two specimens which were positive in both
confirmatory tests were regarded as HTLV III-IgG positive.






































































































K9214 0. 201 -ve -ve
M68&7 0. 230 -ve -ve
P706 0. 218 -ve - ve
P1122 0. 367 - ve - ve
P2827 0. 596 +ve +ve
P4331 0. 266 - ve -ve
PH7&0 0. 210 -ve -ve
P5612 0. 597 +ve +ve
P6671 0. 380 +ve -ve
P7173 0. 232 -ve - ve
Positive control OD = 0.531; negative control OD = 0.027.
Table 27: HTLV IXI-IgG IIF and Western blot immunostalning
results of specimens considered positive by ELISA.
DISCUSSION
Exposure to CMV infection In male homosexuals
The detection of CMV-specific serum antibodies is the
most accessible means of determining the extent of past CMV
infection in a given population. This method has been
successfully applied in the present project to compare
exposure to infection in male homosexuals and heterosexuals.
The results clearly show a large, very significant difference
in exposure, CMV infection being approximately three times
more common in the homosexual group. This is in general
agreement with the findings of others (Drew et al., 1981;
Goldmeier et al., 1893; Mindel & Sutherland, 198/1). Antibody
prevalence among homosexuals was 75%. This is similar to that
found by others in the UK; Goldmeier et al. (1983) reported a
figure of 76%. Mindel & Sutherland (1984) however found that
92% were seropositive in one study. This is more akin to
prevalences reported from the USA where up to 94% of
homosexuals are seropositive (Drew et al., 1981). Antibody
prevalence in the heterosexual group under study was 24%, a
figure much lower than those reported by the above groups
where 50% of heterosexuals have been found to be
seropositive.
The rate of exposure to CMV infection is known to
increase in an age-dependent fashion in the general
population; the proportion who are seropositive has been
estimated to increase by 2% for each successive year of life
between the ages of 20 and 50 years (Kane et al., 1975)
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although the rate may be higher than this in the younger end
of this range due to the onset of sexual activity. The
homosexual group under study was on average four years older
than the heterosexual group. This then cannot explain the
large difference in antibody prevalence, even assuming a
higher than average seroconversion rate in this age group.
Additionally, comparison between age-matched subgroups still
reveals striking differences in antibody prevalence, except
in older age groups where exposure to CMV Infection in
heterosexuals approaches that observed in homosexuals.
Comparison of antibody prevalence within each cohort
reveals a slight age-dependent increase among homosexuals.
This increase is much lower than might be expected,
considering the age range of the group and suggests that the
influence of homosexuality on antibody prevalence largely
overrides that of age, a conclusion also reached by Mindel &
Sutherland (198/1). The heterosexual group in contrast showed
a striking age-dependent increase in antibody prevalence,
particularly during the late twenties. This increase is
statistically significant despite the small numbers involved
in the older age group. This probably explains the low
antibody prevalence in this group compared to heterosexual
groups studied by others, who were on average ten years older.
The high prevalence of CMV infection in homosexuals is
frequently attributed to the fact that homosexuals are
generally more promiscuous than heterosexuals. This may
explain the greater level of exposure in homosexuals from the
USA over that in homosexuals from the UK as many of the
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former group are known to be extremely promiscuous, often
reporting several hundred lifetime partners. The present
results indicate that this explanation in itself is
insufficient to account for the high rate of seropositivity
in the homosexuals studied in this project. Using the
reported number of sexual partners in the previous three
months as an indicator of promiscuity, there was little
indication of a higher antibody prevalence among more
promiscuous individuals within either group although numbers
were insufficient for meaningful comparison in the
heterosexual group. On matching subgroups of the two cohorts
for recent partner number significantly more homosexuals were
seropositive. If exposure to CMV was related to the extent of
sexual activity then differences may be expected on comparing
those who have recently become sexually active with those
with a longer history of sexual activity. This was true of
the heterosexuals studied; the increase in antibody
prevalence with increasing length of sexual history was large
and significant, again despite small numbers. The same was also
true to a lesser extent of the homosexuals studied.
Significant differences were observed. However the magnitude
of this difference between the more sexually experienced and
the less so was much smaller.
The most plausible conclusion is that CMV-
seroconversion usually occurs rapidly following the onset of
homosexual activity. As this did not seem to be related to
greater promiscuity in homosexuals compared to heterosexuals,
it would appear that some other aspect of homosexuality
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predisposes to CMV infection. It is possible that the
transmission route(s) associated with homosexual contact are
more efficient than those associated with heterosexual
contact. Oro-anal and ano-genital contact are often practised
by homosexuals and can be presumed to be common in the group
under study on the basis of the high frequency of anal and
rectal infections. As discussed in Chapter anal
intercourse may allow infectious agents to enter directly
into the circulation, and so to avoid the initial defence
mechanisms of innate immunity at mucosal membranes. An
alternative possibility is that the immune control of CMV
infection in seropositive homosexuals is defective. This
would result in increased excretion of virus due to
reactivated or persistent infections and consequently more
efficient transmission to seronegative partners. A
consideration of other aspects of CMV infection and immunity
in homosexuals may allow these possible explanations for CMV
susceptibility in this group to be evaluated further.
Active CMV infection in male homosexuals
Active CMV infection can be diagnosed by demonstrating
replicating virus in biopsy or autopsy tissue, by
demonstrating virus excretion, or by detecting virus-
specific serum IgM antibody. The last two of these methods
were employed in this study.
a) CMV excretion
Virus excretion was detected in a significant proportion
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of homosexuals, but only in one heterosexual. The proportion
in the homosexual group who were viruric was 8.3%. a figure
similar to that of 7-8% reported by Drew et al. (1981). In
contrast, Goldmeier et al. (1983) found no instances of
viruria in homosexuals. Drew et al. (1981) found that viruria
and virusemenia in homosexuals were confined to those under
years old. Biggar et al. (1983) also found that virusemenia
was largely confined to younger men, except in those with
evidence of immune deficiency. The present findings are
consistent with these results, as no instances of viruria
were detected in homosexuals over 25 years old, and most
excretors were in the range of 18-21 years of age. This
probably explains the absence of viruria in the study of
Goldmeier et al. (1983) as the mean age of those studied was
33 years. Based on the findings of others who have studied
both viruria and virusemenia in homosexuals (Chapter 3) it
would be anticipated that the rate of virusemenia would be
higher than that of viruria in the present study group. This
parameter was not assessed in this study as isolation
specimens are not readily available.
The age distribution of viruric homosexuals suggests
that much of this excretion is related to recent primary
infection. In the present study this is also borne out by the
srong inverse correlation between viruria and the duration o
homosexual activity, in particular, the strikingly high
incidence of viruria in those with less than two years of
homosexual experience. This evidence does not rule out the
possibility that reactivations and/or reinfections may occur
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in older* homosexuals, but suggests that these infections are
not detected using normal virus isolation procedures. Virus
excretion following primary infection is often prolonged, at
least in those with CMV-mononucleosis (Chapter 3). It is
therefore possible that homosexuals who have recently
seroconverted are a significant source of infection to
seronegative partners. Follow up of contacts may have
clarified this but was not possible. The main argument
against this sequence of events being responsible for the
proposed high seroconversion rate among inexperienced
homosexuals is that it is dependent upon a certain level of
promiscuity for its perpetuation whereas viruria in this
group was entirely confined to those reporting only one
recent sexual partner. It is still possible that infection in
these individuals may have followed contact with a
promiscuous homosexual who was actively infected at the time,
however the absence of detectable viruria in the promiscuous
group and the lack of correlation between the number of
recent partners and antibody prevalence suggest that other
factors are responsible for the high exposure to CMV in
homosexuals. Insufflcent data was available to determine the
duration of excretion in the present study.
b) CMV-IgM detection in male homosexuals
CMV-specific IgM is a useful diagnostic marker for CMV
infection and in non-immunocompromised individuals is
indicative of primary infection. The standard detection
method is indirect immunofluorescence, however this has been
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shown to be both insensitive and non-specific (Griffiths et
al. (1982b). In accounting for the possibilities that the
prevalence of CMV-IgM may be low in the groups under study
and that IgM titres may be low in asymptomatically infected
individuals, it was considered important to use an
alternative CMV-IgM detection assay in order to obtain an
indication of its prevalence which was as accurate as
possible. An indirect RIA (Kangro, 1980) was considered but
was found to be time-consuming and very demanding on
the quality of antigen used; most batches were found to be
unsuitable for use in this assay. It was therefore decided to
develop an IgM-capture assay. This type of assay has at least
two theoretical advantages over indirect IgM assays. Firstly
the presence of specific IgG antibody at high titre does not
inhibit the detection of IgM as the initial test serum
reaction is entirely IgM specific. In indirect assays it is
necessary to use a large excess of antigen or to selectively
remove IgG from test specimens to overcome this problem.
Secondly the presence of IgM rheumatoid factor (antibody which
binds to the Fc component of IgG when the latter is bound to
antigen) should not give false positive results, except perhaps
in sera with antigen-antibody complexes or denatured antibody,
as IgG is removed by washing prior to the addition of antigen.
Initial investigation was aimed towards developing an
IgM-capture RIA (MACRIA) using radiolabelled monoclonal
antibody (McAb) to detect IgM-bound antigen. The major
problem encountered appeared to be the non-specific binding
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of antigen to the solid phase in the absence of solid phase-
bound specific IgM. As this resulted in poor differentiation
between the strong positive and negative control sera, the
test was considered unsuitable for the detection of low titre
IgM antibody. Initial experiments using a MACELISA system
indicated that this problem persisted when McAbs were used as
detector antibody but was much less noticeable when a rabbit
antiserum was used. This may indicate that the McAbs used
were reactive with antigens which tended to bind to the solid
phase non-specifically whereas the rabbit antiserum reacted
with antigens which did not. The McAbs were directed against
a variety of antigens however and it is also possible that a
component of the test antigen which bound to the solid phase
non-specifically also reacted with mouse IgG in a
non-specific way.
It was decided to develop the MACELISA with rabbit
antiserum as detector antibody (MACELISA 1) using unlabelled
rabbit antibody followed by enzyme-labelled anti-rabbit IgG
rather than use enzyme-labelled rabbit antibody, as it was
considered that the extra amplification step may give greater
sensitivity. The assay was found to be sensitive when
compared to the results of previous testing by indirect RIA,
but the suspicion that this sensitivity was somewhat
selective was Justified in the light of results from the
modified assay using biotinylated McAb as detector antibody
(MACELISA 2). This assay was of comparable sensitivity to the
VirEnz - M CMV kit but was also found to be selective in its
detection of positive sera. This is perhaps a disadvantage of
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the IgM-capture principle compared to the indirect system
where IgM reactive with all components of the antigen is
detected. The former assay type does however offer the
possiblity of measuring IgM responses to individual antigens
which may be of value in distinguishing between acute and
convalescent phases of infection, or between primary and
non-primary infection in immunocompromised patients. It is
probable that a MACELISA of broader sensitivity could be
acheived by using a pool of biotinylated McAbs selected for
their antigenic reactivity as detector antibody. In the
absence of such an assay the results of the two MACELISA
tests were combined for the purposes of this project.
Some sera from patients with infectious mononucleosis
(IM) were found to give high IgM values in these assays,
particulary in MACELISA 2. These sera do not appear to be
reactive in indirect RIA tests for CMV-IgM (Kangro, 1980;
Rasmussen et al„ 1982) but are Known to be reactive in the
CMV-IgM IIF (Hanshaw et al.. 1972), in a CMV MACRIA using
radiolabelled human immune serum as detector antibody
(Sutherland & Briggs, 1983) and in a rubella MACRIA using
radiolabelled McAb as detector antibody (Morgan-Capner et
al., 1983)- In view of this last observation in particular,
it is likely that this reactivity is due to the polyclonal
IgM stimulation that occurs in IM (Chapter 3) and is not due
to cross-reactivity between EBV-IgM and other viral
antigens. In the development of MACELISA 2 it was noticed
that one serum from an IM case gave positive results when
three different McAbs were used as detector antibody; one of
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which reacted with an immediate early glycoprotein, one with
an early nuclear antigen and one with a late glycoprotein. It
is unlikely that EBV-IgM antibodies would be cross-reactive
with three different CMV antigens and this too points to
polyclonal IgM stimulation as the source of this reactivity.
Testing of MACELISA positive specimens by EBV-IgM IIF is a
straightforward means of identifying such reactivity as the
EBV-CMV cross-reactivity is one way (Horwitz et_al., 1977)
probably due to the lower level of polyclonal IgM stimulation
that occurs in CMV infection.
Some sera from patients with other acute infections gave
high background IgM values. This may have been due to
increased hydrophobic interactions between glycoproteins and
the solid phase in the presence of solid phase-bound non¬
specific IgM.
Application of these MACELISA tests in the screening of
plasmas from the homosexual and heterosexual study groups
revealed a significantly higher prevalence of IgM antibodies
in the homosexual group, which was confined to the lower age
groups and to those with a shorter history of sexual
activity. Although statistical analysis was not possible
within the heterosexual cohort it was noticed that the three
IgM positive individuals were not restricted to the lower age
range. These results supplement those of virus isolation and
provide further evidence for the hypothesis that primary CMV
infection occurs commonly in young homosexuals. The less than
complete concordance between viruria and the presence of
CMV—IgM probably reflects the fact that the phase of virus
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excretion only partially overlaps with the period when IgM is
present (Chapter 3).
These results are in contrast to those reported by Mintz
et al. (1983) who found that CMV-IgM was present in 95% of
homosexuals on at least one occasion and was present in 66%
of all specimens from homosexual men. IgM was unrelated to
virus excretion. This suggests that immune function was
deranged in this American group of homosexuals. This may have
resulted from excessive immune stimulation from multiple
antigenic exposures encountered as a result of highly
promiscuous behaviour. It is also possible that polyclonal
stimulation of immunoglobulin synthesis associated with
asymptomatic stages of HTLV III infection was responsible.
Certainly this is not a constant feature of all homosexual
groups in the light of the present study.
There was some indication from the testing of
retrospective sera that persistence or reactivation of CMV-IgM
occurred in the homosexuals under study here also. Prospective
study is required to establish how frequently this occurs and
to elucidate its causes.
Antibodies to CMV IEA and CMV EA in male homosexuals
Antibodies to CMV IEA and EA are present in a proportion
of seropositive individuals. As discussed in Chapter 3. their
significance, if any, is not known. Antibody to CMV EA has
been found with greater frequency in transplant patients (The
et al., 1977) who are known to be susceptible to serious CMV
infections, and have been found at high titre in patients with
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early rheumatoid arthritis (Male et al.t 1982). CMV excretion
has been observed in these patients both prior to and during
corticosteroid therapy (Dowling et al.t 1976). This indicates
that the development or persistence of CMV EA-IgG occurs more
readily when CMV infection takes place in certain clinical
settings. The significantly increased prevalence of CMV EA-
IgG in seropositive homosexuals compared to heterosexuals
also indicates that their presence is of some significance.
Screening for the presence of CMV IEA-IgG has not been
used in seroepidemiological surveys of this nature before,
although the time course of their development following
infection or vaccination has been studied in some groups. The
present results demonstrate that their presence may also be
of significance. The difference in prevalence between the two
study groups is less striking however than that of CMV EA-
IgG, largely due to the greater background prevalence of CMV
IEA-IgG in the heterosexual group.
A number of explanations may be offerred to account for
this difference in the prevalence rates of these antibody
reactivities. Their greater prevalence in seropositive
homosexuals may be due to the fact that primary CMV infection
has been a more recent occurrence in a greater proportion of
this group, since these antibodies may decline in titre with
time in a proportion of cases (The et al.. 1984). Several
observations argue against this. Firstly, CMV EA-IgG was not
observed any more frequently in those who were viruric or
CMV-IgM positive compared to those who were not (although CMV
IEA-IgG was universal in those who were IgM positive.)
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Secondly, the presence of these antibodies in seropositive
homosexuals did not correlate in any way with age or duration
of sexual activity. More of the younger and less sexually
experienced would be expected to be CMV IEA— and CMV EA-IgG
positive if their presence was related to recent Infection.
Thirdly, the limited study in which repeat specimens from
seropositive laboratory personnel were tested indicates that
the presence or absence of these antibodies, particularly CMV
IEA-IgG is a relatively constant feature in many individuals.
In no case was a decline in their titre observed in this study.
Their presence does not therefore seem to be related in a
temporal fashion to CMV infection.
A second possibility is that the presence of CMV IEA-
and CMV EA-IgG is a reflection of the frequency of
reactivation and/or reinfection, or possibly of the level at
which immune control of "latent" infection operates. To test
this would require the development of more sensitive means of
detecting CMV infection. If true however this may indicate a
reduced capacity to contain latent infection or to resist
reinfection in homosexuals. Yao et al. (1985) have shown that
the EBV carrier state in seropositive individuals may be
maintained at different levels, reflected in the extent of
oral excretion of virus. In no way, however was the nature of
the carrier state related to the serological profile.
A third possibility is that the development and
persistence of CMV IEA- and CMV EA-IgG is determined by the
extent of viral replication during the initial infection.
Where this is considerable the increased antigenic load may
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result in greater immunisation to antigens which are of low
immunogenicity in other infections. The extent to which such
antigens are presented to the immune system may determine
whether the antibody response is detectable or not and, if
so, whether it is transient or persistent. Increased viral
replication may occur if the local immune response at the
site of initial infection is deficient or is bypassed. The
importance of local immune functions has often been
overlooked. However it is becoming apparent that they may
significantly influence events at later stages of infection
(Dhar & Ogra, 1985). CMV infection probably begins at the
oral or genital mucosal membranes in most individuals, where
local immune functions are highly active. In homosexuals, CMV
infection may also be encountered via the rectal mucosa. The
possibility that this structure may be breached, allowing
infectious agents to avoid the local immune response has
already been considered. The presence of immunomodulating
agents in semen may also inhibit local immune responses at
this site. This particular infection route may then not only
result in efficient transmission of CMV infection, but may
also favour more extensive viral infection resulting in
greater stimulation of humoral immunity at later stages of
infection.
Cellular immunity in male homosexuals
In view of the prevalence of AIDS in male homosexuals
functional capacity of immune responses in this group prior
disease has been the subject of frequent speculation. This
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study provides no evidence of this in male homosexuals, as
determined by CMV-specific and mitogen-induced lymphocyte
proliferation responses. It could be argued that this
assessment of cellular immunity is unsuitable for detecting all
but gross abnormalities in immunity; the standard deviations
observed in mitogen responses were large and would probably
mask slight impairments in the response. Others however have
observed lowered responses in healthy homosexuals (Chapter 4).
This may be caused by the early stages of AIDS-related
immunodeficiency in some as Krohn et al. (1985) found that
serological analysis for HTLV III infection distinguished those
who had reduced mitogenic responses from those who did not.
That healthy, HTLV III infection-free homosexuals are
immunocompromised to any significant extent therefore remains
to be established. It is possible that assessment of other
aspects of acquired and innate immunity which have been shown
to be deficient in AIDS such as NK and CTL functions may reveal
differences in healthy homosexuals.
Absence of CMV-specific lymphocyte proliferation
responses in healthy seropositive individuals was frequently
recorded in this study and has been reported by others
(Chapter 3). The reason(s) for this are not known, however
sequential investigation of healthy laboratory personnel
indicated fluctuations in responsiveness in some individuals.
The relevance of this assay as an assessment of CMV-specific
cellular immunity, then is uncertain. The presence of serum
inhibitory factors did not appear to be responsible for
unresponsiveness in this study, except perhaps in a few cases
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which are interesting because they include two individuals
who had evidence of CMV and EBV infection.
Proliferative responses revealed no consistent immune
deficiency in those with current or recent active CMV
infection. This may indicate that asymptomatic CMV infection
is not associated with the immunological effects observed in
CMV-mononucleosis and other CMV syndromes. Clearly further
work is required in this area.
Antibodies to HTLV III in the homosexual study group
The results of HTLV III serological analysis clearly show
that the homosexual population under study was largely free of
infection with this virus as had originally been assumed. Two
or possibly three of the &U studied were seropositive. It could
not be decided if the discrepancy between Western blot
immunostaining and IIF was due to insensitivity of the former
or nonspecificity of the latter, however this combination of
tests is the best indication of seropositivity that is
currently available. One of those who was seropositive was one
of the individuals with evidence of a persistent or reactivated
IgM response to CMV. This individual may have experienced an
unusually vigourous non-primary CMV infection in the setting of
HTLV III infection. It is also possible however and perhaps
more likely that the CMV-IgM detected was the result of
polyclonal stimulation of immunoglobulin synthesis associated
with HTLV III infection. This might explain the unusual IgM
profile in this case as indicated by the striking differential
reactivity in the two MACELISA tests. Other than this, no
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abnormalities were noticed among the HTLV III seropositive
individuals although the numbers are clearly too small for
meaningful comparison.
Conclusion
This project clearly demonstrates a high prevalence of
CMV infection in healthy male homosexuals who are not in
incubation or prodromal phases of AIDS. This infection
appears to be acquired readily through homosexual contact and
this is probably related to the nature of this contact rather
than to its frequency. The profile of the humoral immune
response to CMV suggests that CMV stimulates immune responses
to a greater extent than usual in many homosexuals. This may
be due to more frequent reactivation or reinfection, which
may point to defective immune control of the virus carrier
state. Alternatively it may indicate greater viral
replication during a past infection. This might also indicate
impaired immunity, or it may be related to the route of
infection. These possibilities of course are not mutually
exclusive. Control of infection appears to be achieved
eventually as older homosexuals have no evidence of active
infection. Transient or low grade virus excretion in such
individuals may nevertheless be a significant source of
infection for other homosexuals.
The present results do not indicate any suppression of
cellular immunity during active CMV infection in individuals
who remain asymptomatic. However this remains an open
question and requires testing using more sensitive assays than
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lymphocyte proliferation responses proved to be in this
project, studies of cellular immunity in other CMV-infected
patients show that cytotoxic responses are more relevant to
protection and recovery from CMV infection (Chapter 3) and
investigation of these responses in the group under study
would be of value.
Although active but subclinical CMV infection may not
normally cause significant disturbances in immunity, this may
not be the case if other infections such as HTLV III
infection concur. It is possible that HTLV III infection
occurring in a young homosexual may result in exacerbation of
low grade CMV infection which had not yet been eliminated
following primary infection. CMV infection may then cause
further cycles of immune suppression. Similar events may also
occur in older, more CMV-immune individuals although a more
vigourous initial immunosuppressive event may be required to
lower immune functions below the threshold at which
reactivation of CMV infection occurs. Such cycles may be
predicted to result in a more severe immune dysfunction and
clinical manifestations of AIDS after a shorter incubation
period than would be expected in the absence of concurrent
CMV infection.
Little is known concerning events in the incubation phase
of AIDS in different groups and their possible influence on the
length of this period. Determination of the incubation period
is difficult as the original exposure which resulted in
infection usually cannot be pinpointed accurately in time.
There is some limited data avaiable however. The time of
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exposure can be identified reasonably confidently when
transfusion-associated infection occurs in otherwise low-risk,
individuals and Jaffe et al. (1984) determined a mean
incubation period of 24.6 months in those patients who had
developed AIDS by the time of assessment. Hanrahan et al.
(1984) studied intravenous drug users who developed AIDS
following imprisonment. Taking the time of imprisonment as the
most recent possible time of exposure, a minimum average
incubation period of 22.6 months was arrived at. In contrast
Auerbach et al. (1984) in studying male homosexuals with AIDS
in whom the probable time of exposure could be estimated by
follow-up of contacts, calculated a mean incubation period of
10.5 months.
This remarkably shorter incubation period may be due to
the occurrence of KS in many of these homosexuals. KS may
occur in less severely immunosuppressed patients, but as its
occurrence results in fulfillment of the criteria by which
AIDS is diagnosed, an apparently shorter incubation phase may
be observed. In view of the possible association between CMV
infection and KS, the development of the latter in
homosexuals with AIDS may support the concept that HTLV III
infection results in increased or altered expression of CMV
infection. A greater frequency of interactions of this nature
in homosexuals may be due to the higher rate of CMV infection
and its more active state in a proportion. A more extensive
replication of HTLV III during the initial acute infection may
also be responsible. Since HTLV III infection may be acquired
by the same route as CMV infection in homosexuals, what has
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been discussed already with regard to the possible consequences
of acquisition of CMV infection via this route may also apply
to HTLV III infection. This may result in more efficient
reactivation of other infections such as CMV or EBV. These
infections may then contribute both to the progressive ablation
of immune function and also to the appearance of malignant
disease.
The other group of AIDS patients in which KS is more
common are cases of African origin. CMV infection is also
highly prevalent in this population and usually occurs in
infancy (Chapter 2). Infection at this age has been suggested
to result later in life in an increased propensity to transmit
CMV infection to the foetus during non-primary maternal
infection (Chapter 3) and may also predispose to the
development of KS in the setting of HTLV III infection.
Further studies
The work presented in this thesis should be considered
as the first part of an ongoing study. The issues raised
regarding the effects of CMV infection in male homosexuals,
its possible differences from infections in other settings
and its possible interactions with other infections, in
particular with HTLV III infection all warrant further
investigation. These issues are important not only in the
immediate context of the pathogenesis of CMV infection, HTLV
III infection and of AIDS, but also in the wider context of
viral pathogenesis in general.
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The conclusions that have been reached are based on
epidemiological evidence from a cross-sectional survey of
homosexuals and heterosexuals. This should ideally be
followed up by a longitudinal survey in smaller numbers which
would enable the persistence of viral excretion and of IgM
responses to be determined. This would also allow the time
course of CMV IEA-IgG and CMV EA-IgG responses to be
determined and their possible significance to be evaluated
further. It is possible that application of Western blot
immunostaining technology or of RIA/ELISA techniques using
antigens captured by solid phase-bound McAbs may permit
further breakdown of the humoral response to CMV infection
and this may reveal further differences between the study
populations. Longitudinal study may also allow the temporal
sequence of events associated with HTLV III infection to be
elucidated. This type of study would be expected to yield
results reasonably quickly if conducted among young,
inexperienced male homosexuals in view of their high
susceptibility to CMV infection.
Other aspects of CMV-specific and general immunity could
be assessed in a cross-sectional survey such as that of the
present project. Determination of CMV-IgG titres in addition
to merely screening for their presence may be of value. It
was anticipated that this would provide little additional
information in this study; as CMV antigen preparations used
for serological methods consist of immediate early, early and
late antigens the magnitude of CMV-IgG titres would probably
be influenced to a greater or lesser extent by the presence
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or absence of CMV IEA-IgG and CMV EA-IgG. Detection of CMV-
IgA antibodies may have provided additional information
regarding the prevalence of current or recent CMV infection.
This would probably be most readily accomplished using an IgA
capture assay analogous to the MACELISA.
Cellular immune parameters are also worthy of study on a
longitudinal basis. This may indicate fluctuations in
response to infection which would not be identified from
single determinations.
Future studies might also investigate the prevalence and
effects of other infections in homosexuals such as EBV.
Significant associations may be less readily demonstrable in
this case however in view of the generally higher prevalence
of past infection in the general population. In addition,
detection of EBV excretion is not a standard procedure in
most laboratories.
Finally, the rationale and techniques employed in this
project may be suitable for the characterisation of CMV
infection in other populations or patient groups where an
abnormal pathogenesis is suspected. Where associations exist,
they may be even more striking than those in homosexuals as
the departures from normal may be subtle in many of the
latter group. Clearly much remains to be clarified regarding
CMV infection and its "protean clinical manifestations"
(Weller, 1971). Epidemiological analysis will be an important
aspect of future endeavours to this end.
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Antibody dependent cellular cytotoxicity
Aquired immune deficiency syndrome
AIDS-related complex
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HLA Human leukocyte antigen
HSV Herpes simplex virus
HTLV Human T cell leukaemla-lymphoma virus or









MACELISA M antiboby capture ELISA
MACRIA M antibody capture RIA
McAb Monoclonal antibody
MHC Major histocompatibility complex
MM Maintenance medium
moi multiplicity of infection
NBCS New-born calf serum
NGU Non-gonococcal urethritis
NK Natural killer
NRS Normal rabbit serum
OD Optical density
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate-buffered saline
PBSAT PBS plus 1% BSA and 0.05% Tween 20













Tris-buffered saline plus 0.025% Tween 20
T cells of helper/inducer phenotype






A SUMMARY OF DEMOGRAPHIC DETAILS AND RESULTS
OF SEROLOGICAL AND VIROLOGICAL INVESTIGATION
OF MALE HOMOSEXUALS AND HETEROSEXUALS.
KEY TO APPENDIX
Horn = male homosexual
Het = male heterosexual
Recent partner number = number of different sexual partners
reported in the preceding three months.
U = unknown
CMV-IgG = IgG antibodies to CMV measured by indirect ELISA.
CMV IEA-IgG = IgG antibodies to CMV immediate early antigens
detected by indirect immunofluorescence (IIF).
CMV EA-IgG = IgG antibodies to CMV early antigens detected by
IIF.
CMV-IgM = IgM antibodies to CMV measured by IgM capture ELISA.
+ = parameter in question was detected.
- = parameter was not detected.
NT = not tested.
342
Codeno.
Sexualpreference
Age
Sexualhistory(yrs)
Recentpartnerno.
CMV-IgG
CMV
IEA
-IgG
CMV
EA-IgG
CMV-IgM
Viruria
H99̂9
Het
30
16
1
+
-
+
-
-
K890
Horn
zu
26
2
+
+
+
-
NT
K591^
Horn
37
15
2
+
+
-
-
NT
K6561
Horn
26
10
3
+
+
-
-
-
K75̂7
Het
26
U
1
-
-
-
-
-
K7512
Horn
36
16
2
+
+
-
-
-
K7967
Horn
29
11
2
+
+
+
-
NT
K9214
Hom
Zil
21
2
+
+
+
-
-
M653
Horn
26
8
8
+
-
+
-
NT
M96̂
Hom
2
Zl
8
3
+
-
+
-
-
M1968
Hom
31
10
1
+
+
-
-
-
M22
UIX
Hom
Zl
3
U
1
+
+
-
-
-
M2866
Het
3ZZ
1
zi
1
+
+
+
-
-
M30/12
Hom
2
Zj.
8
1
+
+
+
-
NT
M3060
Het
28
U
1
-
-
-
-
-
Codeno.
Sexualpreference
Age
Sexualhistory(yrs )
Recentpartnerno.
CMV-IgG
CMV
IEA
—
IgG
CMV
EA-IgG
CMV-IgM
Viruria
MU158
Horn
33
15
3
+
-
+
-
NT
M4394
Horn
33
10
2
+
-
+
-
-
M4812
Horn
25
8
2
-
-
-
-
NT
M5058
Horn
21
7
1
+
-
-
-
+
M5928
Horn
31
15
6
+
-
-
-
NT
M6266
Horn
30
11
2
-
-
-
-
-
M6615
Het
25
U
1
+
NT
-
-
-
M6845
Horn
4
2
22
2
+
+
+
-
NT
M6847
Horn
24
10
12
+
+
+
-
NT
M7228
Het
28
U
2
-
-
-
-
-
M8018
Horn
21
3
1
+
+
+
-
NT
M8092
Horn
21
8
10
+
+
+
-
-
M8661
Het
22
3
2
-
-
-
-
NT
M8723
Horn
23
6
3
+
-
-
-
-
M9415
Horn
24
8
4
+
-
-
-
-
Codeno.
Sexualpreference
Age
Sexualhistory(yrs)
Recentpartnerno.
CMV-IgG
CMV
IEA
-IgG
CMV
EA-IgG
CMV-IgM
Viruria
M9516
Het
27
U
2
-
-
-
-
-
M9937
Horn
18
U
2
+
+
+
+
NT
P118
Het
21
2
1
-
-
-
-
NT
P31̂
Horn
23
U
10
+
+
+
-
NT
P56/i
Horn
2IX
6
1
-
-
-
-
NT
P706
Hom
45
25
>20
+
-
+
-
NT
P1122
Horn
25
9
2
+
-
-
-
-
PlillO
Hom
35
16
12
-
-
-
-
-
P1805
Het
21
U
1
-
-
-
-
-
P2039
Hom
33
15
8
+
+
+
-
-
P2152
Het
22
3
1
-
-
-
-
-
P2182
Hom
22
3
2
+
+
-
-
-
P2768
Hom
36
15
1
+
-
-
-
-
P2827
Hom
22
6
3
+
+
-
-
NT
P3007
Hom
20
3
3
+
+
+
-
NT
Codeno.
Sexualpreference
Age
Sexualhistory(yrs )
Recentpartnerno.
CMV-IgG
CMV
IEA
-IgG
CMV
EA-IgG
CMV-IgM
Vlruria
P3455
Het
22
3
2
-
NT
-
-
-
P3688
Het
20
2
1
-
-
-
-
-
P3713
Horn
23
6
1
-
-
-
-
-
P3848
Horn
23
U
1
4-
+
+
-
-
P3881
Horn
33
16
1
+•
+
+
-
-
P/J001
Hom
25
3
6
+
+
-
-
-
P4153
Horn
25
tl
1
-
-
-
-
-
P4331
Horn
18
3
2
+
+
+
+
+
P4351
Hom
33
16
1
+
+
+
-
-
P4541
Hom
29
11
2
+
-
-
-
NT
PU60H
Hom
23
3
1
+
+
+
-
-
P462/1
Hom
22
3
2
-
-
-
-
NT
P4683
Het
19
U
1
+
+
-
-
-
P/1710
Hom
20
6
2
+
+
+
+
NT
P/i780
Hom
35
U
2
+
-
—
-
NT
Codeno.
Sexualpreference
Age
Sexualhistory(yrs)
Recentpartnerno.
CMV-IgG
CMV
IEA
-
IgG
CMV
EA-IgG
CMV-IgM
Viruria
P5056
Horn
19
1
1
-
-
-
-
-
P5058
Horn
21
4
2
+
-
+
-
NT
P5278
Het
20
2
1
-
-
-
-
NT
P5586
Het
19
2
1
-
-
-
-
NT
P5612
Horn
22
5
6
+
+
+
+
NT
P5666
Horn
21
3
2
-
-
-
-
MT
P5832
Horn
29
8
2
+
-
-
-
NT
P5997
Horn
20
1
2
+
+
+
-
+
P6069
Het
21
U
1
+
-
-
-
NT
P6074
Hom
25
6
2
-
-
-
-
NT
P6091
Het
18
3
4
-
-
-
-
-
P6097
Het
22
U
1
-
-
-
-
NT
P6147
Het
27
U
2
-
-
-
-
NT
P6155
Hom
29
U
U
-
-
-
-
NT
P6224
Het
24
U
1
-
NT
-
-
NT
Codeno.
Sexualpreference
Age
Sexualhistory(yrs )
Recentpartnerno.
CMV-igG
CMV
IEA
-IgG
CMV
EA-IgG
CMV-IgM
Viruria
P6239
Het
25
U
1
+
-
-
-
NT
P6335
Het
21
U
1
-
-
-
-
NT
P6470
Het
23
U
1
-
-
-
-
-
P6592
Horn
19
1
1
+
-
-
-
+
P6671
Horn
27
10
1
+
+
-
-
NT
P6671
Het
18
U
1
-
NT
-
-
-
P6685
Het
28
U
2
+
-
-
-
-
P6687
Het
27
U
1
-
NT
-
-
-
P6821
Horn
20
u
2
+
+
+
-
-
P682E
Het
30
u
1
+
-
-
-
NT
P6860
Het
27
u
U
-
NT
-
-
-
P6867
Het
22
u
1
+
NT
+
+
NT
P6872
Het
21
u
1
-
-
-
-
NT
P6882
Het
23
u
1
-
-
-
-
NT
P6897
Het
16
0.
5
1
-
NT
-
-
-
Codeno.
Sexualpreference
Age
Sexualhistory(yrs )
Recentpartnerno.
CMV-IgG
CMV
IEA
-IgG
CMV
EA-IgG
CMV-IgM
Viruria
P6898
Horn
34
10
1
-
-
-
-
-
P6907
Horn
22
3
1
-
-
-
-
NT
P6910
Het
21
U
1
+
-
-
-
NT
P6935
Het
18
U
1
-
-
-
-
-
P6976
Het
20
3
2
-
-
-
-
NT
P6977
Het
23
4
1
-
-
-
-
NT
P698O
Horn
22
4
3
-
-
-
-
NT
P6987
Horn
21
2
2
+
+
-
-
NT
P7004
Het
48
1
1
+
+
+
-
NT
P7045
Het
22
U
2
-
-
-
-
NT
P7046
Het
19
U
2
-
-
-
-
NT
P7072
Het
28
U
1
+
NT
-
-
NT
P7097
Het
22
U
1
+
NT
-
-
NT
P7102
Het
20
U
2
-
-
-
-
NT
P7105
Het
23
U
1
-
-
-
-
NT
Codeno.
Sexualpreference
Age
Sexualhistory(yrs )
Recentpartnerno.
CMV-IgG
CMV
IEA
-IgG
CMV
EA-IgG
CMV-IgM
Vlrurla
P7125
Het
28
U
2
+
-
-
-
NT
P7129
Het
2k
U
1
-
-
-
-
-
P7138
Het
30
U
2
+
+
-
+
-
P7111
Het
18
1
1
-
-
-
-
NT
P715̂
Horn
30
8
3
+
+
+
-
-
P7181
Het
21
U
2
+
-
+
-
NT
P7202
Horn
2k
5
8
+
+
-
+
NT
P722U
Het
17
u
1
+
-
-
-
-
P7226
Het
2
k
u
1
-
-
-
-
-
P72U7
Het
27
u
2
-
-
-
-
-
P7252
Het
2k
u
2
-
-
-
-
NT
P725^
Het
17
1
1
-
-
-
-
-
P7262
Het
22
u
2
+
+
-
-
-
P7280
Het
18
0.5
1
-
-
-
-
NT
P7286
Het
27
u
1
-
-
-
-
NT
Codeno.
Sexualpreference
Age
Sexualhistory(yrs)
Recentpartner
CMV-
no.
IgG
CMV
IEA
-IgG
CMV
EA-IgG
CMV-IgM
Viruria
P7300
Het
18
U
1
-
-
-
-
P7304
Het
20
U
1
-
-
-
-
P7305
Het
24
U
1
-
-
-
-
P731t
Het
18
1
1
-
-
-
NT
P7315
Het
23
u
1
NT
-
-
-
P7319
Het
28
u
1
-
-
-
-
P7321
Horn
17
0.
25
2
-
-
-
NT
P7334
Het
24
U
1
-
-
-
NT
P7337
Het
21
U
2
-
-
-
-
P7348
Het
20
U
1
-
-
-
-
P7356
Het
29
U
1
+
-
-
-
-
P7367
Het
25
U
2
-
-
-
-
P7370
Het
19
U
1
-
-
-
-
P7372
Het
19
u
1
-
-
-
-
P7376
Het
27
u
U
-
-
-
-
Codeno.
Sexualpreference
Age
Sexualhistory(yrs )
Recentpartner
CMV-
no.
IgG
CMV
IEA
-IgG
CMV
EA-IgG
CMV-IgM
Vlruria
P7379
Het
25
U
5
-
-
-
-
P7388
Het
16
0.
25
2
-
-
-
NT
P7392
Het
23
U
1
-
-
-
-
P739S
Het
20
U
1
-
-
-
NT
P73̂5
Het
27
U
1
-
-
-
NT
P7U38
Het
21
U
1
-
-
-
-
P75̂0
Het
29
u
2
-
-
-
-
P7454
Het
23
u
U
-
-
-
-
P7466
Het
19
u
1
-
-
-
NT
P77̂3
Horn
21
3
2
+
+
+
+
+
P77̂6
Het
22
u
1
-
-
-
NT
P77̂9
Het
19
u
2
-
-
-
NT
P7642
Het
22
u
1
-
-
-
NT
P765/J.
Het
18
u
2
-
-
-
-
P7655
Horn
28
u
2
-
-
-
-
Codeno.
Sexualpreference
Age
Sexualhistory(yrs )
Recentpartnerno.
CMV-IgG
CMV
IEA
-IgG
CMV
EA-IgG
CMV-IgM
Viruria
P7656
Het
2U
U
2
-
-
-
-
-
P7658
Het
19
U
1
-
-
-
-
-
P7661
Het
23
U
1
-
-
-
-
-
P7663
Horn
20
3
3
+
+
+
+
-
P7680
Het
17
U
1
-
-
-
-
-
P7693
Het
17
0.
25
1
-
-
-
-
-
P7757
Horn
25
5
2
+
+
+
-
-
P7759
Het
21
3
2
-
-
-
-
-
P7760
Horn
21
U
3
+
+
-
-
NT
P7775
Het
26
IX
3
+
+
-
NT
P7779
Het
21
2
1
-
-
-
-
-
P7802
Het
20
U
1
+
+
+
-
-
P7806
Het
18
1
1
-
-
-
-
NT
P7807
Het
19
U
1
-
-
-
-
-
P7819
Horn
27
6
2
-
-
-
-
-
Codeno.
Sexualpreference
Age
Sexualhistory(yrs )
Recentpartnerno.
CMV-IgG
CMV
IEA-IgG
CMV
EA-IgG
CMV
—
IgM
Viruria
P7821
Het
20
3
1
-
-
-
-
-
P7824
Het
23
k
1
+
+
-
-
+
P7829
Het
20
2
1
+
-
-
-
NT
P7832
Het
18
U
1
-
-
-
-
-
P7842
Horn
21
3
1
+
+
-
-
NT
P785t
Het
2k
u
1
-
-
-
-
-
P7886
Het
37
17
1
+
+
-
-
-
P7888
Het
20
1
1
-
-
-
-
-
P7890
Het
22
3
2
-
-
-
-
-
P7892
Horn
2k
k
6
-
-
-
-
-
P789^i
Horn
25
6
2
+
-t-
+
-
+
;
P7895
Horn
18
1
2
+
+
+
-
+
P7910
Het
22
U
1
+
+
-
-
-
P7914
Horn
35
15
2
+
+
+
-
-
P7922
Het
19
1
1
-
-
-
-
NT
Codeno.
Sexualpreference
Age
Sexualhistory(yrs )
Recentpartnerno.
CMV-IgG
CMV
IEA
-
IgG
CMV
EA-IgG
CMV-IgM
Viruria
P7923
Horn
28
8
1
+
+
+
-
-
P7932
Horn
18
U
1
+
+
-
-
-
P7938
Het
19
U
1
-
-
-
-
-
P79H
Het
2H
6
1
-
-
-
-
-
P7992
Het
23
1
1
-
-
-
-
-
P7997
Het
21
U
1
-
-
-
-
-
P7999
Horn
26
U
1
-
-
-
-
-
P&OUO
Horn
26
7
1
-
NT
-
-
NT
P8053
Het
22
1
1
-
-
-
-
-
P8060
Het
21
2
1
-
-
-
-
-
P8201
Het
28
U
1
+
-
-
-
P8215
Het
32
u
2
-
-
-
-
-
P8242
Het
19
1
1
-
-
-
-
NT
P8260
Het
19
u
1
-
-
-
-
-
P8264
Het
23
u
1
-
-
-
-
-
Codeno.
Sexualpreference
Age
Sexualhistory(yrs )
Recentpartnerno.
CMV-IgG
CMV
IEA
-IgG
CMV
EA-IgG
CMV
—
IgM
Vlruria
P8269
Het
2k
U
1
+
+
-
-
-
P828^
Het
19
U
1
-
-
-
-
NT
P8286
Het
23
U
1
-
-
-
-
-
P8295
Het
31
U
2
+
+
-
-
NT
P8303
Het
17
6
1
+
+
-
-
P837^
Het
19
U
1
-
-
-
-
NT
P8385
Het
19
U
2
-
-
-
-
-
P8391
Het
28
U
1
-
-
-
-
-
P8392
Het
27
U
2
+
+
-
+
-
P8407
Het
20
U
1
-
-
-
-
NT
P8417
Hom
18
2
2
+
+
+
-
-
2&k2k
Het
23
U
1
-
-
-
-
-
P8427
Hom
23
2
2
+
+
-
-
-
P8U29
Het
19
U
1
-
-
-
-
-
P8U30
Het
22
U
1
-
-
-
-
NT
Codeno.
Sexualpreference
Age
Sexualhistory(yrs )
Recentpartnerno.
CMV-IgG
CMV
IEA
-IgG
CMV
EA-IgG
CMV-IgM
Viruria
P8/I53
Horn
17
1
2
-
-
-
-
-
Horn
22
2
1
+
-
-
-
-
P8455
Het
21
U
1
-
-
-
-
-
P8462
Het
21
U
1
-
-
-
-
-
P8/t69
Het
17
1
1
+
+
-
-
-
P8il78
Het
21
u
1
+
-
-
-
-
P8578
Het
27
u
1
-
-
-
-
-
P8591
Het
16
0.
02
1
-
-
-
-
-
P8591
Het
21
U
2
-
-
-
-
-
P8599
Het
18
2
1
+
-
-
-
-
